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Abstract 
 
Mucosa-associated adherent, invasive Escherichia coli (AIEC), found in increased number in 
Crohn’s disease (CD) ileal and colonic mucosae, can survive and replicate within underlying 
host immune competent cells (e.g. macrophages and dendritic cells) without triggering host 
cell death. The intra-macrophage environment plays an essential role in bacterial killing 
where engulfed bacteria are exposed to a hostile environment of low pH, high levels of 
proteolytic/lysosomal enzymes, high nitrosative and high oxidative stress, and the activation 
of a respiratory burst with generation of superoxide ions. Although a few stress response 
genes have been identified that likely support the paradigm ileal AIEC isolate LF82 to 
survive and replicate within the macrophage, the key molecular mechanisms involved in 
supporting Crohn’s disease (CD) mucosa-associated AIEC to resist killing by host mucosal 
macrophages within harsh environment of the phagolysosome still remains largely unclear.  
Here we aimed to compare the ability of a number of E. coli strains to survive and replicate 
inside macrophages, including a number of clinical isolates (from CD, colorectal cancer 
(CRC) and ulcerative colitis (UC) patients and other infective or non-inflamed sources), and 
this to toleration of growth in chemical-induced stress conditions mimicking the intra-
phagolysosome environment. In addition, a focus was to further understand the molecular 
mechanisms responsible for acid tolerance of the paradigm CD isolates and examine their 
replication within macrophages defective in NF-κB pathway signalling. Finally, to also assess 
whether CD AIEC possess ability to alter host oxidative stress response gene expression in 
macrophages to support their survival/replication. 
 
Both ileal and colonic CD isolates (AIEC) were found to possess ability to either survive 
and/or replicate within murine macrophages (i.e. J774-A1 cell-line and wild-type (WT) 
C57BL/6 bone marrow derived macrophages [BMDM]) and to tolerate all stress conditions 
mimicking those within the phagolysosome, e.g. low nutrient, high acid, high nitrosative, 
high oxidative stress including exposure to superoxide ions. Interestingly pathogenic E. coli 
isolates from urinary tract infection (UTI) and some healthy-mucosa associated E. coli strains 
behaved similarly. Crohn’s AIEC were unable to survive and replicate inside Nfκb1-/- and 
Nfκb2-/- BMDM, whilst they survived/replicated within WT and c-Rel-/- BMDM. Thus 
Crohn’s AIEC survival and replication appears dependent on host NFκB signalling within the 
macrophage. Conversely, all CRC and UC isolates tested and the majority of laboratory E. 
coli strains studied were unable to survive inside murine J774-A1 macrophage 
phagolysosomes and they were also intolerant to most stress conditions, in particular 
superoxidative stress. Colonic CD AIEC isolate HM605 showed higher initial levels of 
expression of acid response genes gadA and gadB that may support adaptation to the intra-
macrophage phagolysosome niche. Adaptation to an intra-macrophage lifestyle appeared not 
to be through any ability to alter host macrophage oxidative stress response to infection as no 
differential changes were observed in the expression of 84 host genes related to oxidative 
stress to that seen with non-replicating laboratory E. coli strain.  
Overall this study provides new insight into how CD mucosa-associated E. coli isolates resist 
killing by mucosal macrophages through adaptation to the acidic, high oxidative environment 
within the macrophage phagolysosome. The data may support future development of new 
therapeutic strategies that target the fundamental pathology of CD, in particular support a 
reduction in bacterial persistence/increased killing of intra-macrophage E. coli in CD patient 
mucosae.  
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Introduction 
  
2 
 
1.1 Definition and epidemiology of inflammatory bowel disease  
 
Crohn’s disease (CD) is a chronic relapsing immunologically mediated inflammatory 
disorder, affecting the bowel and along with ulcerative colitis (UC), they form the two major 
groups of inflammatory bowel disease (IBD). Significant overlap in the clinical features of 
both CD and UC is evident, although the immune response in CD is different from that seen 
in UC. CD may affect any part of the gastrointestinal tract from mouth to anus, but 
commonly affects the terminal ileum  at which the precise reasoning remains unexplained [1]. 
Crohn’s patients usually suffer from abdominal pain, diarrhoea, tenesmus and significant 
weight loss which may be associated with extra-intestinal manifestations such as skin rashes 
(e.g. erythema nodosum and pyoderma gangrenosum), eye inflammation  (episcleritis and 
uveitis), venous thromboembolism, arthritis and renal stones [2, 3]. Meta-analysis also 
showed a positive association between IBD and the risk of stroke (7 studies for CD and 6 
studies for UC) [4]; Extraintestinal manifestations of CD are illustrated in Figure 1.1. CD 
patients may have symptoms for many years before diagnosis, because the clinical 
manifestations of CD are more variable than UC [5, 6]. The diagnosis of CD is usually 
established with the imaging studies and endoscopic findings in a patient with a compatible 
clinical history. 
 
The intestinal pathological findings in CD are characterised by transmural inflammation 
(inflammation in all layers from mucosa to serosa), deep mucosal ulcers, increased goblet 
cells, abscesses, fissures and granuloma formation; see Figure 1.1 [7]. These chronic 
inflammatory lesions are proposed to develop due to a disrupted intestinal barrier, Paneth cell 
dysfunction and a disturbed innate immune response, resulting in the accumulation antigen-
presenting cells, such as dendritic cells and macrophages, lymphocytes and plasma cells 
within the intestinal mucosal layer [1, 8]. Pathological characteristics resemble the mucosal 
lesions and intestinal inflammation seen in response to classic enteric infection, with gut 
pathogen such as Shigella, Yersinia and Salmonella species (spp.) [9]. Whilst in UC, there is 
no inflammation beyond the submucosal level and inflammatory cells such as neutrophils are 
present in the lamina propria, with forming crypt abscesses and associated depletion of goblet 
cells (and mucins) from the epithelium is evident [10]. 
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Males and females are equally affected in CD and has  classically been described to have a 
bimodal incidence with the highest rates seen in adolescents and young adults and a second 
peak in later years[11, 12]. The CD concordance rate in monozygotic twins is estimated to be 
in the region of  20 to 50%, meanwhile in dizygotic twins, brought up in the same 
environment, it is  below 10% [13]. The concordance rate of UC in monozygotic twins has 
been reported at around 16% and that in dizygotic twins, around 4% [14].  When it comes to 
the epidemiology, CD is more common in Europe and North America than observed in 
Africa and Asia [15]. For example, CD affects more than 115,000 people in the UK [16], and 
the frequency of onset and relapse in IBD showed seasonality in CD with a peak in July and 
August, but this has not been established for UC [17]. However, incidence rate of CD is 
rapidly increasing worldwide particularly in developing and developed nations adopting a 
western-style diet [15], as seen in Japan [18]. Likewise, those emigrating from poor and 
developing nations to the West, within a few years of moving are at increased risk of 
developing CD presumably due to a key change in their lifestyle and environment [19]. 
Animal studies in support of this include experiments in mice which have established that 
maternal high-fat diet (HFD) and resultant obesity promotes the early onset of severe CD-like 
ileitis in genetically susceptible offspring [20]. CD is associated with very considerable 
morbidity, disrupting ability to work and study and family life, and also confers a small 
increase in mortality, with a standardised mortality ratio of 1.52 [21, 22]. Two meta-analyses 
also concluded that mortality in CD did not decrease over time, despite changes in patient 
management [21, 23]. Historically, nearly 80% of CD cases need surgery at some time during 
lifetime [24]. However, the use of immunosuppressants and biologics is associated with a 
reduction in risk of major surgery [25].  
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Figure 1.1 Crohn’s disease manifestations. 
(A) The appearance of intestinal mucosa of a healthy individual and a Crohn’s patient. (B) The diagram 
illustrates extraintestinal manifestations of Crohn’s disease, adapted from http://www.physio-
pedia.com/Crohn's_Disease (accessed 08-12-2016).  
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1.2 Factors involved in Crohn’s disease pathogenesis: 
1.2.1 Defective mucosal barrier function and alteration in the gut 
microbiota  
 
The intestinal epithelium, as well as it established absorptive and digestive functions, is an 
efficient barrier against encroachment of the resident commensal microbiota and 
opportunistic enteric gut pathogens. There are a number of contributing factors involved in 
mucosal defence including the mucus layer, intestinal peristalsis, innate antibacterial factors 
such as lactoferrin and lysozyme, and hydrophobic antibacterial peptides produced by Paneth 
cells present at the base (crypts) of the small intestine. The intestinal mucosa also possesses 
specific immunological protection strongly facilitated by secretion of immunoglobulin A 
(IgA) [26].  
 
Human gut microbiota plays an essential role in the shaping of the intestinal immune 
response in the healthy individuals [27]. Gut microbiome is established during the first 2 
weeks of life and usually remains stable thereafter [28]. All human gut microbiome consists 
of around 1150 species, and each individual hosts approximately 160 species in which 
anaerobes of the Firmicutes and Bacteriodetes phyla are predominant [29].  
 
In order to broaden insight into the pathogenesis of CD, multiple studies have been intensely 
carried out on CD intestinal microbiota over the last decade. Based on a number of previous 
human and animal experimental studies, the microbiota has been proposed to be involved in 
chronic inflammatory lesions formation particularly in two ways: first, a low-grade infection 
by a persistent pathogen, either traditional or opportunistic; and second, an imbalance 
between the beneficial commensals and the potentially harmful microbiota [30]. 
 
Results confirm a decrease in ‘protective’ bacterial phyla beneficial to gut health, including 
Firmicutes and Bacteriodetes (containing Gram-positive bacteria species) as compared to the 
microbiota of healthy controls, and the increase in abundance of Proteobacteria, including 
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potentially harmful Gram-negative intestinal bacteria, including Escherichia coli (E. coli) 
[31, 32]. E. coli which are known to be numerically dominant inhabitants of the healthy 
human gut microbiota and play an essential role for maintaining normal intestinal 
homeostasis and the stability of luminal microbiota via, for example involvement in 
synthesizing vitamin B and K as well as metabolizing bile acids [33]. However, there are 
virulent E. coli strains that are likely to cause a variety of intestinal and extra-intestinal 
diseases; this imbalance in the gut microbial population is referred to as 'dysbiosis'. Studies of 
faecal and gut mucosal-associated microbiota in patients with UC, demonstrated quantitative 
and qualitative changes in the composition, suggestive of dysbiosis [34-36]. 
 
Reduced diversity of other micro-organisms is also recently been described in IBD patients, 
including fungal microbiota (mycobiome) [37-39] and viruses (virome) [40, 41] and 
suggested to play a possible role in disease pathogenesis. 
 
The correlations between CD and dysbiosis have been established to be more clearly marked 
in the mucosal biopsies (mucosa–associated bacteria populations) than bacterial communities 
from the intestinal lumen (faecal samples) [42-46]. In addition, the significant shift of normal 
gut microbial community is associated with intestinal inflammation in both experimental 
colitis and human IBD [47]. Even though CD pathogenesis is still poorly understood and the 
exact aetiology is still unknown, there is clear evidence suggestive that a number of lifestyle 
factors contribute to the dysbiosis of gut microbiota, including environmental triggers such as 
smoking [48, 49], ‘adolescent’ diet (notably a ‘westernised’ diet, high in fat and refined 
sugar, low in intake of fruit and vegetable fibre [50, 51]. For example, recent studies  report 
that Western-style diet alters the microbiota composition within 1 day [52], and can result in  
increase in gut colonisation of a Crohn’s associated E. coli  in transgenic CEABAC10 mice, 
expressing human CEACAMs, including CEACAM6, a receptor for CD-mucosa-associated 
ileal E. coli strains [53]. A result from a meta-analysis study indicated that the intake of 
dietary fibre, particularly fruit fibre, was significantly associated with a decreased risk of 
inflammatory bowel disease [54, 55]. It was also reported that supplementation of some types 
of dietary fibre may prolong remission and reduce the intestinal mucosa lesions during the 
course of the disease [56]. Avoidance of fibre was found to be associated with a greater risk 
of CD flare within a period of 6 months [57]. In addition, other  studies , have revealed that 
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acute ileitis promotes dysbiosis, especially increased mucosa association of E. coli in mice, 
and colonic inflammation (colitis) induced in rats can drive dysbiosis and lead to barrier 
disruption of the intestinal mucosa [58, 59]. 
 
Smoking has been proven to increase the risk of CD development and is associated with a 
higher rate of recurrence post-operation for CD patients [60]. It has also been proven to play 
a role in the pathogenesis of CD in children who are exposed to passive smoking, [61]. 
Smoking alters the gut microbial community (dysbiosis) and also results in dysfunction of 
mucosal macrophages to handle gut pathogens [62, 63]. Conversely for UC, the protective 
effects of smoking are well described with a reduction in the relapse rate among smokers 
with UC [64, 65].  
 
Other key predisposing factors include genetic susceptibility (see section 1.2.2) and an 
inappropriate innate and adaptive immune host response have been proven as well to be 
implicated in increasing the susceptibility of the intestines to bacterial infection, chronic 
intestinal inflammation and consequently CD development (see Figure 1.2) [66].  A 
population-based cohort study from Denmark, demonstrated that individuals were at an 
increased risk of developing CD especially in those who had had previous gastrointestinal 
inflammation caused by Salmonella spp.[67].  
 
Taken together, primary gut infections by specific bacterial pathogens might lead to dysbiosis 
of gut microbiota, and also to a defective intestinal mucosal barrier function which are 
implicated in CD aetiology. However, more efforts and further investigations are required to 
identify what the principal origin driving dysbiosis is, and also to understand the mechanisms 
of how whether the recent exposure to gastrointestinal pathogens or chronic carriers of these 
pathogens are implicated in the predisposition of CD [68]. The ‘Hygiene hypothesis’ suggests 
that those individuals having reduced microbial exposure during childhood might lend them 
to an immune hypersensitivity response later in their lives when challenged with bacteria, 
including those involved in CD pathogenesis [69]. The effect of sex hormones on IBD 
pathogenesis is still largely unclear. However, a key in vivo study showed that female mice 
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are less sensitive to dextran sodium sulphate (DSS)-induced colitis and this protection was 
proposed to be conferred by oestradiol [70]. 
 
 
1.2.2 Immunological and genetic susceptibility factors in bacterial 
recognition, autophagy and phagocyte function 
 
The recent identification of genes associated with CD has been informative in improving our 
understanding of its pathogenesis, highlighting impairment of genetic components essential 
for innate immunity, intestinal barrier integrity and in microbial recognition and 
clearance[71] (see Figure 1.2). Following on from earlier work [72, 73], Genome-wide 
association studies (GWAS) have now identified 163 IBD risk loci, 30 of which are CD 
specific and 110 shared between UC and CD [74]. Many IBD loci are reported to be 
implicated in other immune-mediated disorders, including ankylosing spondylitis and 
psoriasis [74]. Key identified polymorphisms in the innate immune system of CD patients 
include genes that are linked to processes such as pathogen recognition [nucleotide-binding 
oligomerisation domain-containing-2 (NOD2)/Caspase-recruitment domain 15 (CARD15) 
and interleukin 23 receptor (IL23R)] and autophagy [immunity-related GTPase M (IRGM) 
and autophagy-related 16-like 1 (ATG16L1)], all relevant to killing of bacteria within 
macrophages [71-73]. 
CARD15 encoding the NOD2 receptor [75, 76]. Mutations in this gene probably account for 
about 15% of CD causation in the West although there are geographical variations with a 
lesser effect in northern European countries and no apparent impact on CD causation in Japan 
[77].  The NOD2/CARD15 protein is part of the innate immune system and is expressed in 
the cytoplasm of macrophages and Paneth cells [78]. CD-associated mutations in 
NOD2/CARD15 affect the leucine-rich domain recognising the bacterial cell wall 
peptidoglycan component, muramyl dipeptide (MDP), of both Gram-positive and Gram-
negative bacteria. After recognition, NOD2 activates nuclear factor kappa B (NF-κB) and 
induces the production and release of proinflammatory cytokines. Crohn’s-associated 
NOD2/CARD15 mutations are considered to be loss of function mutations with evidence for 
reduced production of anti-bacterial defensins by Paneth cells and for a reduced IL-8 
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response to MDP by macrophages [79].  In association with NOD2/CARD15 mutations, 
polymorphism in genes SLC22A4 and SLC22A5, encoding the organic cation transporters 
OCTN1 and OCTN2 have also been identified with variants expressed in intestinal epithelial 
cells, T cells and macrophages[80]. In addition, a mutation in two haplotypes of DLG5, 
encoding scaffolding protein, has also been confirmed to be associated with NOD2/CARD15 
mutations in CD patients [81].  
 
ATG16L1 and IRGM autophagy genes: Two key genes associated with CD are the 
autophagy genes Autophagy-related 16-like 1 (ATG16L1) and immunity-related GTPase M 
(IRGM) [82-84]. Both encode proteins that play a key role in facilitating disposal of protein 
aggregates, DNA, lipids and damaged organelles but also in the mechanistic events by which 
macrophages degrade, kill and clear invading phagocytosed bacteria (a process also termed 
‘xenophagy’), including pathogens such as Mycobacteria and Salmonella spp. [85-87].  
 
Other microbial handling/recognition genes: Additional CD susceptibility loci relevant to 
aberrant microbial recognition and handling and/or phagocyte function include toll-like 
receptor 4 (TLR4), leucine-rich repeat serine, threonine protein kinase-2 (LRRK2), neutrophil 
cytosolic factor-4 (NCF4) and IL-23R. TLR4 is an apical cell-surface pathogen recognition 
receptor on intestinal epithelial cells, macrophages and dendritic cells, key in detection of 
lipopolysaccharide (LPS) presented on the outer-membrane surface of Gram negative 
bacteria, with polymorphism of TLR4 at D299G leading to hypo-responsiveness to LPS [88]. 
LRRK2 has been linked to CD through the association of a single nucleotide polymorphism 
on chromosome 12q12 [73] and in murine studies where LRRK2-deficiency resulted in 
increased inflammation and significantly poorer clinical outcomes following administration 
of dextran sodium sulphate to induce colitis [89]. A Meta-analysis study showed that the 
T1237C polymorphism of the TLR9 gene is implicated in the susceptibility of IBD [90]. 
 
The identification of NCF4 as a CD susceptibility gene is also important  as it  encodes the 
p40-phox subunit of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase crucial 
for reactive oxygen species (ROS) production by phagocytic cells in response to microbial 
infection [83]. Similar molecular defect in NADPH oxidase had also been established to be 
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associated in chronic granulomatous disease [91, 92]. Key studies show that altered 
neutrophil recruitment, along with an abnormal production of cytokines and reduced bacterial 
clearance, follow either acute trauma to the rectum and ileum [93] or subcutaneous injection 
of heat-killed E. coli in CD patients [94]. The latter of these studies suggests that 
macrophages may be involved in a key step of the observed immune dysfunction in CD. 
However, it is not yet clear whether this represents an inherent defect in macrophage 
function. Variants of the IL-23R gene have also been linked to CD [95, 96]. IL-23R is 
expressed by activated dendritic cells and macrophages, and IL-23 can induce production of 
pro-inflammatory cytokines that may contribute to intestinal inflammation [97]. CD is 
defined as a T helper 1 (Th1)-mediated disease where there is abundant interferon gamma 
(IFN-γ) producing lymphocytes found within the inflamed gut of CD patients [98], also 
associated with elevated levels of IL-12, inducing Th1 cell differentiation in humans [99]. 
Further studies in mice also reported the key involvement of loss of anti-inflammatory IL-10 
in CD and UC pathogenesis [100, 101]. For example, Il-10-/- mice lacking Il-10 are observed 
to be colitis-free when were raised in a germ-free environment. However, when exposed to 
gut microbiota following transfer to specific pathogen-free conditions, a rapid development 
of chronic bacterial antigen-specific T-cell-mediated colitis resembling IBD was noticed, 
suggesting the importance of commensal intestinal bacteria in the pathogenesis of chronic, 
immune-mediated experimental colitis [102-104].  
 
The role of vitamin D in several immune related diseases, including IBD, has been 
established [105]. For example in a mouse model (Il-10-/- mice), vitamin D deficiency 
increased susceptibility to dextran sodium sulphate (DSS)-induced colitis, whereas dietary 
supplementation with active 1,25(OH)2 vitamin D3 ameliorated symptoms [106]. Vitamin D 
deficiency also predisposes to adherent, invasive E. coli (AIEC)-induced barrier dysfunction 
and experimental colonic injury [107]. Additional evidence supporting this comes from the 
study of Lagishetty et al. where elevated levels of colonic bacteria (~50-fold higher) were 
seen in colonic tissue of vitamin D deficient mice with DSS-induced colitis and reduced 
levels of anti-microbial peptides [108]. In addition, results of a cross-sectional study 
concluded an association between vitamin D deficiency/insufficiency and higher disease 
activity in IBD patients [109-111]. It is also reported that 70% of quiescent CD patients are 
deficient in vitamin D [112]. Vitamin D receptor (VDR) polymorphisms are also associated 
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with CD [113]. Treatment with vitamin D reduces the risk of clinical relapse in CD [114, 
115].  
 
 
 
 
 
Figure 1.2  A model for the development of Crohn’s disease. 
Multiple predisposing factors are proposed to impair the intestinal mucosal barrier and promote alteration in the 
gut microbiota, resulting in an increase in mucosal recruitment by of Enterobacteriaceae, especially adherent, 
invasive E. coli. Dysbiosis of gut microbiota may increase the susceptibility to infection or vice versa. 
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1.3 The role of specific bacteria in Crohn’s disease pathogenesis 
 
Increased luminal concentrations of Bacteroides spp., Eubacterium spp., Peptostreptococcus 
spp., and Coprococcus spp. were reported in CD patients [116]. Key early studies from 
France [117], Netherlands [118], and Germany [119, 120] all reported an increase in mucosa-
associated bacteria in CD. Listeria spp., and Streptococci, along with E. coli were also 
reported to play a role in the pathogenesis of CD [121]. 
 
There have been a number of distinctive studies that strongly favour the hypothesis that a 
specific bacterium plays a pivotal role in the initiation of chronic inflammation and 
development of CD. Early serological and culture studies suggested that Mycobacterium 
avium subspecies paratuberculosis (MAP), an obligate intracellular bacterium, causing a 
similar chronic inflammatory disease that primarily affect small intestine of cattle known as 
Johne’s disease, was more prevalent in CD patients [122-125]. A study by Ryan and 
colleagues [126] supports the idea of the presence of MAP DNA in granulomatous lesions of 
CD patients. MAP-reactive CD4 T cells have also been found in patients with CD [124, 127]. 
Even though, MAP has been hypothesised to be as contributing agent for CD pathogenesis, 
there is still great controversy, and absence of conclusive evidence, to fully supporting this 
hypothesis [128, 129]. However, a new study using better laboratory techniques proved the 
frequency detection of MAP in CD-patients which was significantly in greater proportion 
than in non-CD individuals [130]. 
 
Our own studies have suggested that microbial mannan (present in yeast cell wall and 
Mycobacterium species such as MAP) may be a key environmental factor to suppress 
macrophage killing of intracellular bacteria, including CD mucosa-associated E. coli, such as 
AIEC [131]. The shared susceptibility association of NOD2 and IL23R polymorphisms seen 
in both CD and Mycobacterial  disease (including leprosy) suggests MAP may yet be 
important in CD pathogenesis [132, 133].  
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Reduction in specific beneficial bacteria such as the Firmicute Faecalibacterium prausnitzii 
(F. prau), may also play an important role here. Low levels of F. prau are strongly associated 
with early disease recurrence after intestinal surgery in CD [43, 134]. This effect may be due 
to reduced production of bacterial anti-inflammatory molecules, with culture supernatants 
from F. prau shown to reduce the severity of colitis in animal models [43, 134].  
 
Enteric E. coli bacterium is a member of the natural microbiota that is present in gut of 
normal healthy individuals, but also can be an opportunistic gut pathogen that when acquired 
causing significant morbidity and mortality worldwide [135]. Early serological studies 
described high antibody titres against mucosa-associated E. coli in the biopsies obtained from 
both paediatric and adult patients with CD [136, 137], and this was later supported by 
immunohistochemical studies demonstrating E. coli antigens within macrophages in CD 
tissue [121]. Many groups, including our own, have shown an increased number of mucosa-
associated E. coli (including those with the AIEC phenotype) in CD, both in the ileum and in 
the colorectum [30, 117, 138-142]. We ourselves observed that aerobic culture of 
colonoscopic biopsies after removal of the mucus layer with dithiothreitol (DTT) is often 
sterile in the colon of control patients (irritable bowel syndrome (n = 13), sporadic polyposis 
(n = 4), piles (n = 3), diverticulitis (n = 2), pruritus ani (n = 1), and healthy (screening; n = 1),  
whereas the colon in CD and colon cancer contains increased bacterial numbers in this sub-
mucus niche, more than 50% of which were E. coli [139], even though these organisms only 
account for less than 1% of the faecal microbiota [28]. Poor correlation between site of 
inflammation and presence of E. coli [142], and tendency to show that the same organisms 
can be identified from various sites within the same colon [139, 143] are compatible with the 
organisms having a causative role in the inflammation rather than merely colonising inflamed 
intestinal mucosa. Evidence for a primary pathogenic role is also given by their presence 
within granulomas [144], the histological hallmark of CD, by their ability to induce 
granuloma formation in vitro [145] and ability for similar E. coli to cause granulomatous 
colitis in Boxer dogs [146], and potentially in cats and swine too [147]. This E. coli pathovar 
associated with CD has been designated AIEC based on their ability to adhere to, and invade 
into, intestinal epithelial cell-lines (differentiated Caco-2 and undifferentiated I-407 cell-
lines), induce release of pro-inflammatory cytokines, and possess an ability to survive and 
replicate within human peripheral blood monocyte-derived macrophages and within murine 
(J774-A1) macrophages [148, 149]. I-407 cell-line, of embryonic intestinal origin, is now 
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well documented to be contaminated with HeLa cells (originating from a cervical carcinoma), 
with other cell-lines derived from colorectal carcinomas, e.g. Caco-2 and HT-29, and the 
HEp-2 epithelial cell-line also documented as being HeLa cell contaminated [150]. 
Therefore, there is some significant doubt as to whether studies using some sources of these 
cell lines are indeed useful to understand mechanisms of CD pathogenesis (given their non-
intestinal, transformed or cancerous origin) and/or their use as a model for measuring the 
ability of enteric bacteria to adhere to, and to invade into, intestinal epithelial cells. 
 
ExPEC, belonging to the normal commensal gut microbiota of healthy individuals, are 
defined as facultative pathogens, having abilities to cause disease outside of the gut. Key 
examples include those strains from major subtypes such as Uropathogenic E. coli (UPEC), 
neonatal meningitis-associated E. coli (NMEC) and sepsis-causing E. coli (SEPEC) [151].  A 
study from Martinez et al., [152]  showed  only 4 out of 63 ExPEC isolates from different 
origins showed an AIEC phenotype suggesting little similarity between ExPEC and AIEC 
despite of the genetic similarities seen using multilocus sequence typing (MLST) [152], a 
technique used for typing of multiple loci of housekeeping genes [153]. 
 
According to the phylogenetic analysis, E. coli strains can be divided into four main 
phylogenic groups (A, B1, B2 and D) [154] although eight phylo-groups are now recognized: 
A, B1, B2, C, D, E, F and the eighth Escherichia cryptic clade I [155]. Most commensal E. 
coli strains belong to group A, and virulent (ExPEC) strains have been shown to mainly 
belong to B2 and D [156].  Mucosa-associated E. coli that were detected in high numbers in 
the mucosal biopsies of patients with CD and those from patients with ulcerative colitis, 
another inflammatory bowel disease, belong to B2 and D phylogenetic groups [142]. 
Nowrouzian et al. also showed that E. coli strains found mainly in the faeces of healthy 
individuals belong to phylogroup A and B1, while E. coli from the microbiota of the 
colorectal mucosae of 13 Swedish schoolgirls sampled in the 1970s (all found to have 
asymptomatic bacteriuria in a school-screening program) belong to B2 and D [157]. 
Genomes of four CD mucosa-associated AIEC strains, belonging to B2 group have been 
sequenced and published [9, 158-160], and novel virulence factors, including those encoding 
a type-6 secretion system, were detected in their genomes [9]. A recent comparative genomic 
analysis of AIEC and non-AIEC strains however did not identify a molecular property 
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exclusive to the AIEC phenotype and recommended that a broader approach to the 
identification of the bacteria-host interactions and its role in CD pathogenesis [161]. 
 
 
1.4 Crohn’s disease associated E. coli - host intestinal mucosa interactions  
 
Crohn’s E. coli phenotype AIEC colonise the intestinal epithelial cells via adhering to form 
biofilms over the intestinal mucosa and invade them via macropinocytosis-like process [162].  
17 out of 27 AIEC strains and only 9 out of 38 intestinal non-AIEC strains were biofilm 
producers [163]. In vitro studies have demonstrated the ‘paradigm’ ileal  AIEC strain  LF82  
is  able to translocate a number of human epithelial cell-lines, including HEp-2, intestine-407, 
Caco-2 and HCT-8 [164] other colonic AIEC strains, meanwhile, behaved similarly [30, 
139]. Aphthous ulcers of the “dome” or follicle-associated epithelium (FAE), overlying 
Peyer’s patches in the distal ileum and lymphoid follicles of the colon are likely the initial 
mucosal lesions occurring in CD patients [165-167], and have been observed in patients using 
magnifying chromoendoscopy [168]. The FAE effectively forms the interface between the 
intestinal lymphoid system and the luminal environment. Specialized microfold (M) cells, 
accounting for about 5% of cells in the FAE, are optimized for antigen adherence and 
transport, and for immunological sampling of microorganisms [169]. 
 
Several invasive bacteria take advantage of the transcytotic characteristics of M cells to cross 
the gut mucosal barrier, including Yersinia, Salmonella and Shigella spp. [170-173]. It was 
suspected that the portal of mucosal entry of CD AIEC was also likely through M cells [174] 
and recent studies successfully modelling M cells in vitro, demonstrated that CD AIEC could 
indeed translocate through M cells (up to 20-fold compared with parent Caco-2 cells) and 
through isolated human ileal FAE [175]. Adhesion and subsequent translocation of CD AIEC 
across murine and human ileal Peyer’s patches, and across M cells in vitro, was observed to 
be dependent on possession of the lpf operon, encoding long polar fimbriae (Lpf) in CD 
AIEC [176, 177]. In a recent study, the genomes of 8 phylogenetically diverse AIEC strains 
were sequenced. AIEC were distributed across different phylogroups, with enrichment seen 
in genes encoding propanediol utilization, iron acquisition and long-polar fimbriae. These 
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traits correlated with the ability of AIEC to utilize fucose and iron, invade epithelial cells, 
translocate across M-cells, and persist within macrophages. It was also identified from 
analysis of the lpfA sequences that there were two variants, distinguished in part by the 
position of the lpf operon, lpfA141 and lpfA154. The lpf141 operon of ileal E. coli encodes Lpf 
that exhibits high amino acid sequence similarity to enteropathogenic E. coli Lpf, whereas the 
lpf154 operon encodes Lpf exhibiting high amino acid sequence similarity to Stg fimbriae 
from avian pathogenic E. coli. Prevalence of lpfA154 was observed in 71% of human ileal 
AIEC examined, and demonstrated to promote translocation of AIEC across M-cells, with 
deletion of lpfA154 from a murine AIEC strain CUMT8 effecting significantly reduced M-cell 
translocation, which is consistent with previous studies showing translocation across M cells 
in vitro and ex-vivo Peyer’s patches of the lpfA141-expressing ileal CD-mucosa associated 
AIEC LF82 [178, 179]. Isolates expressing lpf have been found to be more prevalent in 
colonic mucosae of CD patients than that of non-IBD controls [180].  
 
Ex vivo studies also indicate a defective mucosal barrier to bacteria in the Peyer’s patches 
from CD patients [181, 182]. It is plausible therefore that increased bacterial load at M cells 
is important in the development of CD. A striking correlation also exists between the age-
related incidence of CD and the number of Peyer’s patches in the small bowel, the latter 
peaking in late adolescence and then falling away [12]. CD ileal AIEC strains also typically 
produce type-1 pili (FimH) on their surface supporting adherence to ileal enterocytes via 
interaction with Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) 
receptors known to be over expressed on the inflamed ileal (but not colonic) epithelium in 
CD [183].  Highly glycosylated CEACAMs have also been proposed as M cell microbial 
receptors [184]. It is plausible that one or more members of the CEACAM receptor family 
may play an important role in regulating endocytosis of CD mucosa-associated E. coli into 
host M cells. A recent study also reported that the glycoprotein 2 (GP2), specifically 
expressed on the apical plasma membrane of M cells among enterocytes, is recognized by 
FimH [185]. Mannose-derived FimH antagonists (such as biaryl or ‘two-ring’ mannosides) 
were reported to have promising therapeutic potential for UTI and CD, and also it was 
predicted that one or more FimH antagonists will be entering the clinic within the next two 
years [186]. 
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A recent study, [187] also reported that the glycoprotein 2 (GP2), specifically expressed on 
the apical plasma membrane of M cells among enterocytes, [188] is recognized by FimH, the 
adhesin of type 1 pili on bacteria. By an intriguing coincidence it has also been found that the 
same GP2 protein is the epitope for the “anti-pancreatic” antibody found in CD sera [189]. In 
addition, CD mucosally-associated AIEC outer-membrane vesicles (OMVs) also show ability 
to interact with enterocyte endoplasmic reticulum stress response glycoprotein 96 receptor, 
increased in expression on the inflamed intestinal epithelium [190]. These OMVs, in 
association with flagellin, also possess significant ability to evoke pro-inflammatory cytokine 
release [149]. Colonic mucosa-associated AIEC strains expressing aﬁmbrial adhesin afa 
operon, more commonly associated with diarrhoeagenic diffusely adherent E. coli (DAEC), 
have also been observed to be more prevalent in CD patients than in non-IBD controls. The 
presence of the afa operon correlates with diffuse adherence to, and invasion of intestinal 
epithelial cells [180]. A summary of Crohn’s AIEC host intestinal mucosal interactions is 
presented in Figure 1.3. CD mucosally-associated AIEC strains have also the ability to 
reduce the autophagy response inside intestinal epithelial cells by up-regulating levels of the 
microRNAs such as miR30C and miR130A [191]. Recently, an in vitro study reported that 
AIEC strain LF82 induces ROS production and mucin expression in intestinal epithelial T84 
cells [192].  
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Figure 1.3 Model for host intestine-ileal Crohn’s disease adherent, invasive E. coli interaction. 
Ileal Crohn’s disease-associated (CD) E. coli colonise and translocate intestinal epithelial cells via binding of 
type 1 fimbrial (FimH) adhesive protein expressed on the surface of CD AIEC with host CEACAM-6 receptors 
over expressed on the apical surface of inflamed ileal tissue epithelial cells. Also interaction via FimH occurs 
with GP2 receptors expressed on the apical surface of Microfold (M) cells overlying Peyer’s patches. In 
addition, interactions have been described via outer membrane vesicles (OMV) binding to GP96 stress response 
protein expressed on the surface of inflamed ileal epithelial cells in CD patients. CD AIEC, after translocation, 
are taken up by, and survive/replicate within mucosal macrophages and dendritic cells (DC). Their residence 
here might then support formation of granulomata, characteristic of CD mucosae. 
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1.5 Neutrophils and their role in CD pathogenesis 
 
Neutrophils are a type of polymorphonuclear leukocytes. They are professional, highly motile 
phagocytes involved in the first line of the innate immune defence against pathogenic 
microbes in healthy individuals and  several lines of evidence indicate that they are also 
involved in chronic inflammatory conditions and adaptive immune responses [193, 194].  
Neutrophils are typically the first leukocytes to be recruited to an inflammatory site and  their 
key strategies to kill invaded pathogenic microorganisms are phagocytosis,  release of soluble 
antimicrobials from their cytoplasm granules, including primary (azurophil), secondary 
(specific) and tertiary (gelatinase) granules, lysosomes [195], and generation of neutrophil 
extracellular traps (NETs) [196]. These killing strategies are activated via receptors that 
recognize bacterial peptides such as N-formyl-Met-Leu-Phe (f-MLP) or via pro-inflammatory 
mediators such as C5a and IL-8 [197, 198]. It is evident that neutrophils possess more rapid 
rates of phagocytosis and higher intensity of oxidative respiratory response than do 
macrophages [199]. 
 
In vitro, ileal AIEC LF82 has been shown survive and replicate inside human neutrophils, 
and also to induce interleukin-8 (IL-8) production from infected neutrophils. Up regulation of 
autophagy of infected-neutrophils enhanced intracellular killing of LF82 and limited the 
AIEC-induced inflammatory response. In other words, subversion of autophagy in LF82-
infected neutrophils induces inflammation and cell death [200]. In vivo studies in CD patients 
on the other hand  demonstrated a defect in neutrophil recruitment along, with an abnormal 
production of cytokines (including IL-8), following either acute trauma to the rectum and 
ileum [201], or subcutaneous injection of heat-killed E. coli (see Figure 1.4) [94]. Therefore, 
a defect of neutrophil chemotaxis has been suggested to be resultant of a reduced IL-8 
secretion from macrophages [202]. However, ex vivo studies reported chemotaxis of CD 
neutrophils is normal [203, 204], and also our recent lab studies on MDM obtained from CD 
patients and healthy controls (HC) infected with colonic mucosa-associated AIEC HM605, E. 
coli K-12 or Staphylococcus aureus Oxford strain revealed that no significant differences 
were observed in killing of these bacteria between CD (active and quiescent) and HC, nor any 
differences in production pro-inflammatory cytokines TNF, IL-6 and IL-8) between groups. 
In addition, E. coli- infected MDM from CD patients and HC showed equivalent ability to 
20 
 
induce neutrophil chemotaxis relative to unaffected controls [205]. Another key study 
however suggested a defect in functionality and in signal transduction activation of peripheral 
neutrophils from quiescent CD patients and a decrease in their trans-epithelial migration in 
vitro in response to IL-8 compared to healthy controls [206].  
 
 
 
 
 
 
Figure 1.4 Patients with Crohn’s disease (CD) exhibit reduced bacteria clearance of subcutaneously 
injected 32P-labelled heat-killed E. coli relative to healthy controls (HC) and patients with ulcerative 
colitis (UC). 
Reproduced with permission, © 2009 Rockefeller University Press. Originally published in Journal of 
Experimental Medicine 206:1883-1897. 
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1.6 Macrophages: Phagocytosis and Autophagy response mechanisms  
 
Macrophages are professional phagocytes, playing an important role in innate immunity 
showing phagocytotic activity against a wide range of pathogens, inducing synthesis and 
release of pro-inflammatory cytokines, although they are relatively less effective at bacterial 
killing than neutrophils [207-209]. Activated macrophages can crudely be classified into 
classically-activated macrophages (M1-macrophages), which are immune effectors against 
pathogenic bacteria associated with a large amount production of lymphokines, and 
alternatively activated macrophages (M2-macrophages), divided into four subgroups (2a, b, c 
and d) having a variety of functions, including immunity regulation, tissue repair and wound 
healing [210-212]. Monocytes and M1 macrophages in the lamina propria are found to invade 
intestinal tissues directly and are involved in disrupting the intestinal epithelial barrier 
through deregulation of tight junction proteins and induction of epithelial cell apoptosis (i.e. 
leading to chronic intestinal inflammation) [213]. Macrophages in UC mainly act within the 
intestinal mucosa, while in CD it can also be found within the muscularis and the mesenteric 
fat tissue compartments [213]. 
 
Within macrophages, pathogenic bacteria are killed and degraded by either phagocytosis or 
autophagy initiated by two distinct mechanisms, although having similarities in the last stages 
where the phagosomes and autosomes merge with lysosomes and mature to phagolysosomes 
and autolysosomes. Phagocytosis is defined as a process at which extracellular particles such 
as pathogens are engulfed and surrounded by a double membrane to form internal vesicles 
termed phagosomes as presented in Figure 1.5.  These phagosomes fuse with lysosomes to 
form mature phagolysosomes, in which their contents are degraded by ROS and proteolytic 
enzymes [209, 214]. ROS are chemically reactive molecules containing free oxygen radicals, 
including superoxide anions (O2
-), hydrogen peroxide (H2O2), and hydroxyl radicals (OH
-) 
produced within the intracellular compartment under aerobic conditions through the 
activation of multicomponent NADPH oxidase. ROS are cytotoxic to foreign cells and are 
essential in microbicidal process of monocytes [215, 216]. Although macrophages and 
neutrophils are phagocytes, there are differences between them in how they perform 
phagocytosis and also in the final outcome of the phagocytotic process [217].   
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Figure 1.5 Bacteria phagocytosis process. 
The phagocytosis process is initiated by the recognition of bacterium pathogen-associated molecular patterns 
(PAMPs) via membrane-bound pattern recognition receptors (PRRs) on phagocytes followed by bacteria 
engulfment into an intracellular vesicle called a phagosome. Phagosome-lysosome fusion then occurs to form a 
mature phagolysosome, followed by degradation of the bacterium. Degraded material is released by exocytosis. 
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Autophagy, or ”self-eating”, is a eukaryotic cellular process implicated in a range of 
physiological processes ranging from control of cell growth [218, 219], removal of old 
cellular structures and maintaining the intracellular nutritional homeostasis during starvation, 
and in contribution to type II programmed cell death [220]. Autophagy is also involved in 
inducing secretion of immune mediators [221], controlling adaptive immunity by inducing 
MHC class-II antigen presentation [222] and T-lymphocyte homeostasis [223], and in 
defence from cellular invasion by pathogenic bacteria, providing immune protection through 
targeted recognition and elimination of microbes such as Mycobacterium tuberculosis [85], 
group A Streptococcus and S. aureus  [224]. Autophagy in response to pathogens is typically 
referred to as ‘xenophagy’. Autophagy is initiated in response to stresses such as hypoxia, 
nutrient starvation, endoplasmic reticulum stress and infection [225, 226]. Engulfed bacteria 
trigger xenophagy via a number of different mechanisms including induction of nutrient 
starvation (i.e. competing for nutrients) and stimulation of the innate immune receptors, 
including membrane bound Toll-like receptors (TLRs), cytoplasmic receptors such as 
ATG16L1 and NOD2 and sequestosome 1-like receptors (SLRs) [86, 219, 227];  as briefly 
summarised in Figure 1.6.  
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Figure 1.6 Intracellular elimination of invading microorganisms by autophagy. 
Once a microorganism is engulfed by host cells, such as a macrophage, the autophagy machinery is activated by 
pathogens through one the following mechanisms: 1, nutrient starvation; 2, stimulating innate immune receptors 
via membrane bound pathogen-recognition receptors (PRRs) and sequestosome1-like receptors (SLRs). 
Pathogens trigger Toll-like receptors (TLRs) leading to activation of TNF receptor-associated factor 6 (TRAF6) 
or NADPH oxidase 2/ reactive oxygen species. (NOX2/ROS) mediated autophagy or microtubule-associated 
protein 1A/1B-light chain 3 (LC3)-associated phagocytosis (LAP). Cytoplasmic PRRs, triggered by pathogens 
include nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and autophagy-related protein 
16‑ like 1. (ATG16L1) receptors). Lysosomes mature to become autolysosomes, where intraphagolysosome 
materials are then degraded by either oxygen-dependent (production of ROS) or oxygen-independent 
(production of granules containing proteolytic enzymes) at the final stage of the autophagy process. Source of 
Figure adapted from [219]. 
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1.7 Defective autophagy and lack of clearance of Crohn’s disease mucosa-
associated AIEC 
 
ATG16L1 and IRGM function in autophagosome formation and evidence from recent studies 
supports a role for autophagy as an antimicrobial mechanism downstream of cell-surface 
TLR and cytosolic NOD-like receptor signalling. Activation of NOD2 by MDP induces 
autophagy in antigen-presenting cells (such as dendritic cells and macrophages) in a receptor-
interacting serine/threonine kinase-2 (RIPK-2) dependent manner [228]. Knock-down of 
ATG16L1 and IRGM mRNA using siRNA approaches resulted in defective recognition and 
clearance of CD mucosa-associated E. coli within host epithelial cells and macrophages [229, 
230]. However, deficiency in either gene did not interfere with the replication and survival 
ability of other non-pathogenic, environmental, commensal, or gastroenteritis-inducing E. 
coli, suggesting a specific role for autophagy in restraining Crohn’s AIEC. Similarly, 
expression of the CD variant ATG16L1*300A in intestinal Caco2 epithelial cells impairs their 
ability to capture internalized Salmonella spp. within autophagosomes [231] and is also 
associated with abnormalities in Paneth cell granule exocytosis [221], impaired production of 
antimicrobial α-defensins [232], and increased production of pro-inflammatory cytokines IL-
1β and IL-18 by macrophages in response to LPS [233]. In addition, Lapaquette and 
colleagues established that impaired expression of ATG16L1, IRGM or NOD2 lead to an 
increase of intra-macrophage CD AIEC, and was associated with an increase secretion of 
both IL-6 and TNF, while induction of autophagy lead to a decrease in AIEC 
intramacrophage survival and replication and in pro-inflammatory cytokine production. It 
seems that any impairment of autophagy leads to a defect in bacterial clearance associated 
with increased intra-cellular bacteria replication within phagocytes (illustrated in Figure 
1.7). Stimulating autophagic machinery in CD patients has therefore been postulated as a 
potential therapeutic approach to restrain the intra-macrophage CD AIEC replication and to 
reduce inflammation [234].  The anti-malarial drug chloroquine, for example, has been 
reported to enhance the late stage of autophagy, particularly fusion of autophagosomes with 
lysosomes [235], inhibiting intra-macrophage replication of Mycobacterium tuberculosis, and 
enhancing the anti-tuberculosis protectiveness of isoniazid and 25 OH-vitamin D3 [236]. 
However, stimulating autophagy with rapamycin, was reported to be ineffective particularly 
when intramacrophage replication of CD AIEC was well established [234]. 
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Figure 1.7 Impairment of autophagy leads to a defect in bacterial clearance associated with increased intra-cellular 
bacteria replication within phagocytes. 
Reproduced with permission from the author: Caprilli R. et al. J. Crohn’s Colitis 2010; 4,(4): 377-83[237] and 
by permission of Oxford University Press; License Number 3700681014379; Copyright (2010). 
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1.8 Virulence factors supporting ability of Crohn’s disease mucosa-
associated E. coli to survive within host macrophages 
 
AIEC strains obtained from CD ileal and colonic biopsy tissue demonstrate ability to, survive 
and replicate within phagolysosomes of macrophages [8, 149]; see Figure 1.8.  However, 
they are not unique in this ability as other pathogens are also known to survive and replicate 
within macrophages, including Mycobacteria, Salmonella, Shigella, Legionella, Coxiella, 
Brucella and Listeria species. Key adaptive defence mechanisms adopted by these pathogens 
support their resistance to killing within the low pH, low nutrient environment, high oxidative 
and nitrosative stress environment of the phagolysosome. Whilst Shigella and Listeria are 
able to escape from the mature phagolysosome, Salmonella spp. prevent fusion of phagosome 
with the lysosome, and Mycobacterium tuberculosis modify the intra-phagolysosome 
environment to support their survival respectively [238-241].  
 
Some of the virulence factors supporting survival and replication of AIEC within 
macrophages have been identified using isogenic mutants of the “paradigm” ileal AIEC 
LF82. Genes identified include htrA (encoding high temperature stress protein), dsbA 
(encoding an oxidoreductase) and hfq (encoding a RNA chaperone important in mediating 
bacterial adaptation to chemical stress) [242-244]. However, HtrA and DsbA are fairly 
ubiquitous in E. coli, and it is likely that other unidentified factors are needed to support 
Crohn’s AIEC survival within the stressful conditions of the phagolysosome. One recently 
identified factor is GipA. GipA deletion impairs Crohn’s AIEC translocation across M cells 
and their ability to replicate inside macrophages; their colonization of PPs and dissemination 
to mesenteric lymph nodes in mice was also impaired. GipA deletion also reduced lpfA 
mRNA levels in Crohn’s AIEC. GipA expression was also found to be induced by bile salts, 
intraphagolysosome reactive oxygen species and acidic pH conditions. In addition, survival 
of Crohn’s AIEC-ΔgipA bacteria was reduced in medium containing either H2O2 or acidic pH 
[245]. 
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Acid stress is the antimicrobial environment likely encountered by active enteric bacteria 
within the phagolysosome. Salmonella spp., Shigella spp. and E. coli have all been reported 
to possess a repertoire of low pH inducible systems that support resistance, tolerance and 
habituation during environmental acid stress. Likewise, Crohn’s AIEC certainly appear to be 
tolerant of the low pH intraphagolysosome environment [246].  E. coli is notable due to its 
possession of four known acid resistance systems. The first system requires sigma factor 
RpoS and the cyclic AMP  (cAMP) receptor protein CRP, with RpoS functioning as a major 
environmental stress response regulator in both E. coli and Salmonella spp. [246].  
 
Deletion of rpoS from a Crohn’s AIEC (strain O83:H1) has been observed to increase 
sensitivity of this clinical isolate to oxidative stress [247]. The second system requires 
extracellular glutamate. The components of glutamate-dependent acid response are two 
isoforms of glutamate decarboxylase encoded by gadA and gadB, and a glutamate-γ-
aminobutyric acid antiporter encoded by gadC [248, 249]. Murine intestinal commensal E. 
coli have been observed to respond to chronic intestinal inflammation by up-regulating 
expression of stress response genes such as gadA and gadB [250].  Proven to be essential as 
regulators of gad stress response gene expression are gadE and gadX [251]. The third acid 
resistance system requires is arginine-dependent utilising of arginine decarboxylase (AdiA 
and AdiC) antiporter [246] and the fourth is lysine dependent, involving lysine decarboxylase 
[249]. In addition, E. coli also harbour specific mechanisms that enable them to resist high 
levels of reactive oxygen species (ROS) that form the oxidative and superoxidative to 
phagocytosed pathogens. These defensive resources have been found to be grouped into two 
regulated sets of genes designated as soxRS and oxyR regulons [252, 253]. E. coli SOS 
system is a network regulating the expression of more than 40 genes which is activated to 
rescue cells from severe DNA damage by physical and chemical factors, including ROS. 
Based on a knock-out study, E. coli SOS genes dinf was reported to protect against oxidative 
stress, although the exact nature of the DinF activity remains to be identified [254, 255]. 
Despite of all these fundamental pieces of knowledge on the virulence genes of Crohn’s-
associated E. coli strains, genetic factors that are characteristic of AIEC phenotypes are still 
required to be studied. 
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Figure 1.8 Transmission electron micrograph of adherent, invasive E. coli within macrophages. 
A: Crohn’s disease colonic mucosa-associated isolate HM605surviving and replicating within vesicles of J774-
A1 murine macrophages; B: Double membrane around intra-macrophage vesicle indicates bacteria are 
contained within phagolysosomes (solid arrow). Images courtesy of Dr. Carol L. Roberts (University of 
Liverpool, United Kingdom). 
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1.9 Current therapeutic approaches for CD and the potential for future 
treatment via targeting intra-macrophage Crohn’s disease mucosa-
associated AIEC 
 
Superficial mucosal lesions in Crohn’s patients are likely to heal, while deep ulcers and 
fissures heal with more difficulty and may lead to the development of fibrotic strictures. 
When the lesions are extensive, CD becomes symptomatic associated with local 
complications such as dilatation, perforation, haemorrhage, abscess and fistula along with 
fibrosis and stricture formations [3]. Smoking cessation was found to be beneficial in patients 
with CD [256], which has been suggested to be as a result of the recovery of immune cell 
function. However, this has not been studied on CD patients [257]. The main goals of 
gastroenterologists, during treatment of CD patients, are first to induce remission and second 
to prevent relapse by either surgery or drugs. However, the ideal therapy that should reduce 
inflammation without inducing immunosuppression remains a challenge.  
 
Current treatment approaches:  
Patients with active CD are routinely treated with immune suppressing drugs such as 
corticosteroids (prednisolone), thiopurines (azathioprine, mercaptopurine) and anti-TNF 
antibody (infliximab and adalimumab) [258]. The use of 5-aminosalicylic acid (5-ASA) 
drugs, including Sulfasalazine and Mesalazine in CD is still controversial and studies 
evaluating their efficacy have produced mixed results [259-261]. According to a recent 
network meta-analysis study, the most effective therapies for induction and maintenance of 
remission of Crohn's disease are adalimumab (ADA) and infliximab+ azathioprine (AZA) 
[262]. It has been reported that biologic therapies had higher durability for induction and 
maintenance therapy than immunomodulators [263]. It is recently reported that ADA 
response in Crohn’s patients is genetically predisposed by a Single Nucleotide Polymorphism 
(SNPs) in CD-associated genes and found ATG16L1 as the most promising candidate gene 
for adalimumab response [264]. Using a polymerase chain reaction-denaturing gradient gel 
electrophoresis (PCR-DGGE) of 16S rRNA gene fragments and quantitative PCR, 
respectively in colonic mucosal biopsies from 15 CD patients compared with 4 healthy 
subjects, treatment with ADA was reported to induce short-term changes in the microbiota 
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with those phyla recovering after treatment including beneficial Firmicutes, and a decrease in 
the prevalence of Proteobacteria, such as E. coli [265].  
 
Monoclonal anti-TNF antibodies used in CD have limitations including increased risk of side 
effects such as reactivation of hepatitis and granulomatous disease (tuberculosis), and bone 
marrow suppression, and long-term complications such as risks of malignancies [266, 267]. 
Since, TNF inhibitors are not useful for one third of all patients,  other strategies have 
recently been developed such as monoclonal antibodies targeting the interleukin (IL)-6 
receptors, which are expected to hold greater promise to be helpful in the future  [268].   
 
Surgical resection of an isolated inflamed ileal segment in adolescents with active CD is very 
effective, leading to a clinical improvement (symptom relief) and a reduction in medication 
requirements [269]. However, the recurrence of CD was  observed approximately in 80% of 
cases after ileal resection surgery of the  inflamed part  and the recurrence was mostly 
occurred in ileal part which was proximal to the anastomosis with the large intestine, 
suggesting  that the recurrence is more likely to be dependent on the proximity to the large 
bowel contents where the bacteria niches are abundant [270].  Identifying the risk factors for 
postoperative CD recurrence will be beneficial in order to assist the clinician in implementing 
more aggressive prophylactic treatment to sustain remission and to prevent recurrence.   
 
Further meta-analysis of six randomised placebo-controlled clinical trials showed that the use 
of antibiotics, including ciprofloxacin, metronidazole and co-trimoxazole in these patients are 
highly likely to induce remission in patients with active CD, and  patients who received 
antibacterial therapy were clinically improved compared with CD patients who received only 
placebo [271, 272]. Another clinical trial demonstrated CD endoscopic recurrence was at a 
high rate following 1 year surgery, but after CD patients received metronidazole or 
ornidazole antibiotics, the post-operative endoscopic recurrence was reduced [273]. However, 
a recent meta-analysis failed to provide any benefit for the use of antibiotics in maintaining 
remission period, and also in the treatment of active intraluminal and perianal disease [274]. 
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Some probiotic microorganisms such as E. coli Nissle 1917 might have  positive effects on 
maintaining remission of IBD, particularly UC [275, 276], and this probably occurs due to 
bacterial competition [277, 278], and they may be effective in maintaining remission period 
in postoperative prophylaxis [279]. However, a number of studies on  children  have shown 
antibiotic exposure in children, mainly at age ≤ 3 months, is a significant risk factor for 
development of CD [280, 281], and a 4-year prospective study established  that most patients 
with IBD, received antibiotic treatment  demonstrate a more severe clinical course [282].  
 
Therapeutic targeting of intra-macrophage Crohn’s disease mucosa-associated AIEC: 
The hypothesis of the implication of AIEC in the pathogenesis of CD was supported by 
clinical and experimental data. Therefore, this bacterium is considered to be as a potential 
target in the treatment of Crohn’s patients using antibiotics [149]. It shows killing of 
intramacrophage E. coli in vitro. However, ileal CD AIEC has been observed to manifest 
resistance to a range of antibiotics, including ciprofloxacin, rifampicin, clarithromycin, 
tetracycline, and trimethoprim/sulfamethoxazole, plus 42% of ileal Crohn’s AIEC are 
categorised as Multidrug-resistant (MDR) [283].  
 
A study investigating CD patients, having an active ileal lesion, with circulating antibodies 
directed against E. coli and Pseudomonas fluorescens, reported that these patients had a 
higher response rate to budesonide in combination with metronidazole and ciprofloxacin 
compared to those patients without circulating anti-bacterial antibodies [284]. The most 
appropriate target for use of antibiotics in CD patients is proposed as being those intra-
macrophage replicating CD AIEC. However, antibiotic treatment for active CD is still 
thought to be non-beneficial, although there is evidence supporting the use of antibiotics to 
prevent post-operative recurrence of CD [273, 285]. In addition, studies on both human and 
animal  clinical isolates indicate that antimicrobial resistance is common in E. coli associated 
with CD and granulomatous colitis, and that resistance to antibiotics such as ciprofloxacin 
and enroﬂoxacin may correlate to poor clinical outcome of disease [283, 286, 287]. 
Administration of a triple antibiotic regimen has been recommended to avoid the antibiotic 
resistance which proved to reduce intra-macrophage survival of CD AIEC to 3% compared to 
untreated controls. Antibiotics that were able to enter macrophages, including azithromycin, 
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ciprofloxacin, rifampicin, sulfamethoxazole, tetracycline and trimethoprim were all effective 
against CD AIEC surviving and replicating within the macrophage phagolysosome, while  
antibiotics that are unable to penetrate macrophages are considered to be ineffective [149]. 
However, due to drug to drug interactions/side effects that may occur  between some class of 
antibiotics and azathioprine (an immunosuppressant regularly used to treat CD patients with 
active disease), other alternative strategies using agents to manipulate the intra-
phagolysosome environment have been explored since CD AIEC are known to be dependent 
on an acidic environment for their survival [242]. This suggests that alkalinisation of the 
intra-phagolysosome would perhaps reduce Crohn’s AIEC survival within macrophages. For 
example, hydroxychloroquine, a weak base with the ability to increase phagolysosome pH, is 
reported to improve intra-macrophage killing of bacteria with an intra-phagolysomal life-
style such as Coxiella burnetii, causing Q-fever [288] and Tropheryma whipplei, causing 
Whipple's disease  [289, 290] . In this context, recent research studies in our own lab revealed 
that hydroxychloroquine directly reduced survival and replication of intra-macrophage AIEC 
and enhanced the efficacy of antibiotics (such as Doxycycline and Ciprofloxacin) to kill 
intra-macrophage Crohn’s AIEC [205]. A recent study on the use of species-specific 
antibiotics termed colicins for treatment of CD-associated AIEC reported that the ability of 
colicins E1 and E9 to kill intra-phagolysosome AIEC in RAW264.7 macrophages, and no 
toxicity was observed toward macrophage cells, indicating the potential of colicins as 
therapeutics for the eradication of E. coli from the gastrointestinal tract of CD disease 
patients [291]. The corticosteroid dexamethasone has been found to promote phagocytosis 
and enhance killing of Staphylococcus aureus inside human monocytes/macrophages in vitro 
[292].   
 
Vitamin D deficiency is common in approximately 70% of CD patients in the either active or 
quiescent phase of disease [112, 293]. A retrospective study where 3217 CD  patients with a 
low requirement for surgery, showed higher levels of vitamin D at which 30ng/ml was 
considered as a cut off [294]. There was a reduction in the risk of relapse following patients 
with quiescent CD given vitamin D supplements [115]. Vitamin D (1, 25 OH2-vitamin D3) 
supplementation also enhanced killing process of intra-macrophage CD AIEC in both murine 
and human macrophage phagolysosomes [205].  However, there is no data yet, proving the 
effects of vitamin D on in vivo macrophage CD AIEC interactions. Several individual studies 
recently verified alterations in the composition of intestinal microbiota in CD patients and the 
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role of abnormal intestinal microbiota in CD pathogenesis. Faecal microbiota transplantation 
(FMT), which was successfully tested in recurrent Clostridium difficile infections [295], has 
been established as a promising therapeutic option for CD via modifying microbiota, 
restoring the balance of intestinal flora and reversing the inappropriate immune stimulation 
make intestinal ecosystem less suitable for intestinal E. coli colonization [296-298].  FMT 
has recently been reported to  improve the quality of life in IBD patients [299]. The efficacy 
of exclusive enteral nutrition (EEN) for CD via (A) down regulation of inflammatory 
cytokines production, (B) reduction of intestinal permeability, and (C) modulating the 
intestinal microbiome have been also established [300-303]. Nutritional supplementation is 
essential for CD patients with evidence of malnutrition and it may help in maintaining 
remission [304]. Whether FMT, EEN and nutritional supplements alter macrophage function 
to support killing intra-macrophage Crohn’s AIEC is as yet undetermined. 
  
 
1.10 Hypothesis and aims:  
 
1.10.1 Hypothesis 
 
Key additional molecular mechanisms are likely to be involved in supporting Crohn’s disease 
(CD) mucosa-associated AIEC to resist killing by host mucosal macrophages, and that these 
mechanism support their ability to survive and replicate within the low pH, low nutrient, high 
oxidative and nitrosative stress environment of the phagolysosome. 
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1.10.2 Aims 
 
In this study, our main targets were to:  
1. Assess and validate the ability of CD mucosally-associated E. coli to survive and 
replicate inside macrophages compared with other E. coli strains, including clinical 
isolates from colorectal cancer and ulcerative colitis patients.  
 
2. To understand the role of host NF-κB pathway activation in supporting intra-
macrophage replication of CD AIEC.  
 
3. Investigate whether CD mucosally-associated E. coli can tolerate and grow in low pH, 
low nutrient, high nitrosative and high superoxidative stress conditions, mimicking 
the harsh environment within an active macrophage phagolysosome.  
 
4. Identify bacterial molecular mechanisms underlying tolerance of CD AIEC surviving 
and replicating within the phagolysosome.  
 
5. To assess whether CD AIEC possess ability to alter host oxidative stress response 
gene expression in macrophages.  
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Chapter 2  
 
Materials and Methods 
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2.1 Bacterial strains and their culture conditions 
2.1.1  Bacterial strains 
 
The heterogeneous population of bacterial strains used throughout this study are:  
1) Ileal CD E. coli isolates 
Ileal Crohn’s disease (CD) E. coli strains LF10, LF11, LF13, LF82* and LF86, isolated from 
inflamed lesions of clinically active Crohn’s patients were kindly provided by the late 
Professor Arlette Darfeuille-Michaud (Pathogénie Bactérienne Intestinale, Laboratoire de 
Bactériologie, Université d'Auvergne, Clermont-Ferrand, France) [243]. An additional ileal 
CD strain, 541-15A*, was obtained from Professor Kenneth Simpson, Cornell University, 
College of Veterinary Medicine, Ithaca NY, USA) [178, 305]. 
 
2) Colonic CD E. coli isolates 
Colonic CD strains were previously isolated from colonic biopsy tissue specimens of CD 
patients in the remission with either a history of active ileal inflammation, ileo-colonic 
disease or colonic inflammation alone [139]. The latter bacteria strains designated as HM 
were isolated from patients attending the Royal Liverpool University Hospital by Dr. Helen 
Martin; Gastroenterology Research Unit, University of Liverpool, Liverpool, UK [139]. 
  
Table 2.1 Sources of colonic CD E. coli isolates. 
HM95*, HM96, HM104, HM413* and 
HM419*  
 
Isolated from non-inflamed colonic tissues of 
Crohn’s patients in the remission with a 
history of active ileal inflammation 
HM427* Obtained from non-inflamed colon tissues of 
Crohn’s patients who previously had ileo-
colonic inflammation 
HM154*, HM580*, HM605* and HM615*   Isolated from inflamed colon tissues of 
Crohn’s patients 
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3) Ulcerative colitis E. coli isolates 
Ulcerative colitis E. coli strains HM233, HM250, HM378, HM394 and HM457* isolated 
from the inflamed colon tissues of clinically active UC patients and HM464 from colon 
tissues of UC patients during remission period.  
 
4) Colorectal cancer (CRC) E. coli isolate 
CRC E. coli strains HM229, HM230, HM244, HM358*, HM312, HM44*, and HM374, 
isolated from colon mucosa of patients with colon cancer [139].  
 
Note - for all IBD (CD and UC) and CRC isolates detailed above, those indicated with an 
asterisk (*) indicates that they are adherent, invasive E. coli (AIEC) as per the definition 
defined by Darfeuille-Michaud A in 2001 [148], i.e. that they adhere to, and invade into, 
intestinal epithelial cell-lines (differentiated Caco-2 and undifferentiated I-407), induce 
release of pro-inflammatory cytokines, and possess an ability to survive and replicate within 
human and murine macrophages [148]. 
 
5) Other E. coli clinical isolates 
E. coli strains ECOR40, ECOR48, ECOR50 and ECOR64 (ECOR48 and 64 from patients 
with acute cystitis, and ECOR40 and 50 with acute pyelonephritis) provided by the STEC 
Centre, Department of Microbiology and Molecular Genetics, Michigan State University 
(MSU), USA. E. coli strains SJH2, J96 and CP9 obtained from patients with urinary tract 
infection, termed Uropathogenic Escherichia coli (UPEC), were obtained from Professor 
Craig Winstanley (Department of Clinical Infection, Microbiology and Immunology, Institute 
of Global Health & Infection, University of Liverpool, UK) and Dr Alison O'Brien 
(Department of Microbiology and Immunology, Uniformed Services University of the Health 
Sciences, Bethesda MD USA) [306], E. coli strains obtained from healthy individuals 
ECOR1, ECOR35, healthy individuals with IBS [HM484 (AIEC) and HM488 (AIEC)] with 
sporadic polyposis [HM428 (AIEC), HM454 (AIEC) and HM456 (AIEC)] and with piles 
[HM463 (AIEC)], and from a healthy infant ECOR51.  
 
Probiotic E. coli Nissle 1917 (EcN) was a kind gift to the department from Dr. C. Enders 
(Ardeypharm; Herdecke, Germany). E. coli K-12, i.e E. coli (Migula) Castellani and 
Chalmers ATCC® Number 10798, was obtained from the American Type Culture Collection 
(LGC Standards; Middlesex, UK) with E. coli XL-1Blue obtained from Agilent Technologies 
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(Santa Clara, USA) and E. coli K-12 derivative (EPI300-T1) from Epicentre (Madison, 
USA). 
 
6) Other bacteria 
Salmonella enterica serovar Typhimurium (S. Typhimurium) strains LT2 and 4/74 were a 
kind gift to the department from Professor Craig Winstanley (Clinical Infection, 
Microbiology and Immunology, University of Liverpool, UK). 
 
 
2.1.2  Bacterial storage and culture 
 
All studied bacteria strains were stored in Protect micro-preservation beads in a -80oC 
freezer, with routine working stocks kept at -20oC and grown on Luria Bertani (LB) agar 
plates for 24 h in the incubator at 37°C and 5% v/v CO2 atmosphere. LB agar plates (pH 7) 
were made by mixing of 10g Bacto-tryptone, 5g Bacto-yeast extract, 5g NaCl, and 15g agar 
in a litre of distilled water and then autoclaving for sterilization, followed by pouring the 
sterile LB agar into sterile Petri dishes. 
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2.2 Murine macrophage J774-A1 cell-line culture 
 
Obtained from the European Collection of Animal Cell Culture (ECACC catalogue number 
91051511; Porton Down; United Kingdom), murine macrophage-like cell line J774-A1 
(taken from ascites or reticulum cell sarcoma of a female mouse;) was maintained in Roswell 
Park Memorial Institute (RPMI) 1640 medium (supplied by Sigma-Aldrich, Poole, UK) 
supplemented with 10% v/v foetal calf serum (FCS) (Gibco; Paisley, Scotland), 100 U/ml 
penicillin (Sigma), 100 µg/ml streptomycin (Sigma), and 4mM L-glutamine (Sigma), within 
75 cm2tissue culture flasks (Appleton Woods Limited; Birmingham, UK) in the incubator at 
37°C in a humidified atmosphere of 95% v/v air and 5% v/v CO2. J774-A1 cells were grown 
to 80% confluency and gently passaged using cell scrapers (Corning®; Chorges, France); see 
Figure 2.1. Macrophages were routinely passaged twice weekly and used in experiments at 
passage numbers between 8 and 20, with cells counted using a glass haemocytometer. In 
order to replenish the stock cultures to the cryobank, 80% confluent J774-A1 cells were 
aliquoted into cryo-vials in freezing media containing 90% v/v FCS and 10% v/v dimethyl 
sulphoxide (DMSO).  
For experiments, J774A1 macrophages were routinely seeded to 24-well tissue culture plates 
at a density of 1x105 cells per well (see section 2.7). 
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Figure 2.1 J774-A1 macrophage cell line at 80% confluency (48h post seeding; Magnification x20) cultured 
in RPMI medium. 
The morphology of our macrophage cultures was representative of those images seen on-line 
http://www.pheculturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=91051511&collecti
on=ecacc_gc (accessed 08-12-2016). 
  
Macrophage cell line (J774-A1)
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2.3 Generation of high yields of healthy bone marrow-derived 
macrophages (BMDM) from murine wild-type, Nf-κb and c-Rel deficient 
bone marrow (BM) cells 
 
Femurs from mice as follows: Wild-type mouse C57BL/6 (n=2♂, n=2♀); mice deficient in 
NF-κB1 (Nfκb1-/-; n=1♂, n=3♀), mice deficient in NF-κB2 (Nfκb2-/-; n=2♂) and those 
deficient in c-Rel (c-Rel-/-; n=3♀ were kindly provided by Dr. Carrie Duckworth and Dr. 
Ahmed Elramli, Henry Wellcome Laboratories of Molecular & Cellular Gastroenterology, 
University of Liverpool, UK). Wild-type C57BL/6 mice supplied by Charles River (Margate, 
UK), and transgenic strains on a C57BL/6 background, including Nfĸb1−/− and Nfĸb2−/− mice 
[307, 308] and c-Rel-/- mice [309] were maintained at the University of Liverpool’s specific 
pathogen-free (SPF) Biomedical Services animal Unit. Bone marrow from Il-1r-/-, Il-18r-/- 
and Myd88-/- (on a C57Bl/6 background) were a kind gift from by Dr. Stuart Marshall-Clarke 
(Human Cell Biology & Anatomy, University of Liverpool, UK), with the Myd88-/- mice 
originally provided with the generous permission of Prof Shizuo. Akira (Osaka University, 
Japan) [310].  
High yields of healthy bone marrow-derived macrophages were obtained following 
adaptation of the method of Manzanero et al. [307, 311]. All femurs were first soaked in 70% 
v/v ethanol inside a Petri dish for disinfection. After 3 to 5 min, bones were rinsed off ethanol 
via placing them into a Petri dish containing sterile PBS, pH 7.3 (Life Technologies; Paisley, 
UK). Both bone ends were carefully trimmed with sterile scissors in order to expose bone 
marrow shaft and a needle was then inserted through a cut made at the top ends with sterile 
scissors, followed by flushing BM with 5 ml per bone of RPMI 1640 medium into a sterile 
tube. After centrifugation (250 g for 5 min), supernatants were removed and pellets of BM 
progenitor cells (at cell density ranging from 1.4 to 2.5 x 106 cells/ml) were resuspended in 
RPMI 1640 medium supplemented with 10% v/v foetal calf serum, 4mM L-glutamine. The 
steps of this procedure are briefly summarised in Figure 2.2. BM progenitor cells could then 
either stored in liquid nitrogen cell bank in freezing media (90% v/v FCS and 10% v/v 
dimethyl sulphoxide (DMSO) for future experimentation, or differentiated to adherent 
macrophages following addition of purified recombinant Mouse Macrophage Colony 
Stimulating Factor (rM-CSF) from PeproTech EC Ltd. (London, UK). For the latter, BM 
cells were placed into 12-well cell culture plates and volume adjusted up to 10 ml per dish 
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with medium supplemented with rM-CSF, followed by incubation at 37°C, in a humidified 
incubator of 95% v/v air and 5% v/v CO2 for 6 d. Using BM progenitor cells from C57Bl/6 
and Nfkb2-/- mice, initial concentrations of rM-CSF ranging from 50-100 ng/ml were 
examined for ability to effect differentiation of, and proliferation and survival of, 
macrophages (see Figure 2.3 and Figure 2.4). A concentration of 100 ng/ml rM-CSF 
showed greater activity and this level was selected therefore to differentiate BM progenitor 
cells from all other wild-type and knockout mouse strains (see Figure 2.5). After incubation, 
media containing the non-adherent, non-differentiated BM cells were discarded. Adherent 
differentiated macrophage cells (elongated in morphology) were washed twice with 5 ml 
sterile PBS, scraped and resuspended in a further 10 ml (5 ml per femur) medium 
supplemented with rM-CSF followed by seeding cells into 24-well plates (i.e. placing 1 ml of 
medium containing cells into each well) and then incubating for overnight prior to infection; 
see section 2.7 for detail of the intra-macrophage replication assay. For more information and 
details on the growth and differentiation of murine BM cells into macrophages, see [311].  
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Figure 2.2 The main steps of preparation of Bone Marrow (BM) cells. 
(1) The femur is first disinfected and then the both ends of the femur are trimmed (2) BM is then flushed using a 
30 gauge needle coupled to a one  ml syringe into a 50mL Falcon tube. (3) After centrifugation (at 250 g for 5 
min), BM cell pellets were resuspended in 10 ml RPMI 1640 medium supplemented with rM-CSF and (4) 
placed into a 10mL Petri dish for culture at 37oC, 95%/5% v/v air/CO2. Adapted from 
http://dx.doi.org/10.14440/jbm.2014.12 (accessed 08-12-2016). Permission sought from authors and publisher. 
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Figure 2.3 Frozen Bone marrow (BM) cells from a wild-type C57BL/6 mouse differentiate into 
macrophages.  
Representative images at magnification x20 of a wild-type mouse (C57BL/6) BM cells differentiated into 
macrophages on day 3 (left hand panel) and day 6 (right hand panel).  
  
C57BL/6 Day 3 C57BL/6 Day 6
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Figure 2.4 Comparative images illustrating morphological features of Nf-κb2 knock-out bone marrow 
(BM) progenitor cells at different rM-CSF concentrations. 
BM progenitor cells were cultured for 6 days in RMPI 1640 medium at rM-CSF concentration of 50 ng/ml (left 
hand panel) compared to those cultured in 100 ng/ml (right hand panel). The differentiation levels (conversion) 
of BM progenitor cells into macrophages are higher at r-MCSF concentration of 100 ng/ml. 
 
 
 
 
 
 
 
 
 
Nfkb2-/- Day 6 (rM-CSF 50ng) Nfkb2-/- Day 6 (rM-CSF 100ng)
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Figure 2.5 Morphology of differentiated BM-derived macrophages from Nf-κb1 (A), Nf-κb2 (B) and c-Rel 
(C) knock-out mice at days 1, 2 and 6 post recombinant mouse colony stimulating factor (rM-CSF) 
treatment.(Panel A). 
Representative images (Magnification x20) illustrate the morphology of BM progenitor cells from (A) Nf-κb1-/- 
(B) Nf-κb2-/-  and (C) c-Rel-/-  mice following1, 2 and 6 days of culture in RPMI 1640 medium supplemented 
with 100 ng/ml of rM-CSF. On day 1, BM progenitor cells are small in size with a defined cell-membrane, 
while adherent differentiated macrophages with branched and extended morphology are clearly visible from day 
3 onwards. 
 
  
Nfkb1-/- Day 1 Nfkb1-/- Day 3
Nfkb1-/- Day 6
A
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Figure 2.5 (Continued): Morphology of differentiated BM-derived macrophages from Nf-κb1 (A), Nf-κb2 
(B) and c-Rel (C) knock-out mice at days 1, 2 and 6 post recombinant mouse colony stimulating factor 
(rM-CSF) treatment.(Panel B) 
Representative images (Magnification x20) illustrate the morphology of BM progenitor cells from (A) Nf-κb1-/- 
(B) Nf-κb2-/-  and (C) c-Rel-/-  mice following1, 2 and 6 days of culture in RPMI 1640 medium supplemented 
with 100 ng/ml of rM-CSF. On day 1, BM progenitor cells are small in size with a defined cell-membrane, 
while adherent differentiated macrophages with branched and extended morphology are clearly visible from day 
3 onwards. 
 
  
Nfkb2-/- Day 1 Nfkb2-/- Day 3
Nfkb2-/- Day 6
B
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Figure 2.5 (Continued): Morphology of differentiated BM-derived macrophages from Nf-κb1 (A), Nf-κb2 
(B) and c-Rel (C) knock-out mice at days 1, 2 and 6 post recombinant mouse colony stimulating factor 
(rM-CSF) treatment. (Panel C). 
Representative images (Magnification x20) illustrate the morphology of BM progenitor cells from (A) Nf-κb1-/- 
(B) Nf-κb2-/-  and (C) c-Rel-/-  mice following1, 2 and 6 days of culture in RPMI 1640 medium supplemented 
with 100 ng/ml of rM-CSF. On day 1, BM progenitor cells are small in size with a defined cell-membrane, 
while adherent differentiated macrophages with branched and extended morphology are clearly visible from day 
3 onwards. 
  
c-Rel-/- Day 1 c-Rel-/- Day 3
c-Rel-/- Day 6
C
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2.4 Generation of BMDM from a variety of genes knock out BM cells 
 
Frozen BM cells from Il-1r-/-, Il-18r-/- and Myd88-/- mice underwent the same growth 
conditions and period of incubation as mentioned above to differentiate them to mature 
adherent macrophages (Figure 2.6). Myeloid differentiation primary response gene 88 
(Myd88) is an adapter protein, used by almost all TLRs (except TLR3) to activate the 
transcription factor NF-κB [312].  
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Figure 2.6 Frozen BM cells from Il-1r-/-, Il-18r-/-, Myd88-/-mice well differentiate into macrophages. 
Representative images (Magnification x20) illustrate the morphology of BM progenitor cells from (A) Il-1r -/- 
(B) Il-18r.-/- and (C) Myd88.-/-  mice after 6 days of culture in RPMI 1640 medium supplemented with 100 ng/ml 
of rM-CSF. Differentiated macrophages with branched and extended morphology are clearly visible. 
Il-1r-/- Day 6A
Il-18r-/- Day 6B
Myd88-/- Day 6C
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2.5 Verification of successful murine BM monocyte differentiation into 
mature macrophages 
 
F4/80 antigen is a mature mouse cell surface glycoprotein expressed at high levels on various 
macrophages including: Kupffer cells, splenic red pulp macrophages, microglia, macrophages 
of the gut lamina propria, and Langerhans cells in the skin [313]. This antigen is also 
expressed on the macrophages within connective tissue, heart, kidney, and those within the 
reproductive and neuroendocrine systems. F4/80 antigen has been established as one of the 
most important antigens used to identify mature mouse macrophages (macrophage marker) 
[313]. Expression levels of F4/80 are frequently used to estimate the maturation of 
macrophage cells [314].  
 
BM cells were first incubated for 6 days in Petri dishes. Cells were then transferred to 12 well 
cell cultures plates on to sterile 13mm glass cover-slips for 24h.Culture medium was then 
removed and replaced with 10% formalin. Following incubation for 30 min at room 
temperature, formalin was replaced with ice-cold 100% methanol and the culture plate was 
incubated for 5-10 min at a -20oC freezer. Methanol was removed and wells washed three 
times with sterile PBS. To block non-specific antibody binding, 10% w/v Bovine Serum 
Albumin (BSA) (Sigma) was applied to the cells for 1h at room temperature. The cells were 
then incubated overnight with primary antibody; F4/80/EMR1 antibody (CI-A3-1; catalogue 
number NB600-404; Novus Europe; Abingdon, United Kingdom) at dilution 1:100. The 
following day, the cells were again washed three times with PBS and the secondary antibody 
(anti-mouse Ig antibody; Vectashield Antifade Mounting Medium with DAPI; VECTOR 
Laboratories Ltd.; Peterborough, UK) as then applied to cells and the plate was incubated for 
an hour at room temperature. After washing with PBS, pre-prepared diaminobenzidine 
(DAB)-substrate solution [Two DAB tablets (Sigma) added to 5 ml distilled water] was 
applied to cells for 5-10 min at room temperature. Cells were then viewed after washing with 
sterile PBS. For more details regarding the F4/80 primary antibody please see the 
manufacturer’s datasheet; see http://ww.novusbio.com/NB600-404 (accessed 08-12-2016). 
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2.6 Intramacrophage replication assay 
 
Survival and replication abilities of CD E. coli strains, compared to other clinical E. coli 
isolates and to S. Typhimurium strains, within J774-A1 murine macrophage cell line were 
assessed by gentamicin protection assay, as previously described [131, 149, 205]. Replication 
assessment of ileal and colonic Crohn’s disease mucosa-associated E. coli strains LF82 and 
HM605 was also performed in wild-type bone marrow-derived macrophages (BMDM) and 
within macrophages derived from the BM of Nfκb1-/-, Nfκb2-/- and c-Rel-/- mice.  
 
All macrophages tested were seeded onto two 24-well tissue culture plates at a density of 
1x105 cells per well, , and incubated for 24 h at 37°C in atmosphere of 5% CO2 . Macrophage 
monolayers were infected in triplicate at multiplicity of infection (MOI) of 10 with a number 
of E. coli strains obtained from biopsies of CD, UC and CRC patients, those with UTI, from 
healthy individuals, and non-pathogenic laboratory E. coli strains. Before infection, these 
bacterial strains were resuspended in sterile PBS to the required optical density (OD) for each 
strain defining a bacteria cell count of 1 x 109 bacteria/ml; see Figure 2.7. In order to allow 
macrophages to phagocytose bacteria, infected cells were incubated for 2 h. After incubation, 
the media were removed and infected macrophages were washed with sterile PBS. One 
millilitre of pre-warmed medium, containing gentamicin (20 µg/ml) in order to kill 
extracellular bacteria was added into each well. The first 24-well plate was then incubated for 
1h, the second meanwhile for 3h to allow those resident intracellular bacteria to either 
replicate or be killed by the macrophage. After washing, cells with sterile PBS, 1 ml 1% v/v 
Triton X-100 (Sigma) in deionized water was added for 5 min to lyse cells. Ten-fold serial 
dilutions of the cell lysates were performed followed by plating of 50 µl of each, starting 
from 102 fold dilution of cell lysates down to 104, on standard Luria broth (LB) agar plates 
(four plates per dilution step). After 24 h incubation at 37°C, bacterial colonies were 
enumerated as colony forming units (CFU). In order to measure the relative replication of 
bacteria strains, CFU at 6h post-infection were compared with CFU at 3h post-infection. 
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Figure 2.7 Bacteria growth calibration curve. 
Representative bacterial growth curve to support E .coli enumeration; by comparison colony forming unit (CFU) 
counts per millilitre (CFU/ml) established by overnight culture on LB agar relative to  optical density (OD600nm) 
reading of the same bacterial suspension. Each value represents the mean ± standard error of the mean (SEM). 
This calibration curve was used to identify the required reading at OD600nm, containing the target number of 
working stock bacteria (1x109 CFU/ml),  OD of 0.9 [n=3]. This curve is representative for the colonic mucosa-
associated CD AIEC HM605. 
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2.7 Assessment of the phagocytic abilities of BMDM from knock-out strains 
of mice 
 
Phagocytosis of Nfκb1-/-, Nfκb2-/-, c-Rel-/-, Il-1r-/- , Il-18r-/-and  Myd88-/- BMDM were studied 
with an assay that detected internalization of Fluorescently-labelled heat-killed Escherichia 
coli K-12 strain BioParticles®, Alexa Fluor® 488 conjugate (Catalogue number E-13231; 
Life Technologies; Paisley, UK) at different time points (3, 6 and 24h post-infection) by 
fluorescence microscopy (Olympus bx51 microscope; images were taken by AQM software 
(Kinetic Imaging) and adjusted by AJ imaging software) C57BL/6 BMDM was used as a 
control. To maintain conditions in the standard intra-macrophage replication assays only, 
following addition of the K-12 BioParticles for 1h, a further 2h incubation in media 
containing gentamicin (20 µg/ml) was performed. Fluorescence of E. coli K-12 BioParticles 
conjugates bound to the macrophage cell surface was quenched with 0.4% w/v Trypan blue 
(Sigma) before imaging. For further information on Alexa Fluor® 488 conjugated 
Escherichia coli K-12 strain BioParticles®, visit 
http://ww.lifetechnologies.com/order/catalog/product/V6694 (accessed 08-12-2016).  
 
 
2.8 Bacteria growth curve in standard nutrient media at differing pH 
 
Overnight bacteria cultures were harvested and washed three times with sterile PBS, and then 
resuspended at an optical density (OD600nm) = 0.1 in RPMI  1640 medium without phenol red 
(Life Technologies). A 2 mL sample was placed into a cuvette tube and OD at wavelength 
600nm was measured hourly using a GeneQuant Pro UV/VIS Spectrophotometer, DNA/RNA 
Calculator (Amersham BioSciences; Piscataway NJ, USA). This was performed using 
standard RPMI medium at pH 7 and at pH 5 (titration using 1M HCl and then 0.2µm sterile 
filtered). 
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2.9 Bacteria survival and growth in acidic nutrient-poor M9 medium 
 
At early exponential growth phase (OD600=0.1), bacteria were resuspended in a differing pH, 
ranging from 4 to 7, nutrient-poor (Minimal salts/Minimal microbial growth M9) medium 
(Life Technologies) supplemented with 100mM Bis-Tris (Sigma), 0.1% w/v Casamino Acids 
(MP Biomedicals; Loughborough Leicester, UK), 0.16% v/v glycerol (Sigma) and 10µM 
magnesium chloride (Sigma), each essential compounds for bacteria to grow. OD at 
wavelength 600nm of each bacterial suspension was subsequently measured hourly at time 
points 0 to 8h by spectrophotometer. 
 
 
2.10 Low pH, high nitrosative and high oxidative stress tests on solid 
growth media  
 
At OD600=0.1, bacteria underwent ten-fold serial dilution steps. 20 µl from each dilution was 
placed, in triplicate, into five LB agar plates, containing one of the following stress agents: 
100 mM 4-Morpholine ethanesulfonic acid (MES) (Sigma) pH 5.0, 100 mM MES pH 5.0 + 1 
mM sodium nitrite (NaNO2) (Sigma), 1 mM methyl viologen (MV) (Sigma) pH 7.0, 1 mM 
hydrogen peroxide (H2O2) (Sigma) pH 7.0, and a plain LB agar at pH 7.0 was used as a 
control. Plates were then subjected to the incubator for overnight incubation at 37°C 
(Summarised in Figure 2.8). This method as per [244]. 
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Figure 2.8 A diagram summarising the main steps of performing bacteria stress tolerance tests. 
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2.11 RNA extraction and cDNA synthesis of intra-macrophage E. coli 
strains besides those grown in acidic M9 media  
 
Using the RNeasy Mini Kit (Qiagen; Ltd, Crawley, UK), bacterial RNA was extracted from 
Crohn’s AIEC strain HM605, and laboratory E. coli strains (EPI300, XL-1Blue and K-12) 
cultured in acidic (pH 4.5) M9 media at 6h time point of their growth curve. In additional 
separate experiments, RNA from was isolated from AIEC HM605 and EPI300 inside J774-
A1 macrophages post 3h and 6h infection.  
 
Bacteria cells were lysed by adding 350 µl of RLT lysis buffer (Qiagen) to each bacterial 
pellet and mixed by pipetting up and down, followed by vortexing and centrifugation at full 
speed (Hawk 15/05 microcentrifuge, with rotor radius of 75 mm) in a 2ml Qia-shredder tube 
(Sigma) for 2 min. One volume of 70% v/v ethanol was added to the lysate and mixed by 
pipetting. A 700µl aliquot of each sample was then transferred into RNeasy Mini spin 
columns (RSC) placed in a 2 ml collection tube and centrifuged ≥8000 rpm (centrifuge as 
above) for 15 seconds. After discarding the flow-through, 700µl buffer RW1 was added to 
the RCS and samples again centrifuged for a further 15 seconds. The flow-through was 
discarded and 500µl buffer RPE was then added to the RCS followed again by 15 seconds 
centrifugation. After discarding flow-through, another 500 µl buffer RPE was again added to 
the RCS and centrifuged for 2 min, again at ≥8000 rpm. The RCS was placed in 1.5 
collection tube and 45µl RNase-free water was directly added to centre of the RCS, and 
centrifuged at ≥8000 rpm for 1 min to elute the extracted RNA. A NanoDrop Lite 
Spectrophotometer (Thermo Fisher Scientific, USA) was used to quantify the eluted RNA 
(with concentrations routinely obtain ranging from 50 to 100 ng/µl). Complementary DNA 
(cDNA) at concentration ranging from 2-2.5 µg/µl was synthesised from the sample RNA 
using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics Ltd., Burgess Hill, 
UK) was initiated by adding the all components presented in the following Table 2.2. The 
reaction tube was then incubated at 25ºC in a bench heating block for 10 min, then at 55ºC 
for a further 30 min, followed by heating to 85ºC for 5 min to inactivate Transcriptor Reverse 
Transcriptase. The sample was then cooled on ice for 5 min. The cDNA was stored at -20ºC 
freezer for use in subsequent qRT-PCR experiments.  
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Table 2.2 Components for setting up a single reverse transcription reaction. 
 
 
  
Component Volume
Sample RNA
Final concentration
2.5 µM
2 µl
1 µl
Anchord-oligo(dt)18 
primer, 50pmol/µl
Water, PCR-grade 10 µl
Transcriptor Reverse 
Transcriptase Reaction 
Buffer, 5x concentration
4 µl 1 x
Protector Rnase 
Inhibitor, 40 U/µl
0.5 µl 20 U
Deoxynucleotide Mix 2 µl 1 mM
Transcriptor Reverse 
Transcriptase,20 U/µl
0.5 µl 10 U
Final volume 20 µl
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2.12 Quantitative real time polymerase chain reaction analysis (qRT-PCR) 
for assessment of bacteria stress genes supporting acid tolerance 
 
Quantitative RT-PCR was performed in order to quantify the expression levels of stress 
response genes of the Glutamic acid decarboxylase operon (gad) system, used for tolerance to 
an acidic environment, by E. coli strains EPI300, K-12, XL-1Blue and CD AIEC HM605 
grown in an acidic (pH 4.5) low nutrient (M9) growth medium and those within the 
phagolysosome of J774-A1 macrophages. After reverse transcription of extracted RNA from 
bacteria, 5 µl of the cDNA template was added into each well of the Light Cycler® 480 
Multiwell plate, containing 15 µl of PCR mix (Roche Diagnostics Ltd., UK) prepared by 
mixing 10 µl Light Cycler® 480 Sybr Green I Master with 2 µl primers, listed in Table 2.3, 
which are real-time oligonucleotide primers designed by Eurogentec (Southampton, UK), in a 
final volume (3 µl) of water, PCR- grade. In each experiment, 5µl of water PCR-grade was 
added into PCR mix regarded as no template control (NTC). As a training test to fulfil our 
curiosity, a PCR mix was prepared by adding 2 µl of uidA primers into 2 µl Taqman probe 
(200nM), 10 µl Light cycler® 480 probe master mix and 2 µl water, PCR-grade and then 5 µl 
of each dilution from the fivefold serial dilutions (1:5) of E. coli K-12 cDNA templates were 
added to the PCR mix in the multiwell plate. Multiwell plates were sealed and then 
centrifuged at 1500 g (Sorvall Heraeus, Multifuge 3S-R, rotor radius 145 mm) for 2 min. 
Using the Light Cycler® 480 Instrument, multiwell plate was loaded and afterwards run with 
conditions as per the manufacturer’s instructions (Light Cycler® 480 Sybr Green I Master, 
Roche): 95 °C for 5 min then 45 cycles of 95 °C for 10 sec and 60 °C for 20 sec followed by 
72°C for 30 seconds and then cooling step of 40 °C for 10 sec. The specificity of 
amplification was confirmed by melting curve analysis.  All reactions were run in duplicate. 
Threshold cycle (Cp) for each well was automatically defined by the real time cycler 
software. 
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Table 2.3 Oligonucleotide primers used in this study to measure gadA and gadB expression by qPCR. 
 
 
Primer sequences taken from Smith et al.[315] 
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2.13 RT2 Profiler PCR Array to quantify host macrophage oxidative stress 
response genes in response to E. coli infection  
 
The Qiagen/SABiosciences RT2 Profiler PCR Array (Catalogue Number 330231 PAMM-
065ZA, Qiagen Ltd, Crawley, UK) was used to quantify the level of 84 oxidative stress genes 
expressed from J774-A1 macrophages post 6h infection with Crohn’s AIEC HM605, LF82 
and laboratory E. coli strain EPI300 (see Table 2.4). RNA of these infected cells was 
extracted using RNeasy, Mini Kit (Qiagen), followed by cDNA synthesis using RT2 First 
Strand Kit (Catalogue Number 330401; Qiagen). An aliquot (91 μl) of RNase-free water was 
then added into each sample cDNA. The cDNA concentration of all samples was ranging 
from 168 to 309 ng/µl, see Table 2.5. 
 
RT2 PCR components mix was prepared in a 5 ml tube as described in Table 2.6. Since the 
PCR Array plate already contains primers, 25 μl PCR components mix was then dispensed to 
each well of the RT2 Profiler PCR Array plate using an 8-channel pipette. The plate was 
carefully sealed and centrifuged for 1 min at 1500 g in a Sorvall Heraeus Multifuge 3S-R, 
rotor radius 145 mm) for 2 min. RT2 Profiler PCR Array plate was placed in Light Cycler 480 
and the PCR cycling program was set up according to Table 2.7.  The Cp values for all wells 
were exported to Excel files and uploaded on 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php (accessed 08-12-2016) 
for analysis. 
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Table 2.4 RT2 PCR Oxidative stress profiler array gene list (Mouse). 
 
Antioxidants 
Glutathione Peroxidases (GPx): Gpx1, Gpx2, Gpx3, Gpx4, Gpx5, Gpx6, Gpx7, Gstk1, Gstp1. 
Peroxiredoxins (TPx): Ehd2, Prdx1, Prdx2, Prdx3, Prdx4, Prdx5, Prdx6 (Aop2). 
Other peroxidases: Apc, Cat, Ctsb, Duox1, Epx, Lpo, Mpo, Ptgs1 (COX1), Ptgs2 (COX2), Rag2, Serpinb1b, Tpo. 
Other Antioxidants: Alb, Gsr, Sod1, Sod3, Srxn1, Txnrd1, Txnrd2, Txnrd3. 
Reactive Oxygen Species (ROS) Metabolism 
Superoxide Dismutases (SOD): Sod1, Sod2, Sod3. 
Superoxide Metabolism Genes: Ccs, Cyba, Ncf1, Ncf2, Nos2  (iNOS), Nox1, Nox4, Noxa1, Noxo1, Recql4, Scd1, Ucp2. 
Other Reactive Oxygen Species (ROS) Metabolism Genes: Aox1, Fmo2, Il19, Il22. 
Oxidative Stress Responsive Genes:  
Als2, Apoe, Cat, Ccl5 (RANTES), Ctsb, Duox1, Epx, Ercc2 (XPD), Ercc6, Fth1, Gclc,Gclm, Gpx1, Gpx2, Gpx3, Gpx4, G
px5, Gpx6, Gpx7, Gsr, Gss, Hmox1, Hspa1a (hsp70A1), Idh1, Krt1, Mpo, Nqo1, Park7,Prdx1, Prdx2, Prdx6 (Aop2), Prnp
, Psmb5, Sod1, Sqstm1, Tpo, Txn1, Txnip, Txnrd1, Txnrd2, Ucp3, Xpa. 
Oxygen Transporters 
Atr, Cygb, Dnm2, Fancc, Ift172, Mb, Ngb, Slc38a1, Vim. 
 
https://www.qiagen.com/gb/shop/pcr/primer-sets/rt2-profiler-pcr-arrays/?catno=PAMM-
065Z#geneglobe (accessed 08-12-2016). 
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Table 2.5 cDNA concentration of J774-A1 at 6h post infection. 
 
 
 
 
Table 2.6 RT2 PCR component mix. 
 
 
 
Table 2.7 Cycling conditions for Roche Light Cycler 480. 
 
 
 
  
J774-A1macrophages Uninfected EPI300 HM605
Sample 1 179 ng/µl 309 ng/µl 195 ng/µl
Sample 2 208 ng/µl 170 ng/µl 168 ng/µl
Sample 3 180 ng/µl 302 ng/µl 206 ng/µl
Array Format 96-well
RT2 SYBR Green Mastermix (2x) 1350µl
cDNA reaction 102µl
RNase free water 1248µl
Total volume 2700µl
Procedure Cycles Duration Temperature (oc)
Pre-incubation 1 10 min 95
Amplification 45 15 sec
1 min
95
60
Melt Curve 1 95
Cooling 1 1 min 30
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2.14 Data analysis 
 
All data sets presented in this thesis are expressed as mean ± SEM unless otherwise stated, 
where N is the total number of individual experiments (or mice) and n is the number of 
sample replicates.  Independent sample groups were assessed for normality by Shapiro-Wilk 
test. Equality of sample variances were analysed by Levene’s test. Following this, statistical 
comparisons of normally distributed data sets were performed by one way analysis of 
variance (ANOVA) followed by Dunnett’s post-hoc test to make pair-wise comparisons of 
treatment means to untreated/uninfected controls (StatsDirect version 2.6.2; Sale, United 
Kingdom). This included comparisons of survival and fold replications of CD E. coli strains 
compared to treatment with a non-replicating control E. coli EPI300 (i.e. for the intra-
macrophage replication assays), and also comparisons of the survival/growth of IBD and 
non-IBD E. coli strains under various chemical stress conditions compared to unstressed 
control conditions. Differences were considered significant when P<0.05. Where appropriate, 
non-parametric correlation coefficient (Spearman’s rank) analysis was used to assess for any 
association between % bacterial growth in stress conditions and ability to replicate inside 
murine macrophages. 
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Chapter 3  
  
Investigating the ability of E. coli strains from various diseases to replicate 
inside murine macrophages 
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3.1 Introduction  
 
Several studies examined gut microbiota in the inflamed and non-inflamed segments of CD 
and UC, and established a significant reduction in the biodiversity of faecal and mucosa-
associated microbiome in IBD patients compared with those healthy controls [66], reported 
that a relative decrease of Firmicutes and Bacteriodetes phyla, and an increase of 
Proteobacteria, particularly the family Enterobacteriaceae (including species such as E. coli) 
in CD, while in UC,  there is reduction in Clostridium spp. and an increase in E. coli [316], 
see Introduction, section 1.2.1. Mucus, coating the healthy intestine is discontinuous in the 
small intestine and continuous in the colorectum, consisting of two layers: the outer of which 
is a loosely adherent layer which contains/is inhabited by commensal bacteria representative 
of the faecal stream and an inner tightly adherent layer which is normally sterile, as is the 
sub-mucus niche, so as to protect the epithelium. Mucosa-associated E. coli (including the 
phenotype AIEC) have been found in increased number in the ileal and colonic mucosae 
(including the inner adherent mucus layer) of CD patients [30, 36, 317, 318] and to a lesser  
extent patients with UC [119, 142] and colorectal cancer (CRC) [139, 143]. AIEC phenotype 
has been found to represent 9.3%, 3.7% and 3.1% of E. coli population obtained from ileal, 
ileo-colonic and colonic biopsies of CD patients [319]. In addition, clear experimental 
evidence has been provided for the causal role of gut bacterial dysbiosis in chronic ileal 
inflammation development (Crohn's disease-like ileitis) [320].  
 
A number of independent studies have reported that intra-mucosal E. coli or mucosa-
associated E. coli isolated from CD patients possess invasive properties. For example, in vitro 
studies on paradigm CD AIEC strains from the ileum, LF82, and from the colon, HM605 
[117, 138, 139] showed they possessed the ability to translocate and replicate within both 
murine and human monocyte-derived macrophages (HMDM) [8, 305, 321, 322].  Electron 
microscopy, in addition, validated the ability of Crohn’s strains LF82 and HM605 replication 
inside vacuoles/phagolysosome [8, 131, 305, 321]. Interestingly, AIEC strains were isolated 
from the mucosa of healthy subjects and found to be more abundant in the ileum than the 
colonic mucosal biopsies [30]. Supported by the fact that AIEC strains have been isolated 
from healthy individuals, they are probably better defined as pathobionts (disease-causing 
organisms that live as symbionts under circumstances of normal gut health) [138, 283]. 
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Despite all the advances that have been made in the last decade, more knowledge on AIEC 
pathogenesis and that regarding AIEC-macrophage interactions are still required, including 
whether AIEC are involved in the aetiology of CD and/or the mechanisms/environmental 
triggers that determine their increased presence in high numbers the inflamed mucosae of CD 
patients. Understanding the mechanisms of AIEC-host macrophage interactions in the 
pathogenesis of CD may provide key insight into CD pathogenesis and enable to develop 
different therapeutic strategies, based on the killing/clearance of this CD mucosa-associated 
pathovar. Here, we aimed, as an initial step, to assess and compare the survival and 
replication abilities of a number of CD, UC and CRC mucosally-associated E. coli strains, 
pathogenic E. coli strains isolated from patients with urinary tract infection (UTI), non-
pathogenic E. coli strains isolated from healthy individuals, and non-pathogenic laboratory E. 
coli strains within murine macrophages in vitro using a gentamicin protection assay (see 
Materials & Methods; section 2.6). This would likely shed light on the best paradigmatic E. 
coli strains representing each disease to be singled for further studies. Some of these studied 
E. coli strains isolated from CD, UC and CRC, meet the criteria of being designated as AIEC 
phenotype [148], including the following examples: CD (HM95, HM605 and HM615, and 
LF82), UC (HM457), and CRC (HM44 and HM358). For a full listing, see Materials & 
Methods, section 2.1.1. For all other E. coli strains, their origin/source is known, but their 
phenotype is not well established, i.e. they have not be examined to determine as to whether 
they can be designated as AIEC or non-AIEC. Crohn’s AIEC strains, during the later phase 
of murine macrophage infection, induce chronic activation of NF-κB, which correlates with 
increased TNF-α secretion [323]. AIEC replication within macrophages is suggested to be 
dependent on TNF-α secretion [8, 149, 324]. In addition, how intra-macrophage replicating 
Crohn’s AIEC strains HM605 and LF82 behave within murine BMDM from various Nfκb  
family member knockout mice, including the classical pathway Nfκb1-/- (p105→p50) and c-
Rel-/- (p65) and alternative pathway Nfκb2-/- (p100→p52) was examined [325]. Phagocytosis 
of these BMDMs from mice with immune response-related gene deletions (e.g., Il-1r-/-, Il-
18r-/- and the TLR adaptor Myd88-/-) was also examined. 
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3.2 Crohn’s disease mucosa-associated AIEC HM605 shows greater ability 
to survive and replicate inside macrophages compared to other E. coli  
 
Determination of fold replication of bacteria within murine J774-A1 macrophages showed 
that the paradigm Crohn’s disease (CD) mucosa-associated ileal isolate LF82 significantly 
survived and replicated within macrophages (4.056 ± 1.16-fold [mean ± SD]) compared to a 
non-adherent, non-invasive laboratory strain E. coli K-12 derivative EPI300 (0.83 ± 0.42); 
P<0.05; n=3, ANOVA. Similarly, and to a greater extent, the two paradigm CD mucosa-
associated colonic E. coli isolates HM615 (4.87 ± 1.06-fold; p<0.01) and HM605 (8.97 ± 
0.67-fold increase; p<0.0001) also showed significant survival and replication within 
macrophages (see Figure 3.1).  
 
 
Figure 3.1  Intramacrophage survival and replication of paradigm Crohn’s disease mucosa-associated 
AIEC. 
Increased replication of Crohn’s disease mucosa-associated AIEC ileal isolate LF82, and two colonic isolates 
HM615 and HM605 compared with the reference non-pathogenic E. coli K-12 derivative strain EPI300 within 
J774-A1 murine macrophages. Results are expressed as the relative number of intracellular bacteria at 6h post 
infection relative to that obtained after 3h post infection (i.e. bacteria fold replication). Each value represents the 
mean ± standard error of the mean (SEM) of three independent experiments (N=3) with 3 replicates undertaken 
(n=3). Differences in survival and replication of each AIEC were statistically significant. *P ≤ 0.05, **P ≤ 0.01, 
and ****P ≤ 0.0001 respectively; ANOVA with Dunnett’s post-hoc test compared to the reference laboratory E. 
coli strain EPI300.  
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The gentamicin exclusion assay, using J774-A1 macrophages, was further expanded to 
compare the paradigm CD AIEC strains with other E. coli from various conditions (including 
additional E. coli strains from CD, mucosally-associated isolates from UC patients, CRC 
patients, UTI isolates and those from the non-inflamed intestine of healthy individuals.  
Overall, Crohn’s disease (ileal and colonic) mucosa-associated E. coli strains showed 
significantly greater ability to survive and replicate within J774-A1 murine macrophages 
compared to E. coli isolates from healthy individuals and patients with UC, CRC and those 
with a UTI ; see Figure 3.2. Comparison of intra-macrophage survival and replication inside 
J774-A1 macrophages of individual strains to that observed with CD AIEC HM605 (10.18 ± 
1.82-fold [mean ± SD]; N=6, n=3) and non-pathogenic EPI300 (0.51 ± 0.16–fold; N=6, n=3) 
were as follows:  CD colonic E. coli isolates HM95 (3.68 ± 0.54-fold) and HM413 (3.7 6± 
0.27-fold) and ileal isolate LF86 (4.54 ± 0.43- fold) and LF82 (4.06 ± 1.16-fold) replicated 
significantly better than CD E. coli HM427 (1.07 ± 0.28-fold), HM96 (1.19 ± 0.20-fold) and 
HM104 (0.94 ± 0.15-fold); N=1-3, n=3; see Figure 3.2. 
 
Non-pathogenic laboratory E. coli strains, including the reference strain EPI300 (see above), 
E. coli XL-1 Blue (0.89 ± 0.07-fold), and two S. Typhimurium strains (ST4/74 and ST LT2 
[0.92 ± 0.06 and 0.88 ± 0.10-fold respectively], showed inability to resist intra-macrophage 
killing at 6h; Figure 3.2. Some isolates were just able to survive at 6h, not to replicate, inside 
macrophages, including E. coli K-12 strain (1.07 ± 0.05-fold), and isolates from healthy 
individuals ECOR51 (1.11 ± 0.18-fold) and HM488 (1.42 ± 0.13-fold). However, some 
healthy E. coli isolates were also seen to replicate effectively inside murine macrophages, 
such as ECOR35 (2.05 ± 0.33-fold) and ECOR1 (5.62 ± 1.28-fold).  All UTI-associated E. 
coli strains showed ability to survive and replicate within J774-A1 macrophages, albeit to 
varying degrees, including significant replication by ECOR64 (7.15 ± 1.24-fold; P<0.001 
ANOVA) and lower level (non-significant) replication by ECOR40 (2.47 ± 0.53), ECOR50 
(2.24 ± 1.05) and ECOR48 (1.59 ± 0.52-fold). In contrast, all CRC mucosa-associated E. coli 
isolates HM44, HM312 and HM358 were killed by J774A1 macrophages at 6h. Similarly, 
some UC mucosa-associated E. coli isolates, including HM250 (0.67 ± 0.21-fold) and 
HM464 (0.50 ± 0.09-fold) were also effectively killed, although other UC mucosa-associated 
E. coli either just survived or minimally replicated within murine macrophages at 6h 
(HM394, 1.07 ± 0.04 -fold and HM233, 2.12 ± 0.50 –fold compared to EPI300).  
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3.3 Confirmation of generation of mature bone marrow-derived 
macrophages (BMDM) from cryopreserved mouse femur bone marrow 
(BM) cells by F4/80 glycoprotein expression analysis 
 
In order to verify that the BM cells from wild-type C57Bl/6 mice and knock-out mice strains 
on C57Bl/6 background differentiated into mature macrophages after being cultured in media 
supplemented with rM-CSF (100 ng/mL) for 6 days, immunocytochemistry using anti-mouse 
F4/80 antibody was performed. The following representative images show the expression of 
F4/80 antigen on mature BMDM from wild-type and one of the knock out strains, Nfκb2-/- 
mice (Figure 3.3). 
 
 
Figure 3.3 Immunocytochemistry using anti-mouse F4/80 EMR1 antibody (CI-A3-1). 
Two representative images of adherent BM cells from Nfκb2-/- (A) and C57BL/6 (B) mice following 6d of 
differentiation in rM-CSF (100ng/mL) showing  branched and extended cellular morphology and 
immunoreactivity with anti-mouse F4/80 antibody. Blue arrows point to sites of mature macrophage aggregation 
with high level F4/80 antigen expression. (Magnification x20) N=2 mice, n=2 replicates. 
Nfkb2-/- BMDM
A
B
C57BL/6 BMDM
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3.4 Crohn disease (CD) mucosa-associated AIEC HM605 and LF82 
replicate inside C57Bl/6 BMDM 
 
Intra-phagolysosome survival and replication of CD AIEC HM605 within wild-type C57Bl/6 
BMDM at 6h post-infection was 4.47 ± 1.00-fold [mean ± SD] above that seen at 3h post 
infection; BM cells were obtained from a wild-type mouse C57BL/6 (n=2♂, n=2♀), N=3, 
n=2 replicates; see Figure 3.4A and Figure 3.4B. The paradigm ileal CD AIEC isolate LF82 
also replicated within wild-type BMDM at a similar level (4.00 ± 0.75-fold), N=1, n=2 
replicates; Figure 3.4A and Figure 3.4C. These results indicate these AIEC strains are able 
to survive and significantly replicate within wild-type C57Bl/6 BMDM differentiated from 
cryopreserved mouse femur bone marrow using rM-CSF (100 ng/mL, over 6 days). 
 
 
3.5 Crohn’s disease AIEC strains HM605 and LF82 are unable to survive 
nor replicate within Nfκb1 and Nfκb2 deficient murine BMDM 
 
Intra-macrophage replicating CD mucosa-associated AIEC strains HM605 and LF82 were 
both unable to replicate or to survive inside BMDM, derived from Nfκb1-/- (Figure 3.5A) or 
Nfκb2-/- mice (Figure 3.5B). Relative replication within BMDM from Nfκb1-/- was 0.47 ± 
0.19-fold and 0.56 ± 0.28-fold respectively for HM605 (N=2, n=2) and LF82 (N=1, n=2); 
with relative replicate in Nfκb2-/- BMDM being 0.82 ± 0.06-fold and 0.25 ± 0.08-fold for 
HM605 (N=3, n=2) and LF82 (N=1, n=2) respectively. 
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Figure 3.4 Intra-macrophage replication of Crohn’s disease AIEC HM605 and LF82 in C57Bl/6 BMDM. 
(A) CD mucosa-associated E. coli HM605 and LF82 showed ability to survive and replicate within wild-type  
C57BL/6 BMDMs as determined by gentamicin protection assay, 6h/3h post infection. Representative images of 
intra-macrophage HM605 and LF82 respectively at 3h and 6h post infection time for (B) HM605 and (C) LF82 
as determined by overnight culture on LB agar and CFU enumeration; HM605; N=3, n=2 replicates, and LF82; 
N=1, n=2 replicates. 
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Figure 3.5 Crohn’s disease (CD) AIEC HM605 and LF82 show inability to survive and replicate within 
Nfκb1-/- and Nfκb2-/- BMDM. 
As determined by gentamicin protection assay, at 6h/3h post infection, both CD mucosa-associated E. coli 
HM605 and LF82 showed inability to survive and replicate within (A) Nfκb1-/- BMDM [N=2, n=2 replicates for 
HM605 and N=1, n=2 replicates for LF82], and (B) Nfκb2-/-BMDM [N=3, n=2 replicates for HM605 and N=1, 
n=2 replicates for LF82]. (C) Representative images of AIEC HM605 CFU grown overnight on LB agar plates 
obtained by lysis of Nfκb2-/- BMDM at 3h and 6h post infection.  
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3.6 Crohn’s disease mucosa-associated AIEC strains HM605 and LF82 
survive and replicate normally within c-Rel-/- BMDMs 
 
Crohn’s AIEC strain HM605 survived and replicated within c-Rel-/- BMDMs (2.70 ± 0.62-
fold; N=1, n=2) at levels similar to those seen for wild-type BMDM; see Figure 3.6A and 
Figure 3.6 B. For ileal CD mucosa-associated LF82, this isolate was seen to only survive 
(and not replicate) at 6h post infection within BMDM from c-Rel-/- mouse (1.10 ± 0.32-fold at 
6h/3h; N=1, n=2) see Figure 3.6A and Figure 3.6C respectively. The ability to only survive 
(and not replicate) has been previously observed in some J774-A1 intramacrophage 
replication assays using the AIEC LF82. 
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Figure 3.6 HM605 and LF82 fold replication within c-Rel-/- BMDM. 
(A) Bacteria fold replication of Crohn’s AIEC HM605 and LF82 within c-Rel-/- BMDM. (B) Representative 
examples of LB agar plates, containing bacteria colonies of AIEC HM605, and (C) AIEC LF82 obtained from 
intra c-Rel-/- BMDM at time points 3h and 6h post infection. N=1, n=2 replicates. 
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3.7 Other immune-related gene knockout BMDM infected with HM605 at 
MOI of 100 show better outcomes 
 
Long-term cryopreserved BM (>10 years frozen in liquid N2) from immune-related gene 
knock-out animals showed high variability in ability to differentiate to BMDM. Whilst Il-1r-/- 
Il-18r-/- and Myd88-/- BM progenitor cells differentiated well into macrophages when cultured 
within media supplemented with rM-CSF. 
 
In gentamicin exclusion assay, the intracellular bacteria were typically counted at 102 fold 
dilution of cell lysates infected at MOI of 10, but unfortunately no intracellular bacteria were 
obtained from, Il-1r-/-, Il-18r-/- , and Myd88-/- BMDM cells in 102 fold dilution plates (N=1, 
n=2 replicates). Therefore, in order to troubleshoot this issue, it was decided to infect 
BMDMs with CD AIEC HM605 and LF82 at both MOI of 10 and 100, and comparisons 
made (Figure 3.7). Representative images (Figure 3.7A and B) show that the intracellular 
bacterial numbers of the plates of the neat and 101 fold dilutions of lysates of cells infected at 
MOI of 100 were higher than those infected at MOI of 10. Figure 3.7C and D show 
comparison between the numbers of intracellular bacteria in the plates of neat and 101 fold 
dilutions of Il-1r-/- cell lysates infected at MOI of 10 at 3h with those at 6h post infection. 
Intra-macrophage replication of both HM605 and LF82 were seen to be higher (∼5 and ∼1.5-
fold respectively) in Il-1r-/- murine BMDM (N=1, n=2). Other knockout BMDMs did not 
yield any conclusive datasets. Since all these BM cells were cryopreserved for many years 
(since 2002), it is more likely that the age of BM presented a challenge to effect adequate 
differentiation to mature/active macrophages and those that had differentiated showed little or 
no functional ability to examine intra-macrophage survival and replication.  
 
Phagocytic function analysis of the various genes knock-out BMDM versus wild-type 
C57BL/6 BMDM cells showed no defect in ability to phagocytose and internalise 
fluorescein-labelled heat-killed E. coli K-12 in Nfκb-/- and Myd88-/- BMDM cells (Figure 
3.8). In contrast, phagocytosis was noticed to be impaired in Il-1r-/- and Il-18r-/- BMDM and 
these two cells were unable to degrade fluorescein-labelled heat-killed E. coli K-12 (Figure 
3.8).  
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Figure 3.7 Comparisons between cells infected at MOI of 10 and MOI of 100 (Panel A). 
Bacteria inside C57BL/6 BMDM cells, 3h post infection with AIEC HM605 at MOI of 10 compared with at 
MOI of 100 (A) and with AIEC LF82 at MOI of 10 compared with at MOI of 100 (B). A comparison between 
the intra- Il-1r-/-   BMDM numbers of HM605 (C) and LF82 (D) at 3h and 6h post infection. N=1, n=2 replicates. 
  
C57BL/6 BMDM
MOI 10
MOI 100
10-1Neat 
Neat 10-1
HM605 HM605
HM605 HM605
A
3h post infection
3h post infection
3h post infection
3h post infection
80 
 
 
 
 
Figure 3.7 (Continued): Comparisons between cells infected at MOI of 10 and MOI of 100 (Panel B). 
Bacteria inside C57BL/6 BMDM cells, 3h post infection with AIEC HM605 at MOI of 10 compared with at 
MOI of 100 (A) and with AIEC LF82 at MOI of 10 compared with at MOI of 100 (B). A comparison between 
the intra- Il-1r-/-   BMDM numbers of HM605 (C) and LF82 (D) at 3h and 6h post infection. N=1, n=2 replicates. 
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Figure 3.7 (Continued): Comparisons between cells infected at MOI of 10 and MOI of 100 (Panel C). 
Bacteria inside C57BL/6 BMDM cells, 3h post infection with AIEC HM605 at MOI of 10 compared with at 
MOI of 100 (A) and with AIEC LF82 at MOI of 10 compared with at MOI of 100 (B). A comparison between 
the intra- Il-1r-/-   BMDM numbers of HM605 (C) and LF82 (D) at 3h and 6h post infection. N=1, n=2 replicate. 
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Figure 3.7 (Continued): Comparisons between cells infected at MOI of 10 and MOI of 100 (Panel D). 
Bacteria inside C57BL/6 BMDM cells, 3h post infection with AIEC HM605 at MOI of 10 compared with at 
MOI of 100 (A) and with AIEC LF82 at MOI of 10 compared with at MOI of 100 (B). A comparison between 
the intra- Il-1r-/-   BMDM numbers of HM605 (C) and LF82 (D) at 3h and 6h post infection. N=1, n=2 replicates. 
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Figure 3.8 Phagocytosis time course studies (Panel A). 
Phagocytosis was intact in C57BL/6 BMDM (A) Nfκb2-/-(B), and Myd88-/-(E) BMDM cells. In contrast, 
phagocytosis was impaired in Il-1r-/- (C) and Il-18r-/- (D) BMDM respectively. 
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Figure 3.8 (Continued):  Phagocytosis time course studies (Panel B). 
Phagocytosis was intact in C57BL/6 BMDM (A) Nfκb2-/-(B), and Myd88-/-(E) BMDM cells. In contrast, 
phagocytosis was impaired in Il-1r-/- (C) and Il-18r-/- (D) BMDM respectively. 
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Figure 3.8 (Continued): Phagocytosis time course studies (Panel C). 
Phagocytosis was intact in C57BL/6 BMDM (A) Nfκb2-/-(B), and Myd88-/-(E) BMDM cells. In contrast, 
phagocytosis was impaired in Il-1r-/- (C) and Il-18r-/- (D) BMDM respectively. 
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Figure 3.8 (Continued): Phagocytosis time course studies (Panel D). 
Phagocytosis was intact in C57BL/6 BMDM (A) Nfκb2-/-(B), and Myd88-/-(E) BMDM cells. In contrast, 
phagocytosis was impaired in Il-1r-/- (C) and Il-18r-/- (D) BMDM respectively. 
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Figure 3.8 (Continued): Phagocytosis time course studies (Panel E). 
Phagocytosis was intact in C57BL/6 BMDM (A) Nfκb2-/-(B), and Myd88-/-(E) BMDM cells. In contrast, 
phagocytosis was impaired in Il-1r-/- (C) and Il-18r-/- (D) BMDM respectively. 
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3.8 Summary of results 
 
1. All Crohn’s ileal- and colonic-mucosa associated E. coli strains, excepting one isolate 
HM104, possessed ability to either survive and/or replicate within murine (J774-A1) 
macrophages. Interestingly, all UTI E. coli isolates and some healthy mucosa-
associated E. coli strains behaved in a similar manner. 
 
2. All CRC mucosa-associated E. coli strains tested, two out of four UC mucosa-
associated isolates and the majority of laboratory E. coli strains (excepting E. coli K-
12) were unable to survive inside J774-A1 macrophage phagolysosomes. 
 
3. Wild-type C57BL/6 mouse BM cells and murine Nfκb1-/-, Nfκb2-/- and c-Rel-/- BM 
progenitor cells (fresh and 2-8 week frozen cells) were successfully differentiated into 
macrophages when cultured within media supplemented with rM-CSF. Mature 
BMDM macrophages generated were identified by cell morphology analysis and by 
their expression of F4/80 epitope using immunocytochemistry. 
 
4. Crohn’s disease paradigm ileal and colonic AIEC strains LF82 and HM605, showed 
ability to survive and replicate within wild-type C57BL/6 BMDMs. Data suggests that 
both paradigm CD isolates were unable to survive and replicate inside Nfκb1-/- and 
Nfκb2-/- BMDMs, whilst they both survived and replicated within BMDM derived 
from c-Rel-/- mice. No defect in the phagocytosis was seen in Nfκb-/- family BMDMs. 
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3.9 Discussion 
 
There is growing evidence supporting the hypothesis that Crohn’s disease (CD), a chronic-
relapsing inflammatory bowel disease (IBD),  is a result of innate immunodeficiency, such as 
a defect in bacteria handling and clearance, and impaired neutrophil chemotaxis [94, 326]. 
However, no abnormality in phagocytosis and respiratory burst function of monocyte-derived 
macrophages (MDM) obtained from CD patients has been described to date [327]. 
 
Our intra-macrophage replication assays, simultaneously comparing relative replication of 
various E. coli strains from 4 different diseases (CD, UC, CRC and patients with a UTI) 
along with from non-IBD control patients, is the first to our knowledge. Paradigm CD ileal 
and colonic AIEC (LF82 and HM605 respectively), were shown to possess ability to survive 
and replicate following engulfment by antigen-presenting immune cells such as macrophages 
and dendritic cells known to play critical roles in the induction of chronic inflammation (see 
Chapter 3, section 3.2) and this is in agreement with our own previous findings [131, 149, 
179]  and that observed by others [8, 229, 242, 243]. E. coli isolates from UTI patients along 
with some healthy-mucosa associated E. coli strains, obtained from healthy individuals also 
showed the ability to replicate within (J774-A1) macrophages. The latter result is consistent 
with findings of Subramanian et al. [149] in which mucosa-associated E. coli strains isolated 
from the non-inflamed intestine of non-IBD patients, diagnosed with sporadic benign polyp 
lesions or with IBS, were able to significantly replicate within J774-A1 macrophages (see 
reference [149]). Likewise, there is some evidence in the literature that UPEC strains isolated 
from patients with UTI can also survive and replicate within mouse macrophages, as well as 
replicating within urogenital epithelial cells [328, 329]. A previous study has shown that 7% 
of UPEC meet the criteria of the AIEC phenotype [30]. In contrast, all CRC mucosa-
associated E. coli strains tested and the majority of laboratory E. coli strains (excepting E. 
coli K-12) were unable to survive inside J774-A1 macrophage phagolysosomes. E. coli K-12 
was able to survive within murine macrophages over 6h and this result has also been 
previously observed by Subramanian and colleagues [149]. Two out of four UC mucosa-
associated isolates and the majority of laboratory E. coli strains (excepting E. coli K-12) were 
unable to survive inside J774-A1 macrophage phagolysosomes. It has been documented that 
there is lower prevalence of E. coli-laden macrophages seen in UC [330], supporting earlier 
90 
 
studies where levels of intramucosal bacteria isolated from UC was found to be much lower 
than that seen in CD [139, 141, 330]. Here 2/3 colonic mucosa-associated isolates from UC 
mucosae were shown to possess ability to replicate within murine macrophages and further 
study on a greater number of clinical isolates is warranted.  
 
A correlation between the colonic E. coli colonization density and the severity of ileal 
inflammation in Crohn’s patients has been demonstrated [157]. Pathogenic E. coli, being able 
to penetrate the intestinal epithelial barrier and resist macrophage killing process, have been  
found to be able to trigger a huge host inflammatory response [331]. Infected murine 
macrophages (J774-A1) harbouring Crohn’s disease AIEC strains within, including LF82 and 
13I, found to secrete high levels of proinflammatory cytokine TNF [323, 324, 332]. AIEC 
LF82 and 13I strains appear to survive within murine macrophage phagolysosomes by 
suppressing acute NF-κB signal pathway activation during the initial phase of infection, a 
common strategy used by other pathogenic bacteria for their intra-cellular survival [323, 333, 
334]. Persistence of intra-macrophage AIEC during the later phase of infection seems to be 
through induction of chronic activation of NF-κB, which correlates with increased TNF 
secretion from infected macrophages [323]. Exogenous addition of TNF was also reported to 
increase intra-macrophage replication of AIEC LF82 [324], with secreted levels correlating to 
number of intra-macrophage AIEC LF82 within infected monocyte-derived macrophages 
(MDM) [335], Interestingly, AIEC (LF82)-infected MDM- from patients with quiescent CD 
appear to release significantly higher amounts of both IL-6 and TNF than those obtained from 
patients with active disease or those from healthy controls. although our own recent 
laboratory studies indicate that peripheral blood monocyte-derived macrophages obtained 
from healthy volunteers and Crohn’s patients produced roughly similar quantities of 
proinflammatory cytokines, including TNF, after infection with Crohn’s mucosa-associated 
AIEC HM605 [205]. 
 
Plasma TNF levels in Crohn’s patients with active disease are known to be significantly high 
[336]. Inhibition of proinflammatory cytokine production (including TNF) by triterpene 
ganoderic acid C1 (GAC1) treatment of  either isolated peripheral blood mononuclear cells 
(PBMCs) or inflamed colonic biopsies taken from Crohn’s patients occurs via blockade of 
NF-κB activation [337, 338]. Gross impairment in the secretion of proinflammatory 
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cytokines TNF, IL-4, IL-5, IL-13, IL-15, and IFN-γ by macrophages from Crohn’s patients 
has been reported in response to infection with heat-killed E. coli NCTC 10418 (HkEc) [94, 
339], and recent published data from two different research  groups showed that monocyte-
derived macrophages (MDM) from Crohn’s patients stimulated with the same E. coli strain 
released attenuated levels of TNF and interferon gamma (IFNγ) compared with those secreted 
from healthy control macrophages [327, 340]. Moreover, THP-1 (human monocytic cell line) 
macrophages infected with the Crohn’s AIEC LF82 secrete large amounts of exosomes (i.e. 
extracellular vesicles that function in intercellular communication and have been implicated 
in host responses to intracellular pathogens) to induce a proinflammatory response [341]. 
 
NF-κB signalling can be attributed to actions of five family member protein subunits/protein 
subunit complexes, including NF-κB1, NF-κB2, RelA (p65), RelB and c-Rel, controlling 
DNA transcription and subsequent  expression of proinflammatory cytokines to  play a 
pivotal role in regulating immune response to infection [342]. Results of our intramacrophage 
replication assays undertaken with Crohn’s AIEC strains within murine BMDM from various 
Nfκb family member knockout mice, indicated that neither ileal not colonic CD 
representative AIEC strains LF82 and HM605 survived within Nfκb1-/- (classical pathway 
p105→p50) nor alternative pathway Nfκb2-/- (p100→p52) BMDM. Both strains were able to 
survive and replicate within wild-type C57BL/6 and c-Rel-/- (p65) BMDM. Our phagocytosis 
function analysis data also showed that this engulfment process was not impaired in BMDM 
deficient in Nfκb family member proteins/protein subunits. Recent in vitro studies on mice 
lacking the c-Rel subunit showed that they were more susceptible to colitis and colitis-
associated cancer than wild-type mice, whilst Nfκb2-/- mice exhibited less severe colitis and 
an attenuated cytokine response in comparison to C57BL/6, Nfκb1-/- and c-Rel-/- mouse 
groups following DSS administration [343].  
 
The fact that NF-κB pathway signalling is found to be chronically active in IBD (as well as in 
other inflammatory conditions, including gastritis) [344] suggests that methods of inhibiting 
NF-κB signalling would likely have potential therapeutic application [345], including 
countering AIEC macrophage persistence seen in ileal and colonic Crohn’s disease mucosae. 
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Chapter 4   
 
Studying the ability of Crohn’s E. coli strains to grow in conditions 
mimicking the harsh environment found inside vacuoles/phagolysosomes of 
the macrophage  
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4.1 Introduction  
 
A number of strategies are adopted by differing pathogenic bacteria to avoid being killed 
inside the intra-cellular vacuoles/phagolysosomes of macrophages. These include a variety of 
adaptive responses, including avoidance of phagocytosis, inhibition of phagolysosome 
maturation and resistance of antimicrobial killing environment of mature phagolysosomes 
(i.e. low pH, low nutrient, high oxidative and nitrosative stress conditions) [346-348]. 
Classical pathogens known to survive and replicate within macrophages, including 
Mycobacterium, Salmonella, Shigella, Brucella, Legionella and Listeria spp. [224]. Key 
defence mechanisms adopted by these pathogens support their resistance to killing within the 
environment of the phagolysosome. Shigella and Listeria are able to escape from the mature 
phagolysosome, whilst Salmonella spp. can inhibit fusion of phagosome with the lysosome, 
and species such as Mycobacterium tuberculosis is able to modify the intra-phagolysosome 
environment [224]. Salmonella spp., Shigella spp. and E. coli have all been reported to 
possess a repertoire of low pH inducible systems that support resistance, tolerance and 
habituation during environmental acid stress likely encountered by active enteric bacteria 
within the phagolysosome. Other examples of pathogens showing adaptation to an intra-
phagolysomal life-style include Coxiella burnetii causing Q-fever [288] and Tropheryma 
whipplei causing Whipple's disease [289, 290].  
 
Paradigm Crohn’s AIEC strains HM605 and LF82, and other CD mucosa-associated E. coli, 
have been shown to be present within mature phagolysosomes by gentamicin exclusion assay 
and microscopy, including transmission electron microscopy (TEM) [8, 131, 149]. Earlier 
studies have shown that ileal AIEC LF82 appears to be tolerant of a low pH intra-
phagolysosome environment thus facilitating ability to replicate within the macrophage 
[349]. This persistence within macrophages supports giant cell formation and development of 
granulomata in vitro [350]. The presence of granulomas in mesenteric lymph nodes (MLN) 
has been found to be associated with postoperative recurrence in CD [351]. 
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The mechanism of how these Crohn’s AIEC isolates resist the killing process and survive, 
even replicate, within macrophage phagolysosomes without inducing cell death is still poorly 
understood. Some key genes supporting AIEC survival and replication within macrophages 
have been identified using isogenic mutants of the ‘paradigm’ ileal AIEC LF82, including 
htrA, dsbA, hfq and gipA [241-245]. However, htrA and dsbA encoded stress response 
proteins HtrA and DsbA are fairly ubiquitous in E. coli, and it is likely that other unidentified 
factors are needed to support AIEC survival within the stressful conditions of the 
phagolysosome. Treatments that target the fundamental pathology of CD are still required 
and therefore studies understanding their ability to resist killing within mucosal macrophages 
are likely to improve current drugs used to maintain and treat this condition, and also support 
development of novel drug therapy that might be much more effective for patients with CD. 
 
In this chapter, we aimed therefore to investigate the growth of intra-macrophage replicating 
Crohn’s mucosa-associated E. coli clinical isolates (including those with confirmed as 
AIEC), other IBD and cancer mucosa-associated E. coli, as well as pathogenic and non-
pathogenic E. coli strains in chemical-induced stress conditions mimicking the intra-
phagolysosome environment. 
 
 
4.2 Growth of E. coli strains in a high nutrient environment 
 
An initial examination of a collection of various E. coli strains isolated from healthy 
individuals and UTI patients (ECOR strains), in comparison to the colonic CD AIEC strain 
HM605 and the non-intra-macrophage replicating laboratory E. coli strain EPI300, grown in 
nutrient rich RPMI culture media showed little differences between strains at both pH 5 and 7 
but that all showed significant reduction in growth at pH 5 (>50% less growth; HM605 54%, 
ECOR1 44%, ECOR35 56%,  ECOR51 48%, ECOR40 49%, ECOR48 51%, ECOR64 52%, 
ECOR50 51%, and EPI300 43%; n=3) (see Figure 4.1)  
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Figure 4.1 E. coli growth patterns in high nutrient RPMI culture medium at differing environmental pH 
(pH 7 and pH 5).  
Changing pH of high-nutrient media from 7 to 5 remarkably affected the bacteria growth. There was no 
significant differences seen in growth between strains. Each point represents the optical density mean of an 
experiment run in triplicate (n=3). 
 
  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 2 4 6 8
O
D
Time(h)
RPMI pH 7
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 2 4 6 8
O
D
Time(h)
RPMI pH 5
96 
 
4.3 Crohn’s disease E. coli isolates are better able to grow in an acidic (pH 
4.5), low nutrient environment 
 
In order to assess their ability Crohn’s E. coli strains, including those of confirmed AIEC 
phenotype such as HM605 and LF82, to survive within the low nutrient, acidic environment 
inside the macrophage phagolysosome, strains were grown in low-nutrient medium (M9) at 
differing pH ranging from pH 4.0 to pH 7.0. The intra-phagolysosome pH of human-and 
murine derived macrophages after infection with bacteria such as Mycobacterium 
tuberculosis has been estimated in previous studies to be ∼ pH 5 (pH 4.8 to 5.5) [352-354]. 
 
Four CD E. coli strains previously characterised as AIEC phenotype, LF82, HM605, HM615 
and HM427 showed increased growth tolerance over 8h to an acidic, low nutrient M9 media, 
especially at pH 4.5, compared to that seen by non-AIEC laboratory E. coli strains K-12 
EPI300 and XL1Blue, which demonstrated intolerance to low nutrient and low acid 
conditions over the same time frame (Figure 4.2). Two S. Typhimurium strains used showed 
better growth than laboratory E. coli strains down to pH 5 but remarkably could not tolerate 
low nutrient at pH 4.5 and below (Figure 4.2). In contrast, not all E. coli strains from CD 
patients (non AIEC types) were able to show significant growth at pH 4.5, suggesting that 
there are specific properties of adaption held by certain strains (see Figure 4.3). Other studied  
E. coli  strains; i.e. those E. coli strains obtained from UC, cancer and UTI patients, and those 
from healthy individuals showed as similar inability, albeit with some variation, to grow at 
pH 4.5 as per the non-AIEC CD E. coli strains (see Figure 4.3). There was no remarkable 
growth in M9 minimal media of any bacteria studied at pH 4 (Figure 4.2). To support future 
studies using fluorophore expressing AIEC isolates, we compared the growth characteristics 
of colonic CD AIEC HM615 expressing enhanced green fluorescent protein (eGFP) which 
showed identical tolerance to growth in M9 minimal media at all differing pH as per the wild-
type isolate (Figure 4.4).  
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Figure 4.2 Comparisons of the growth patterns of Crohn’s-associated E. coli strains and non-Crohn’s E. 
coli isolates in low-nutrient medium (M9) at differing pH from 7 to 4.  
Four CD AIEC strains showed increased growth tolerance over 8 h to an acidic, low nutrient M9 media, at pH 
4.5, All grew over 8h at pH 5, 6 and 7 and no significant differences among them were observed, Laboratory E. 
coli strains, XL-1 Blue, S. Typhimurium LT2 and 4/74 were unable to grow well at pH 4.5 and below. No 
bacteria studied were able to grow in M9 minimal media at pH 4; n=3.  
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Figure 4.3 The growth curves of a collection of E. coli strains isolated from a range of diseased 
individuals, besides two Crohn’s-associated E. coli strains, in a M9 medium at pH 4.5. 
All bacteria’s growth lines increased regularly over time and no noticeable differences among them were 
observed. n=3. 
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Figure 4.4 A comparison of the growth curves of wild-type Crohn’s disease colonic mucosa-associated 
AIEC strain HM615 in differing pH M9 media with those of HM615 strain engineered to express 
enhanced Green fluorescent protein (eGFP). 
eGFP expression has no adverse effect on the ability of this bacteria strain to grow in minimal media over an 
range of pH environments. n=3. 
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4.4 The majority of Crohn’s E. coli strains not only have better ability to 
tolerate low pH but also to tolerate high oxidative and nitrosative stress 
conditions typical of the phagolysosome environment 
 
Bacterial strains were grown on plain solid LB agar plates at pH 7 (referred to as normal 
growth condition controls), and on LB agar plates providing environmental stress conditions, 
including (i)  acid (low pH) stress, (ii) high nitrosative stress at pH 5, and (iii) oxidative and 
(iii) superoxidative stress, both at pH 7 (see Methods section 2.10) . Unfortunately, it was 
not possible to grow bacterial strains on LB agar media at pH 4.5 and 4.0 because we found 
that warm LB agar media at each of these  pH conditions resulted in inability of the agar to  
set/solidify in petri dishes.  According to the results illustrated in Figure 4.5, the growth of 
Crohn’s E. coli strains (AIEC) HM605, HM615 and LF82, HM427 was not influenced by 
any of the chemical stress conditions that mimicked the harsh low pH, high nitrosative, and 
low and high oxidative stress environment within macrophage phagolysosome. All were able 
to tolerate growth on LB agar under these conditions at a similar level to that seen on LB agar 
at pH7 (Figure 4.5). Conversely, the growth of laboratory E. coli strains EPI300 and XL-
1Blue were both significantly inhibited all of the stress conditions compared with growth 
seen on LB agar control plates at pH 7 (see Figure 4.6).  Interestingly, S. Typhimurium 
strains LT2 and 4/74 and colonic cancer E. coli isolate HM358 showed the ability to tolerate 
the stress of low pH (pH 5), high nitrosative stress and mild oxidative stress conditions, but 
showed no tolerance under superoxidative stress condition where growth was remarkably 
impaired (see Figure 4.6). Surprisingly, non-pathogenic E. coli K-12 tolerated and grew in 
all stress challenge conditions (Figure 4.6). Again to support future in vivo intestinal mucosa 
oxidative stress response studies using fluorophore expressing AIEC isolates, we compared 
the growth characteristics of colonic CD AIEC HM615 expressing eGFP under the four stress 
environments compared to wild-type. Both wild type and the eGFP expressing isolate showed 
tolerance to all conditions tested (Figure 4.7) and this is consistent with the results observed 
for growth in minimal media at differing pH; Figure 4.4. 
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Figure 4.5 Crohn’s E. coli strains have better ability to tolerate low pH, high oxidative and nitrosative 
stress. 
Crohn’s E. coli strains (AIEC); HM605 (A), LF82 (B), HM615 (C) and, and HM427 (D) in low pH, nitrosative, 
low oxidative, and superoxidative conditions. Bacteria growth in plain LB at pH 7 was used as a control.  
Bacteria CFUs were frequently counted at dilution factor 105 and presented as relative growth response. N=4, 
n=3 replicates. Morpholine ethanesulphonic acid (MES) sodium nitrite (NaNO2), methyl viologen (MV) and 
hydrogen peroxide (H2O2). 
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Figure 4.6 Laboratory E. coli strains, except K-12, and colonic cancer E. coli isolate HM358 and S. 
Typhimurium strains showed no tolerance under superoxidative stress condition. 
Stress tolerance tests of Laboratory E. coli strains EPI300 (A), XL-1Blue (B) and ST strains 4/74 (C) and LT2 
(D), Cancer AIEC strain HM358 (E) and E. coli strain K-12 (F) in low pH, nitrosative, oxidative, and 
superoxidative conditions. Bacteria growth in plain LB at pH 7 was used as a control.  Bacteria CFUs were 
frequently counted at dilution factor 105 and presented as relative growth response. N=4, n=3 replicates. * P 
≤0.05, ** P ≤ 0.01, **** P ≤ 0.0001, ANOVA with Dunnett’s post-hoc test. Morpholine ethanesulphonic acid 
(MES) sodium nitrite (NaNO2), methyl viologen (MV) and hydrogen peroxide (H2O2). 
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Figure 4.7 A comparison of the growth  of wild-type Crohn’s disease  colonic mucosa-associated AIEC 
strain HM615 in stress conditions  with those of HM615 strain engineered to express enhanced Green 
fluorescent protein (eGFP). 
eGFP expression has no adverse effect on the ability of this bacteria strain to grow in low pH, nitrosative and 
low and high oxidative stress environments. N=4, n=3 replicates. 
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4.5 CD AIEC isolates survive the combined stress of low pH (pH 5) 
oxidative and superoxidative stress of the intra-macrophage 
phagolysosome  
 
It is already known that bacteria within macrophage phagolysosomes face low pH 
environment, ranging from pH 4.8 to pH 5.5 [352-354] associated with other harsh conditions 
such as high nitrosative and oxidative/superoxidative stress. We therefore attempted to 
compare the survival and growth of some E. coli strains in an acidic environment (pH 5) in 
combination of either oxidative or superoxidative stress conditions to those bacteria grown 
under stress but under  non-acid conditions (i.e. pH 7). Bacteria were also grown on standard 
LB agar plates at pH 7 and at low pH, pH 5 as controls. The results (see Figure 4.8; panels 
A, B, C and D) showed that Crohn’s E. coli strains had significantly greater ability to tolerate 
all oxidative and superoxidative stress conditions at both acidic and non-acidic environments. 
Likewise, similar results were seen for non-pathogenic E. coli K-12 (Figure 4.9; panel C). It 
was also noted that non-pathogenic and laboratory E. coli strains were seen to show greater 
growth under superoxidative stress conditions at pH 5 compared to superoxidative stress at 
pH 7 (see Figure 4.9; panels A and B), potentially suggesting that acidic pH affected 
negatively production of superoxide radicals from MV and perhaps to some degree H2O2 
activities. Non-AIEC CRC strain HM358 was able to tolerate oxidative stress condition 
effected by H2O2
 but not under superoxidative conditions at pH 7 (see Figure 4.8; panel D) 
and refer to Figure 4.6; panel E).  
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Figure 4.8: CD AIEC isolates survive the combined stress of low pH (pH 5) oxidative or superoxidative 
stress environments on solid LB a growth media, mimicking the environment of intra-macrophage 
phagolysosome. 
(A-D) Comparisons of the growth of CD E. coli strains in LB media containing chemical stress conditions, 
either superoxidative (Left hand panel) or oxidative (right hand panel) at differing pH (pH 5 and  pH 7) to that 
growth seen at differing pH but on plain LB media (control). N=4, n=3 replicates. 
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Figure 4.8 (continued): CD AIEC isolates survive the combined stress of low pH (pH 5) oxidative or 
superoxidative stress environments on solid LB a growth media, mimicking the environment of intra-
macrophage phagolysosome.  
(A-D) Comparisons of the growth of CD E. coli strains in LB media containing chemical stress conditions, 
either superoxidative (Left hand panel) or oxidative (right hand panel) at differing pH (pH 5 and  pH 7) to that 
growth seen at differing pH but on plain LB media (control). N=4, n=3 replicates. 
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Figure 4.9: Laboratory E. coli strains and a CRC mucosa-associated E. coli show greater growth under 
superoxidative stress conditions at pH 5 compared to superoxidative stress at pH 7. 
(A-D) Comparisons of the growth of three laboratory and one CRC E. coli strain in LB media containing 
chemical  stress conditions, either superoxidative (Left hand panel) or oxidative (right hand panel) at differing 
pH (pH 5 and  pH 7) to that growth seen at differing pH but on plain LB media (control). It is speculated that the 
acidic environment (at pH 5) negatively impacted on the production of superoxide radicals from MV and 
perhaps to some degree hydroxyl radicals from H2O2. N=4, n=3 replicates. * P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 
0.0001; ANOVA with Dunnett’s post-hoc test (using LB pH 7 as control).  
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Figure 4.9 (continued): Laboratory E. coli strains and a CRC mucosa-associated E. coli show greater 
growth under superoxidative stress conditions at pH 5 compared to superoxidative stress at pH 7. 
(A-D) Comparisons of the growth of three laboratory and one CRC E. coli strain in LB media containing 
chemical  stress conditions, either superoxidative (Left hand panel) or oxidative (right hand panel) at differing 
pH (pH 5 and  pH 7) to that growth seen at differing pH but on plain LB media (control). It is speculated that the 
acidic environment (at pH 5) negatively impacted on the production of superoxide radicals from MV and 
perhaps to some degree hydroxyl radicals from H2O2. N=4, n=3 replicates. * P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 
0.0001; ANOVA with Dunnett’s post-hoc test (using LB pH 7 as control).  
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4.6  Correlation of the growth of various E. coli strains in superoxidative 
stress environment to ability to survive and replicate within macrophages 
 
Given the interesting preliminary data from the solid LB agar bacteria stress tolerance tests, 
particularly in the MV-induced superoxidative stress environment, seen for a number of CD 
E. coli strains when compared to intolerant laboratory strains and one CRC isolate, we 
therefore decided to perform further studies on a wider range of E. coli strains obtained from 
Crohn’s disease, UC, CRC and UTI patients and those from non-inflamed disease controls 
and healthy individuals (see Appendix, Section 9.3 - supplementary stress tolerance data). 
This data is summarised in Figure 4.10, panel A, which includes the previous experimental 
datasets in section 4.5 and 4.6. Interestingly, other Crohn’s disease ileal mucosa-associated 
E. coli isolates LF10, LF11, LF13 and 541-15A, and colonic mucosa-associated isolates, 
HM96, and HM104, were unable to tolerate superoxidative stress conditions as seen by 
Crohn’s AIEC strains such as, for example, LF82 and HM605 (see Figure 4.5). Interestingly, 
other intra-macrophage replicating E. coli strains, obtained from healthy and UTI patients, 
were also observed to significantly tolerate (i.e. survive and replicate) in growth media 
containing MV. Other clinical isolates able to show survival on MV containing LB agar were 
E. coli K-12 and E. coli Nissle 1917 (EcN). On the other hand, all UC E. coli isolates studied, 
all CRC isolates (excepting for HM229) and all non-pathogenic laboratory E. coli showed 
inability to survive superoxidative conditions. Since, the majority of intra-macrophage 
replicating E. coli strains tolerated growing in the superoxidative stress environment, a 
correlation between fold replication of E. coli strains inside macrophages, previously shown 
in Figure 3.2, with their % growth observed in MV agar was performed (see Figure 4.10 
panels B and C). Overall, although results indicate that there is variation in the data sets, 
Spearman's Rank Correlation Coefficient analysis showed that there is a strong link between 
the ability of bacteria to grow under superoxidative stress conditions and their ability to 
significantly replicate inside murine macrophage phagolysosomes. (rho = 0.74). This was 
supported by Principal component analysis (PCA) also indicating that a strong pattern exists 
between these measurable factors. 
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Figure 4.10: Comparison between the % growth of E. coli strains from different diseases in MV and their 
fold replication within murine macrophages. E. coli strains from different diseases. (Panel A) 
(A) Survival and growth of a variety of E. coli strains in superoxidative stress condition and (B) comparison of 
their growth in MV with their fold replication inside macrophage phagolysosomes. Spearman’s rank correlation 
coefficient for this dataset is (rho =0.74. Principal component analysis (PCA) of % bacteria growth in MV and 
bacteria fold of replication (C). 
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Figure 4.10 (continued): Comparison between the % growth of E. coli strains from different diseases in 
MV and their fold replication within murine macrophages. E. coli strains from different diseases. (Panel 
B) 
(A) Survival and growth of a variety of E. coli strains in superoxidative stress condition and (B) comparison of 
their growth in MV with their fold replication inside macrophage phagolysosomes. Spearman’s rank correlation 
coefficient for this dataset is (rho =0.74. Principal component analysis (PCA) of % bacteria growth in MV and 
bacteria fold of replication (C). 
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Figure 4.10 (continued): Comparison between the % growth of E. coli strains from different diseases in 
MV and their fold replication within murine macrophages. E. coli strains from different diseases. (Panel 
C) 
(A) Survival and growth of a variety of E. coli strains in superoxidative stress condition and (B) comparison of 
their growth in MV with their fold replication inside macrophage phagolysosomes. Spearman’s rank correlation 
coefficient for this dataset is (rho =0.74. Principal component analysis (PCA) of % bacteria growth in MV and 
bacteria fold of replication (C). 
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4.7 Summary of results 
 
1. Chemical stress conditions mimicking the intra-macrophage phagolysosome 
environment (low pH, low nutrient, high nitrosative stress, high oxidative/super- 
oxidative stress) were seen to have no adverse effects on the growth of  Crohn’s 
disease mucosa-associated AIEC, and intramacrophage replicating UTI and healthy-
mucosa associated E. coli isolates. 
 
2. All laboratory, CRC and UC mucosally associated E. coli isolates (with only a few 
exceptions) were seen to be intolerant to stress conditions mimicking those within the 
phagolysosome, in particular superoxidative stress conditions.  
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4.8 Discussion  
 
Within the macrophage phagolysosome, engulfed bacteria are killed and degraded in an 
acidic, high nitrosative, high oxidative, nutrient-limited stress environment to support 
subsequent antigen presentation [355]. Oxygen-dependent degradation in the phagolysosome 
relies on ROS and RNS, whereas oxygen-independent degradation depends on the release of 
proteolytic enzymes and antimicrobial peptides [356]. Tolerance of this acidic, nutrient-
limiting environment inside intra-macrophage vacuoles has been found to be important for 
the survival and replication of key enteric bacteria such as Salmonella spp. [357, 358] and has 
also been suggested as important for ileal Crohn’s disease (CD) mucosa-associated adherent, 
invasive E. coli (AIEC) isolate LF82 [322]. 
 
The mechanism of how Crohn’s disease AIEC isolates resist the killing process and survive, 
even replicate, within macrophage phagolysosomes without inducing cell death is still poorly 
understood. Here we studied the ability of a collection of E. coli, including CD mucosa-
associated E. coli isolates, to tolerate stressful growth conditions that would closely mimic 
the harsh environmental conditions typical of the macrophage intra-phagolysosome. Wild-
type (and eGFP expressing) CD mucosa-associated isolates, including colonic and ileal 
strains (including LF82), showed tolerance to growth in nutrient minimal media at differing 
pH (including acidic conditions) and to all stress environments tested, including high 
oxidative, high superoxidative and high nitrosative conditions. This supports the previous 
study of AIEC LF82-containing phagosomes which when treated with alkalinising agents 
chloroquine and ammonium chloride, intracellular replication of this was inhibited [322]. It 
should be noted also, that alteration of phagolysosome pH in macrophages causes inhibition 
of acidic proteases which leads to a diminished proteolytic activity against intracellular 
pathogens [359]. 
 
Some key genes have been identified in AIEC LF82 as supporting intramacrophage 
replication, such as htrA and DsbA [242, 243] but these are fairly ubiquitous to all E. coli 
strains including colonic CD mucosa-associated E. coli [180]. A more recent paper has 
identified that gipA may be more importance in supporting Crohn’s disease AIEC to persist in 
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this phagolysosome niche [245]. The phagolysosomes stress environment (particulalry acidic 
pH) may switch on expression of tolerance/virulence genes. Expression of gipA was induced 
by reactive oxygen and low pH treatment conditions [245].  
 
Chemical stress conditions mimicking the intra-macrophage phagolysosome environment 
(low pH, low nutrient, high nitrosative stress, high oxidative/super- oxidative stress) were 
also seen to have no adverse effects on the growth of intramacrophage replicating UTI and 
healthy-mucosa associated E. coli isolates. Likewise, there is some evidence in the literature 
that UPEC strains isolated from patients with UTI can also survive and replicate within 
mouse macrophages, as well as replicating within urogenital epithelial cells [328, 329]. A 
previous study has shown that 7% of UPEC meet the criteria of the AIEC phenotype [30]. 
Having invaded bladder epithelial cells, internalized UPEC can clonally replicate into 
biofilm-like intracellular bacterial communities (IBCs) of thousands of bacteria while 
avoiding key host clearance mechanisms and that these  bacteria tolerate oxidative stress 
within the IBCs [360]. 
 
Our data showed that all laboratory, CRC and UC mucosally-associated E. coli isolates (with 
only a few exceptions) were seen to be intolerant to stress conditions mimicking those harsh 
conditions encountered within the phagolysosome, in particular high superoxidative stress (as 
generated experimentally by MV). Two notable exceptions included non-pathogenic 
reference E. coli K-12 and Gram-negative EcN. Both strains tolerated all growth stress 
conditions (see Appendix, section 9.3). E. coli K-12 has previously been reported to tolerate 
1.5 mM hydrogen peroxide (H2O2) levels over 24 hours of incubation in LB broth [149, 361] 
and this may perhaps support its noted ability to survive/persist (but not to replicate 
significantly) inside both murine J774-A1 macrophages and human peripheral blood 
monocyte-derived  macrophages [149]. Gram-negative EcN,  reported to be useful in 
maintenance of remission of UC [362], and its ability to tolerate growing within macrophages 
might perhaps support its anti-inflammatory activity in UC and counter  increased numbers of 
mucosa-associated E. coli observed in UC some studies , albeit in lower numbers than that 
seen in CD mucosae. EcN and E. coli K-12 are genetically very similar strains, but differ 
markedly in their ability to activate the inflammasome where E. coli K-12 has a markedly 
greater ability than EcN [363]. 
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Some of the mucosa-associated non-inflamed E. coli isolates and those ECOR healthy control 
E. coli isolates tested also showed ability to survive and/or replicate in our study and tolerate 
all stress conditions. The ability of commensal Escherichia coli to survive killing within 
macrophages (including murine commensal E. coli NC101, with an AIEC phenotype) has 
been previously documented, facilitated by the protective action of small heat-
shock/chaperone proteins (e.g. IbpAB) specifically to prevent killing by macrophage-derived 
reactive oxygen species [364]. 
 
We had tried to further mimic the phagolysosome environment with a combination 
environment of both oxidative and superoxidative stress with low pH but it was also noted 
that non-pathogenic and laboratory E. coli strains (as per AIEC) were seen to show greater 
growth under superoxidative stress conditions at pH 5 compared to superoxidative stress at 
pH 7. We hypothesised that the acidic pH had negatively affected the production of 
superoxide radicals from MV and perhaps to some degree H2O2 oxidative activities. Our 
results were found to be consistent with findings of a published paper by van Dijk and 
colleagues [365] which demonstrated that MV generates superoxide radicals only at pH 
environments higher than 6 and not at pH 5 as tested in our studies [365]. Thus creating in 
vitro growth conditions to mimic multiple elements of the phagolysosome environment is a 
challenge for future studies, and may only be achievable in live isolated macrophages or in 
vivo with oxidative, nitrosative and pH sensitive molecular probes, and probes that measure 
proteolytic enzyme activities too.  
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Chapter 5  
 
To characterise genes relevant to the ability of Crohn’s AIEC to tolerate the 
intraphagolysosome environment that would support their growth, survival 
and replication within macrophages. 
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5.1 Introduction 
 
A number of key genes have been implicated as being important to support survival and 
replication of Crohn’s AIEC strains within macrophages including htrA, dsbA, hfq and gipA 
[190, 245, 366-368]. A screening study using a transposon mutant library constructed from 
AIEC LF82 identified both htrA and dsbA favouring LF82’s ability to resist macrophage 
killing and to replicate within macrophages [243, 367]. DsbA had already been reported to be 
necessary for virulence (including colonisation, adhesion, invasion and intra-macrophage 
survival) of pathogens such as S. Typhimurium [369], E. coli K-12 [370], Enteropathogenic 
E. coli [371] and Shigella flexneri [372]. Hfq protein was already shown  to play a pivotal 
role in controlling the virulence of AIEC LF82, with hfq deletion found to affect both the 
bacteria stress tolerance and its motility, confirming the importance of this protein in LF82 
virulence by RpoS and RpoE-independent mechanisms [244]. Previous studies had already 
established that Hfq is essential for bacteria virulence (motility and invasiveness) [373] of 
UPEC [374], Pseudomonas aeruginosa [375] and S. Typhimurium [376]. It was also reported 
that the absence of ibeA in the genome of AIEC strain NRG857c could result in inability of 
this strain to invade the mucosa, and to subsequently survive within macrophages of the 
inflamed murine intestine [377], which is consistent with the role of this invasion in other 
pathogenic E. coli strains, such as APEC [378]. In Crohn’s disease AIEC LF82, gipA appears 
important to support persistence in the phagolysosome niche with its expression induced by 
reactive oxygen and low pH [245]. Other virulence genes such as afaC (encoding afimbrial 
adhesin (Afa), pks, and lpf, which are not usually present in non-pathogenic E. coli, also been 
frequently found, in AIEC strains [179, 180], but none of these appear to be relevant in 
supporting survival and growth within macrophages. 
 
It is however known that E. coli harbour specific mechanisms that enable them to resist high 
levels of reactive oxygen species (ROS) that form the oxidative and super-oxidative response 
to phagocytosed pathogens. These defensive resources may be grouped into two regulated 
gene sets, the soxRS and oxyR regulons [252, 253]. The soxRS and oxyR regulons orchestrate 
defence mechanisms of E. coli against oxidative stress via induction of transcription of a set 
of genes that increase resistance to oxidative stress [379, 380]. An additional study has also  
shown that overexpression of btuE, encoding glutathione peroxidase (GPXs) BtuE peroxidase 
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protein, causes a decrease in the amounts of oxidative damage and also a decrease in the 
levels of transcription of key stress-induced genes such as ibpA, soxS and katG [381]. 
 
Of significant note, E. coli may also possess acid environment tolerance response systems. Of 
the 4 known, the first system requires sigma factor RpoS and the cyclic AMP receptor protein 
CRP, with RpoS functioning as a major environmental stress response regulator in both E. 
coli and Salmonella spp. [246]. Deletion of RpoS from a CD AIEC (strain O83:H1) has been 
observed to increase sensitivity of this clinical isolate to oxidative stress [247]. The second 
acid resistance system requires is arginine-dependent utilising of arginine decarboxylase 
(AdiA and AdiC) antiporter [246]. The third system is lysine dependent, involving lysine 
decarboxylase [249]. The system requires extracellular glutamate. The components of 
glutamate-dependent acid response are two isoforms of glutamate decarboxylase encoded by 
gadA and gadB, and a glutamate-ƴ-aminobutyric acid (Gad) antiporter encoded by gadC 
[248, 249]. Various types of E. coli strains are already known to contain acid stress response 
genes of this system, including gadA and gadB which are up regulated in response to acidic 
environment changes ranging from pH 2.5 to 4.5 [246, 248, 382]. Of note, murine commensal 
E. coli have been observed to respond to chronic intestinal inflammation by up-regulating 
expression of gadA and gadB [250]. This altered expression of gadA and gadB in luminal 
commensal E. coli was shown to reduce bacterial survival and attenuate the colitis, which 
likely occurred due to decreased translocation of bacteria across intestinal epithelium and 
increase of their susceptibility to bacterial killing by host antimicrobial peptides (AMPs) 
[250]. 
 
We therefore aimed to measure the expression levels of acid stress genes gadA and gadB in 4 
E. coli (CD AIEC colonic isolate HM605 or non-intra-macrophage replicating laboratory E. 
coli EPI300 in response to changes in M9 media under acidic conditions and also the 
expression levels of these two genes 3h and 6h post infection of J774-A1 macrophages. Also 
examined was the host oxidative stress responses that occurred when macrophages were 
infected with either CD AIEC colonic isolate HM605 or non-intra-macrophage replicating 
laboratory E. coli EPI300 (i.e. a strain susceptible to macrophage killing), using a Mouse 
Oxidative Stress RT2 Profiler PCR Array (which profiles the expression of 84 genes related 
to oxidative stress; see Methods section 2.13). 
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5.2 Acid stress response genes gadA and gadB expression increases 
following a change of pH from 7 to 4.5 in M9 minimal nutrient media 
 
Laboratory E. coli strains EPI300, XL-1Blue and E. coli K-12 showed some ability to tolerate 
acidic stress in M9 media at pH 4.5 following.  Crohn’s disease AIEC HM605 growth in M9 
demonstrated increased growth at 6h compared to 3h (see OD growth curves, Figure 5.1). 
 
 
 
 
Figure 5.1 A comparison of the studied E. coli strains (samples) growth in M9 minimal nutrient media 
under acidic stress conditions (pH 4.5) at 3h to 6h time points.  
All strains were able to grow in this stress medium at pH 4.5 despite of the growth variations among them; N=2, 
n=3. 
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Bacteria were then taken for RNA extraction and amplified using qRT-PCR for gadA 
expression. E. coli strains EPI300, XL-Blue and K-12 all showed an increase shift in gene 
expression when grown at pH 4.5 compared to growth in media at pH 7 over 6h (see Figure 
5.2; N=2, n=2). The expression of gadB was at similar levels to that seen for gadA in each of 
the 4 E. coli strains studied (see Figure 5.3; N=2, n=2).  Shift in gadA gene expression (i.e. 
shift in Cp value, Cp ranged from 3.5 to 7.0 when grown at pH 4.5 compared to growth in 
media at pH 7 over 6h. For gadB, Cp ranged from 2.2 to 6.5; see Figure 5.4A and Figure 
5.4B. The biggest shift in gad expression in response to acidic stress was seen with E. coli K-
12 with a Cp for gadA of 7.00  2.9 and gadB of 6.57  1.78 (mean  SEM) and confirms 
previous observations of tolerance to solid agar stress responses to acid (Chapter 4; Figure 
4.6). Interestingly, both gadA and gadB expression was seen to be significantly high in the 
CD AIEC isolate HM605 grown in M9 media for 6h at pH 7 and as a consequence, following 
growth in M9 media at pH 4.5, this isolate showed much less of an increase shift in gad 
expression when grown at pH 4.5 (Figure 5.4A and Figure 5.4B; N=2, n=2). 
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Figure 5.4 (A) Shift in gadA and (B) gadB expression (∆Cp) from E. coli strains HM605, K-12, EPI300 
and XL-1Blue  when grown at pH 4.5 compared to growth in media at pH 7 over 6h.  
Each value represents the mean ± standard error of the mean (SEM) of three independent experiments (N=2, 
n=2 replicate).  
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It was attempted to undertake qPCR analysis of gad expression in CD AIEC HM605 and all 
four E. coli strains (EPI300, XL-1Blue, K-12 and HM605) following a gentamicin protection 
assay of infected J774-A1 macrophages at 6h compared to 3h post-infection. Figure 5.5 and 
Figure 5.6 shows Cp values of gadA and gadB expression which was detected at lower 
expression levels for all E. coli strains expressed from the E. coli strains inside murine 
macrophages studied showed similar but smaller shifts in gad expression at 6h within 
macrophages. (N=1, n=2). 
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5.3  Mouse J774-A1 macrophage oxidative stress gene expression levels 6h 
post-infection with Crohn’s disease AIEC HM605 
 
The expression of 84 genes related to oxidative stress, including peroxidases and reactive 
oxygen species following infection of J774-A1 murine macrophages for 6h with CD AIEC 
isolate HM605 or non-replicating strain E. coli K-12 derivative EPI300 were analysed using 
RT2 Profiler Array. Scatter plot figures show the host oxidative stress response genes that 
show increased expression (in red), no change (in black) and lowered expression (in green) 
after infection with EPI300 (group 1; Figure 5.5) and Crohn’s disease AIEC HM605 (group 
2; Figure 5.6) compared to uninfected controls. Ten genes were up-regulated and 8 down-
regulated in response to EPI300 infection (Figure 5.5) and 9 up-regulated and 4 down-
regulated following CD AIEC HM605 infection (Figure 5.6). Common up-regulated genes to 
both infections were Cat and Ptgs2 (Peroxidase/cyclooxygenase), Ccl5, Prdx5 and Sqtsm1 
(Oxidative Stress response), Gpx3 (Glutathione Peroxidase), Ncf1 and Nos2 (Superoxide 
Metabolism) and Sod2 (Superoxide Dismutases). Significant changes (>2 fold) seen in same 
8 genes in response to EPI300 and HM605 infection (4 genes elevated and 4 decreased; see 
Figure 5.7). Superoxide stress response genes Ncf1 and Sod2 were all upregulated to similar 
levels at 6h (>2-fold) in both E. coli HM605 and K-12 derivative EPI300-infected 
macrophages compared to uninfected controls, suggesting that CD isolate HM605 does not 
alter macrophage oxidative stress response to infection to promote its own intra-
phagolysosome growth (see Figure 5.7). For further detail of expression of those genes 
changed/unaltered by EPI300 and HM605 infection of J774A1 murine macrophages 
following RT2 Profiler PCR Array analysis can be found in Chapter 9; see Appendix 
section 9.1 (Table 9.1) and section 9.2 (Table 9.2). 
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Figure 5.7 Scatter plot of host oxidative stress response genes following infection with non-pathogenic E. 
coli EPI300 compared to uninfected control.  
Scatter plot figure illustrating host oxidative stress response genes that show increased expression (in red), no 
change (in black) and lowered expression (in green) after infection with E. coli EPI300 (group 1) compared to 
uninfected control. N=3, RT2 Profiler PCR Array Data Analysis programme version 3.5. The id of the genes, 
their fold change and their position on the array plates can be found in Appendix 9, Table 9.2. 
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Figure 5.8 Scatter plot of host oxidative stress response genes following infection with Crohn’s mucosa-
associated AIEC HM605 compared to uninfected control.  
Scatter plot figure illustrating host oxidative stress response genes that show increased expression (in red), no 
change (in black) and lowered expression (in green) after infection with CD AIEC HM605 (group 2) compared 
to uninfected control. N=3, RT2 Profiler PCR Array Data Analysis programme version 3.5. The id of the genes, 
their fold change and their position on the array plates can be found in Appendix 9, Table 9.2. 
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Figure 5.9 Bar chart illustrating oxidative stress genes expression in J7774-A1 murine macrophages 
infected with E. coli EPI300 or HM605. 
Barr indicate > 2-fold change (mean ± SEM) of key oxidative stress genes that were either over- or under-
expressed (in J7774-A1 murine macrophages infected with E. coli EPI300 or HM605, each compared to 
uninfected controls. N=3. 
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5.4 Summary of results 
 
1. Expression of bacteria acid stress response antiporter glutamate-ƴ-aminobutyric acid 
(Gad) genes gadA and gadB were observed to be much higher in the E. coli strains 
studied following 6h growth in minimal nutrient media at pH 4.5 (i.e. mimicking the 
environment inside murine macrophage phagolysosome), than that observed at pH 7.  
 
2. Crohn’s disease mucosa-associated AIEC HM605 showed higher initial levels of 
expression of both gadA and gadB in low nutrient media at pH 7 and this elevated 
state of gad expression may support adaptation to an intra-macrophage 
phagolysosome survival/replication lifestyle (see Chapter 3; Figure 3.1 and Figure 
3.2).  
 
3. Other non-pathogenic E. coli strains that show some ability to tolerate acid stress, 
such as E. coli K-12 (see Chapter 4, Figure 4.6), were seen to show the greatest 
upregulation of gad gene expression in response to acid stress in low nutrient media.  
 
4. The expression of gadB was observed to be at similar levels to that seen for gadA in 
each of the 4 E. coli strains studied (i.e. HM605, K-12,  EPI300 and  XL-1Blue), and 
again all strains showed an increase shift in expression of this particular gene when 
grown at pH 4.5 compared to growth in media at pH 7 over 6h. 
 
5. Adaptation of Crohn’s disease AIEC HM605 to the phagolysosome niche appears not 
to be through its ability to alter host macrophage oxidative stress response to 
infection, as no differential changes were observed in the expression of 84 host genes 
related to oxidative stress to that response seen with EPI300, a non-intra-macrophage 
replicating laboratory E. coli strain.  
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5.5 Discussion 
 
Having previously verified that Crohn’s disease AIEC strains possess greater ability to 
survive and replicate inside macrophages and that they may  endure growth in chemical 
stress-induced conditions resembling that of the intra-macrophage phagolysosome 
environment, we subsequently examined for potential genes that might play a role in its 
virulence phenotype, using the AIEC strain, HM605 as a representative isolate. Gad system 
genes seemed likely good initial candidates, given that various types of E. coli are already 
known to contain this acid stress response system, which is upregulated in response to 
exposure to a low pH environment [382], and that two previous studies have shown that 
luminal commensal AIEC strain NC101 responds to chronic intestinal inflammation by 
upregulation of expression of these two acid stress response genes, gadA and gadB [250, 
383]. We therefore initially looked for expression of these genes in CD E. coli strain HM605 
compared to non-pathogenic and laboratory strains (i.e. EPI300, XL-1Blue and K-12). Higher 
initial basal levels of gad gene expression seen for the AIEC isolate HM605 meant that as a 
consequence this isolate showed much less of an increase shift in gad expression when grown 
in nutrient poor media at low (acidic) pH. One could speculate that E. coli with an AIEC 
phenotype may perhaps already be adapted with high level of gad expression to 
counter/respond rapidly to acid stress encountered when phagocytosed into the macrophage 
phagosome environment, and that they may use this acid stress tolerance system to not only 
facilitate their initial survival but also subsequently to extensively replicate rapidly within 
maturing macrophage vacuoles, i.e. when phagosomes fuses with lysosomes. Notably, the 
largest shift observed in gad gene expression in response to the experimentally-induced 
acidic stress conditions was for the non-pathogenic E. coli K-12 strain, suggesting this strain 
rapidly adapts to acid stress to facilitate its survival/tolerance of high acid growth conditions. 
This response was also seen in the earlier solid agar chemical stress growth assays described 
in Chapter 4 (see Figure 4.6). This gad system activation response may explain the 
observations in this study (Chapter 3; Figure 3.2) and that of others [149] that E. coli K-12 
is also able to survive, albeit not replicate extensively, within murine macrophages over 6h 
study time. 
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Macrophages are well known to effectively generate reactive oxygen and nitrogen species, to 
facilitate intra-macrophage bacteria killing [384], and in order to defend themselves from the 
intra-phagolysosome toxic reactive oxygen species, E. coli strains trigger transcription of 
other stress-response regulators, such as OxyR, PerR and SoxR, which promote/enhance 
virulence [385, 386]. The RT2 Profiler PCR Array results presented here in this Chapter 
clearly illustrated that a number of key host macrophage oxidative stress genes were 
significantly upregulated in response to infection with AIEC HM605. This included; 1.) the 
neutrophil cytosolic factor 1 gene Ncf1 which encodes a cytosolic subunit protein of NADPH 
oxidase, p47 (phox) [387]; 2.) superoxide dismutase 2 mitochondrial gene Sod2, encoding a 
protein that binds superoxide by products of oxidative phosphorylation and then converts 
them to hydrogen peroxide and diatomic oxygen [388]; 3.) the p62/sequestosome 1 gene 
Sqstm1, encoding an autophagosome cargo protein that interacts with other proteins 
responsible for selective autophagy [389, 390]; and 4 ) Prdx5, encoding  peroxiredoxin-5 
protein [391]. These proteins are all involved in defending against superoxide/reactive 
oxygen species and control excessive inflammatory responses after macrophage activation 
[392], with peroxiredoxin 5 (PRX5) and manganese-containing superoxide dismutase (Sod2) 
being highly upregulated after TLR activation of macrophages during microbial infection 
[388, 393]. 
 
Oxidative stress genes that were significantly down-regulated in AIEC-infected macrophages, 
included the following; 1.) The glutamate-cysteine ligase gene Gclc, encoding a catalytic 
protein involved in the first step in the synthesis of glutathione important for protection 
against infection [394, 395]; 2.) The isocitrate dehydrogenase 1 gene Idh1, catalysing 
oxidative decarboxylation of citrate cytosolic NADP+-dependent ribozyme [396]; 3.) RecQ 
protein-like 4 gene Recql4, encoding the ATP-dependent DNA helicase Q4 [397], and 4.) 
The antioxidant prostaglandin-endoperoxide synthase 1/cyclooxygenase 1 gene Ptgs1, 
catalysing the conversion of arachidonic acid to prostaglandin [398]. Our data also indicate 
that no differential changes were observed in the expression of 84 host genes related to 
oxidative stress to that seen with the non-replicating laboratory E. coli strain EPI300 in terms 
of both up-regulation and down-regulation of the mouse oxidative stress genes post 6h 
infection. Overall, this result suggest that adaptation to the phagolysosome niche of Crohn’s 
disease AIEC, such as HM605, appears not to be through any ability to alter host macrophage 
oxidative stress response to infection. 
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Studies have identified presence of key virulence genes thought to associate to a ‘AIEC’ 
phenotype, i.e. being significantly higher among AIEC strains isolated from CD patients than 
non-IBD controls [180, 245, 399, 400]. Comparison of the complete genome of ileal CD 
AIEC E. coli NRG857c (O83:H1) had confirmed a phylogenetic linkage between AIEC and 
ExPECs [9]. A more recent comparative RNASeq analysis of AIEC strain LF82 compared to 
a non-invasive strain HS also showed enrichment for pdu operon genes [401], as did the 
study of Dogan et al. [178] and further analysis of the complete genomes for 13 AIEC and 11 
non-invasive E. coli revealed that a number of CRISPR-associated Cas genes (encoding 
proteins that recognize foreign genetic material in plasmids and phages) may serve as AIEC-
specific biomarkers [401]. One particular gene ibeA (encoding an invasion protein) also 
shown to be enriched in AIEC in the same study [401], plays a role in resistance of E. coli to 
hydrogen peroxide stress [402] and supporting survival of AIEC within macrophage [377]. 
However, a recent whole genome sequencing study of 41 B2 phylogroup E. coli strains, 
isolated from 19 patients with IBD (i.e. 14 with CD, 5 with UC), and 17 without IBD, 
interestingly showed no exclusive identifiable molecular features for the AIEC phenotype 
[161].  
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Chapter 6  
 
Overall study outcomes  
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6.1 Overall summary of the key findings 
 
The following list summarises the key findings on CD-E. coli isolates that have been 
identified throughout working in the lab so far: 
 
1. The majority of Crohn’s ileal- and colonic-mucosa associated E. coli strains possess 
ability to either survive and/or replicate within murine (J774-A1) macrophages. 
Notably, all pathogenic UTI E. coli isolates examined and some healthy mucosa-
associated E. coli strains behaved in a similar manner. All CRC mucosa-associated E. 
coli strains tested, two out of four UC mucosa-associated isolates and the majority of 
laboratory E. coli strains were unable to survive inside J774-A1 macrophage 
phagolysosomes (see Chapter 3, Figure 3.2). 
 
2. Bone marrow progenitor cells from wild-type C57BL/6, Nfκb1-/-, Nfκb2-/- and c-Rel-/- 
mice were successfully differentiated into mature adherent macrophages when 
cultured in media supplemented with rM-CSF (see Chapter 2, section 2.3). Paradigm 
Crohn’s ileal and colonic AIEC isolates LF82 and HM605 showed ability to survive 
and replicate within wild-type C57BL/6 bone-marrow derived macrophages 
(BMDM). They were, however, unable to survive and replicate inside Nfκb1-/- and 
Nfκb2-/- BMDM, whilst they both survived and replicated within c-Rel-/- BMDM. (see 
Chapter 3, section 3.4, 3.5 and 3.6). 
 
3. Chemical stress conditions mimicking the intra-macrophage phagolysosome 
environment were observed to have no adverse effects on the growth of Crohn’s 
disease mucosa-associated AIEC, and those intra-macrophage replicating UTI and 
healthy-mucosa-associated E. coli isolates. All laboratory, CRC and UC mucosally-
associated E. coli isolates (with only a few exceptions) were seen to be intolerant to 
the same stress conditions, in particular superoxidative stress. (see Chapter 4, section 
4.2 and 4.3). 
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4. Expression of bacteria acid stress response antiporter glutamate-ƴ-aminobutyric acid 
genes gadA and gadB were observed to be much higher in the studied E. coli strains in 
minimal nutrient, low pH (acidic) growth conditions. CD AIEC HM605 showed 
higher base levels of expression of both gadA and gadB suggesting this may benefit 
survival in a highly acidic phagolysosome environment (see Chapter 5, section 5.2). 
 
5. Adaptation to the phagolysosome niche of Crohn’s disease AIEC HM605 appears not 
to be any ability to alter host macrophage oxidative stress response to infection, as no 
differential changes were observed in the expression of 84 host genes related to 
oxidative stress to that seen with the non-replicating laboratory E. coli strain EPI300 
(see Chapter 5, section 5.3). 
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Chapter 7  
 
Discussion 
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7.1 Intra-macrophage survival and replication of Crohn’s disease mucosa-
associated AIEC isolates inside the vacuolar environment of the mature 
phagolysosome 
 
There is accumulating evidence supporting the importance of host–microbe interactions in 
the pathogenesis of CD and this has been consolidated by genome-wide association  studies 
[326]. Delayed/aberrant clearance of bacteria from mucosal tissues of Crohn’s patients by 
macrophages, along with retention of undigested bacteria has been proposed to cause chronic 
granulomatous inflammation and stimulation of secondary adaptive immune response [403]. 
Th1-related cytokines (TNF, IFN-γ, and IL-12) and Th17-associated cytokines (IL-17A, IL-
21, and IL-23) have been reported to markedly increase in the inflamed mucosa of Crohn’s 
patients and their increased levels are associated with the progression of CD [7, 404].  
 
Several international research groups have identified the increased abundance of E. coli 
(including the proposed ‘pathovar’ AIEC ) in both the ileal and colonic mucosa of active and 
newly diagnosed Crohn’s patients (both adult and paediatric) [30, 46, 117, 139, 305, 405]. 
These E. coli have frequently been observed to translocate the Crohn’s intestinal mucosae of 
patients to be found scattered within the lamina propria, submucosa, the muscle layers, and 
the perivascular areas of the subserosa [120]. Other studies have also reported increased E. 
coli abundance in active UC patients as well as in those with active CD [140, 142, 406-410]. 
These E. coli have been detected in the lamina propria of UC patients [120], but there is no 
evidence for their ability to translocate to mucosa layer [411, 412]. In addition, intra-
macrophage E. coli were commonly found in lamina propria (LP) macrophages in mucosal 
biopsies from 71% CD, 11% UC patients, but from non-inflamed controls (0%) [330]. A 
Canadian group had also previously shown that E. coli strains from UC showed higher 
percent survival inside murine (RAW264.7) macrophages than those isolates from CD and 
healthy controls after 20h infection [410]. Similar intra-mucosal and intra-epithelial E. coli 
have also been found in increased numbers from patients with CRC [139, 143]. This is 
supported by recent studies, including quantitative profiling/detection by PCR [413, 414]. 
Some of these E. coli strains were shown to possess the characteristics of both DAEC and 
genotoxic AIEC [180],[413, 414]. Several studies have identified presence of key virulence 
genes thought to associate to a ‘AIEC’ phenotype, i.e. being significantly higher among 
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AIEC strains isolated from CD patients than non-IBD controls [180, 245, 399, 400]. 
Virulence factors supporting survival and replication within macrophages have been 
identified using isogenic mutants of the “paradigm” ileal AIEC LF82, including HtrA, DsbA, 
Hfq and GipA [242-245]. The AIEC phenotype has also been frequently observed amongst 
intestinal pathogenic E. coli (InPEC) strains from various animal species [415]. However, a 
recent whole genome sequencing study showed no identifiable molecular features for an 
exclusive AIEC phenotype [161].  
 
In our study we have provided further evidence of the ability of Crohn’s disease mucosa- 
associated E. coli to replicate within murine macrophages and also shown that Crohn’s AIEC 
strains have better ability to survive and replicate than those isolates obtained from both CRC 
and UC patients. We have also shown that E. coli strains from other disease and non-
inflamed conditions also share AIEC phenotypic properties (especially those obtained from 
UTI patients). AIEC replication within macrophages is suggested to be dependent on host 
TNF secretion [8, 149, 323, 324]. Crohn’s AIEC LF82 and 13I have been reported during 
macrophage infection to induce chronic activation/nuclear translocation of NF-κB, which 
correlates with increased TNF secretion and ongoing intracellular replication of these strains 
[323]. In this study, intra-macrophage Crohn’s AIEC strains HM605 and LF82 survival and 
replication were observed within murine BMDM from various Nfκb family member 
knockout mice, including the classical pathway, Nfκb1-/- (p105→p50) and c-Rel-/- (p65), and 
the alternative pathway, Nfκb2-/- (p100→p52). Phagocytosis of these AIEC was not impaired, 
but our data showed that both isolates showed little ability to replicate within Nfκb1-/- and 
Nfκb2-/- BMDM, while they managed to survive and replicate within c-Rel-/- BMDM, like that 
of WT BMDM. This supports the role of host Nfκb signal pathway activation in supporting 
intra-macrophage survival and persistence, although whether subsequent elevation TNF 
levels occur to support survival/replication was not studied here. However, previous data 
from our own lab show that peripheral blood monocyte-derived macrophages obtained from 
healthy volunteers and Crohn’s patients produced roughly similar quantities of 
proinflammatory cytokines, including TNF, after infection with Crohn’s mucosa-associated 
AIEC HM605 [205]. This contradicts other studies showing that exogenous addition of TNF 
increases numbers of intra-macrophage replicating AIEC LF82 [324, 335]. It would be 
interesting to examine the replication of these paradigm AIEC isolates replication within 
BMDM derived from knock-outs of TNF and TNF receptor family members [416, 417]. CD 
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AIEC LF82 isolate have also been reported to have the ability to delay apoptosis in the 
infected macrophages by a mechanism involving increase of S-nitrosylation and proteasomal 
degradation of Caspase-3 [418]. Interestingly, tumour necrosis factor-like weak inducer of 
apoptosis (sTWEAK) has been found to be elevated in Crohn’s patients, suggesting that 
TWEAK may play a role in the aetiology of CD [404]. 
 
Adaptation to an intracellular lifestyle is not uncommon in the pathogen world including Q-
fever-associated Coxiella burnetii [288] and Whipple's disease-associated Tropheryma 
whipplei [289, 290] as key examples. Likewise, enteric pathogens Salmonella and Shigella  
have both been reported to possess a repertoire of inducible systems that support tolerance of 
the harsh phagolysosome environment [224]. Paradigm Crohn’s AIEC strain LF82, has also 
been shown to be present within mature phagolysosomes and appears to be tolerant of a low 
pH and high oxidative stress environment typical of the phagolysosome [322]. This 
persistence within macrophages supports giant cell formation and development of 
granulomata in vitro [145]  
 
Our study data supports these earlier observations and extend this to a wider range of CD 
isolates. Here we demonstrated that following acid, oxidative, superoxidative and nitrosative 
stress, Crohn’s disease mucosa-associated E. coli strains possessing the AIEC phenotype 
were better able to tolerate growth in ‘killing’ conditions inside the macrophage 
phagolysosome. Interestingly, other studies on ExPEC strains has also demonstrated the 
ability to survive/adapt to/tolerate the intracellular bactericidal mechanisms within peripheral 
blood-derived human neutrophils [419].  
Other important mechanisms may also be important for intracellular survival of CD mucosa-
associated E. coli at the level of the epithelial interface. Hypoxia inducible transcription 
factor (HIF)-1α protein, encoded by HIF1A gene, plays an essential role in cellular and 
systemic responses to hypoxia [420]. There is strong evidence showing that CD AIEC strains 
promote gastrointestinal inflammatory disorders via activation of HIF-dependent responses 
leading to an over expression of HIF-1α protein in inflamed ileal epithelium of Crohn’s 
patients [421] and also HIF-1α was found to mediate CEACAM6 expression and regulate the 
xenophagy process of CD AIEC within intestinal epithelial cells [422]. 
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Identifying the other stress response genes favouring Crohn’s AIEC survival and replication 
ability within the macrophage phagolysosome was a key target in this study. The glutamate-
dependent acid response system, particularly two isoforms of glutamate decarboxylase 
encoded by gadA and gadB [248, 249], was a good target given that a number of E. coli are 
already known to contain acid stress response genes of this system [246, 248, 382], and  is 
likely the most effective system in protecting E. coli strains from low pH compared with 
other acid resistance mechanisms [423-425]. Here we showed that expression of the acid 
stress response antiporter glutamate-ƴ-aminobutyric acid system genes gadA and gadB from 
bacteria grown in low nutrient media (pH 4.5) mimicking the active phagocytic-vacuole 
environment, were observed to be much higher in all E. coli strains than that seen at pH 7. 
Crohn’s AIEC HM605 showed higher initial levels of expression of both gadA and gadB in 
low nutrient media at pH 7, which might suggest that elevated levels at initial entry to the 
phagolysosome confer an advantageous position in adaptation for survival/replication within 
this niche. AIEC adaptation to the phagolysosome niche appears not to be through ability to 
alter host macrophage oxidative stress response to infection as no differential  changes were 
observed in the expression of 84 host genes related to oxidative stress to that seen by with 
non-replicating laboratory E. coli strain EPI300. Murine commensal E. coli have been 
observed to respond to chronic intestinal inflammation by up-regulating expression of gadA 
and gadB [250] and in the same study, it was hypothesised that these strains might upregulate 
these acid response genes during inflammation to enhance their survival and virulence. 
Conversely, they showed that upregulation of acid tolerance pathways limited commensal E. 
coli survival and colitogenic potential [250]. Notably though, the largest shift observed in gad 
gene expression to the experimentally-induced acidic stress conditions in our study was for 
the non-pathogenic E. coli K-12 strain, and this certainly supported its survival/tolerance of 
high acid growth conditions. The higher initial gad gene levels observed here in human CD 
mucosa-associated E. coli may also suggest that AIEC differ considerably to commensal 
strains. 
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7.2  Host macrophage–Crohn’s disease mucosa-associated AIEC interactions: 
Opening up new therapeutic strategies 
 
Understanding the Crohn’s disease (CD) mucosa-associated E. coli-host macrophage 
interaction may perhaps provide key insight into CD pathogenesis and support the 
development of new therapeutic strategies that target the fundamental pathology of CD and 
support development of novel drugs that might be much more effective for patients with CD. 
The main focus of the studies of this thesis, i.e. to investigate how CD mucosa-associated 
AIEC isolates resist killing process of mucosal macrophages through adaptation to the 
environment within the macrophage phagolysosomes, would clearly lend towards this goal.  
 
Our data has clearly validated the ability of Crohn’s ileal- and colonic-mucosa associated 
AIEC isolates to survive and replicate within mucosal macrophages, while the majority of 
ulcerative colitis (UC) and colorectal cancer (CRC) mucosa-associated E. coli isolates were 
unable to replicate. Crohn’s AIEC survival and replication appear also to be dependent on 
host NFκB signalling and possibly subsequent host TNF secretion from the macrophage. 
Blockade of the NFκB signaling pathway, both classical and alternative pathways, has 
become a potential target for pharmacological intervention [426]. Various anti-inflammatory 
agents including glucocorticoids, non-steroid anti-inflammatory drugs (NSAIDs), and 
immunosuppressants (some commonly used to treat CD patients) strongly inhibit NF-κB 
activation by mechanisms that are not fully understood [426] but may support a reduction in 
bacterial persistence/increase in killing of intra-macrophage E. coli as part of their therapeutic 
action to get CD patients into remission and maintain them there. Clearly, future agents that 
might specifically target NFκB activation within antigen-presenting cells harbouring 
persistence AIEC may have greater therapeutic potential here.  
 
These CD E. coli isolates are also clearly tolerant of the harsh chemical environment within 
the phagolysosome suggesting innate or acquired adaptation to an intracellular 
lifestyle/persistence. Therefore, understanding the factors that support intra-macrophage E. 
coli (mainly AIEC) persistence needs to reach beyond conventional immune response 
manipulation; i.e. approaches that decrease the intra-macrophage bacterial load. Such 
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approaches are being undertaken, including use of a) vitamin D supplementation to enhance 
AIEC intra-macrophage killing [205], supported by Vitamin D supplementation trail data to 
prevent relapse in Crohn’s [115]; b) antibiotics to target AIEC [149] and use of 
phagolysosome environment modifying agents that change the niche to support killing of 
intra-vacuolar persisting E. coli [205]. The latter study has led to a trial of combination 
Antibiotics and Hydroxychloroquine (APRiCOT Trial) 
[https://clinicaltrials.gov/ct2/show/NCT01783106 ].  
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9.1 Appendix  
 
Table 9.1 Fold-change values of all 82 stress related gene, expressed from mouse J774-A1 macrophage 
after infection with either E. coli EPI300 or HM605, each compared to uninfected control, using the 
Qiagen/SABiosciences RT2 Profiler PCR Array. Increased expression (in red), no change (in black) and 
lowered expression (in green) (N=3). 
 
Position 
Gene 
Symbol 
Fold Change (comparing to control group)* 
EPI300 HM605 
Fold 
Change 
95% CI  Comments** 
Fold 
Change 
95% CI  Comments** 
A01 ALB 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
A02 ALOX12 0.65 
(0.34, 
0.96) 
A 0.71 
(0.51, 
0.91) 
A 
A03 AOX1 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
A04 APOE 1.09 
(0.90, 
1.28) 
B 0.93 
(0.82, 
1.04) 
B 
A05 ATOX1 0.59 
(0.20, 
0.98) 
B 0.52 
(0.23, 
0.81) 
B 
A06 BNIP3 1.00 
(0.68, 
1.32) 
OKAY 0.80 
(0.55, 
1.05) 
OKAY 
A07 CAT 4.05 
(0.00001, 
17.81) 
OKAY 4.79 
(0.00001, 
21.05) 
OKAY 
A08 CCL5 1602.38 
(603.17, 
2601.59) 
A 1126.79 
(632.71, 
1620.87) 
A 
A09 CCS 0.77 
(0.61, 
0.93) 
OKAY 0.94 
(0.79, 
1.09) 
OKAY 
A10 CYBB 0.74 
(0.07, 
1.41) 
OKAY 1.02 
(0.92, 
1.12) 
OKAY 
A11 CYGB 0.95 
(0.42, 
1.48) 
OKAY 1.05 
(0.89, 
1.21) 
OKAY 
A12 DHCR24 1.47 
(0.65, 
2.29) 
B 0.98 
(0.69, 
1.27) 
B 
B01 DUOX1 0.62 
(0.28, 
0.96) 
OKAY 0.78 
(0.65, 
0.91) 
OKAY 
B02 DUOX2 0.50 
(0.00001, 
C 0.55 
(0.38, 
C 
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1.23) 0.72) 
B03 DUSP1 1.36 
(0.71, 
2.01) 
B 0.80 
(0.49, 
1.11) 
B 
B04 EPHX2 0.52 
(0.00001, 
1.26) 
B 0.55 
(0.38, 
0.72) 
C 
B05 EPX 0.72 
(0.22, 
1.22) 
OKAY 1.04 
(0.92, 
1.16) 
OKAY 
B06 FOXM1 0.93 
(0.45, 
1.41) 
B 0.84 
(0.63, 
1.05) 
B 
B07 FTH1 0.65 
(0.31, 
0.99) 
B 1.00 
(0.66, 
1.34) 
B 
B08 GCLC 0.47 
(0.00001, 
1.15) 
B 0.51 
(0.41, 
0.61) 
OKAY 
B09 GCLM 1.72 
(0.33, 
3.11) 
OKAY 1.46 
(1.16, 
1.76) 
OKAY 
B10 GPX1 0.27 
(0.18, 
0.36) 
OKAY 0.30 
(0.24, 
0.36) 
OKAY 
B11 GPX2 0.63 
(0.51, 
0.75) 
OKAY 0.72 
(0.69, 
0.75) 
OKAY 
B12 GPX3 0.71 
(0.00001, 
1.56) 
OKAY 0.73 
(0.59, 
0.87) 
OKAY 
C01 GPX4 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
C02 GPX5 3.12 
(1.25, 
4.99) 
B 2.28 
(2.06, 
2.50) 
OKAY 
C03 GPX6 0.45 
(0.41, 
0.49) 
OKAY 0.60 
(0.54, 
0.66) 
OKAY 
C04 GPX7 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
C05 GSR 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
C06 GSS 0.50 
(0.00001, 
1.23) 
C 0.57 
(0.39, 
0.75) 
OKAY 
C07 GSTP1 0.86 
(0.54, 
1.18) 
OKAY 0.95 
(0.90, 
1.00) 
OKAY 
C08 GSTZ1 0.75 
(0.51, 
0.99) 
OKAY 1.07 
(0.90, 
1.24) 
OKAY 
C09 GTF2I 0.61 
(0.34, 
0.88) 
OKAY 0.66 
(0.45, 
0.87) 
OKAY 
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C10 HMOX1 0.55 
(0.25, 
0.85) 
B 0.58 
(0.29, 
0.87) 
B 
C11 HSPA1A 1.05 
(0.32, 
1.78) 
OKAY 0.95 
(0.89, 
1.01) 
OKAY 
C12 KRT1 0.51 
(0.00001, 
1.25) 
B 0.55 
(0.38, 
0.72) 
C 
D01 LPO 0.34 
(0.20, 
0.48) 
OKAY 0.42 
(0.32, 
0.52) 
OKAY 
D02 MB 0.64 
(0.13, 
1.15) 
B 1.00 
(0.65, 
1.35) 
B 
D03 MBL2 1.58 
(0.89, 
2.27) 
B 0.87 
(0.57, 
1.17) 
B 
D04 MGST3 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
D05 MPO 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
D06 MPV17 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
D07 MSRA 1.06 
(0.20, 
1.92) 
B 1.00 
(0.00001, 
2.02) 
B 
D08 MT3 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
D09 NCF1 2.05 
(1.24, 
2.86) 
OKAY 2.33 
(1.81, 
2.85) 
OKAY 
D10 NCF2 0.74 
(0.43, 
1.05) 
OKAY 0.77 
(0.66, 
0.88) 
OKAY 
D11 NOS2 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
D12 NOX4 125.89 
(67.99, 
183.79) 
A 105.27 
(72.11, 
138.43) 
A 
E01 NOX5 1.79 
(1.15, 
2.43) 
OKAY 1.30 
(0.07, 
2.53) 
B 
E02 NQO1 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
E03 NUDT1 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
E04 OXR1 0.69 
(0.54, 
0.84) 
OKAY 0.78 
(0.24, 
1.32) 
B 
E05 OXSR1 0.67 
(0.00001, 
1.42) 
B 0.85 
(0.35, 
1.35) 
B 
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E06 PDLIM1 0.84 
(0.41, 
1.27) 
OKAY 0.83 
(0.70, 
0.96) 
OKAY 
E07 PNKP 1.21 
(0.73, 
1.69) 
OKAY 1.12 
(0.90, 
1.34) 
OKAY 
E08 PRDX1 0.59 
(0.48, 
0.70) 
OKAY 0.67 
(0.40, 
0.94) 
OKAY 
E09 PRDX2 0.77 
(0.73, 
0.81) 
OKAY 0.83 
(0.81, 
0.85) 
OKAY 
E10 PRDX3 0.89 
(0.00001, 
1.82) 
OKAY 0.90 
(0.78, 
1.02) 
OKAY 
E11 PRDX4 2.30 
(1.21, 
3.39) 
OKAY 2.67 
(2.21, 
3.13) 
OKAY 
E12 PRDX5 0.78 
(0.50, 
1.06) 
OKAY 0.65 
(0.52, 
0.78) 
OKAY 
F01 PRDX6 0.48 
(0.00001, 
1.02) 
B 0.65 
(0.57, 
0.73) 
OKAY 
F02 PREX1 0.89 
(0.26, 
1.52) 
OKAY 0.95 
(0.82, 
1.08) 
OKAY 
F03 PRNP 0.23 
(0.16, 
0.30) 
OKAY 0.33 
(0.29, 
0.37) 
OKAY 
F04 PTGS1 141.63 
(59.90, 
223.36) 
A 68.82 
(37.19, 
100.45) 
A 
F05 PTGS2 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
F06 PXDN 0.30 
(0.19, 
0.41) 
OKAY 0.34 
(0.30, 
0.38) 
OKAY 
F07 RNF7 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
F08 SCARA3 1.15 
(0.47, 
1.83) 
B 0.98 
(0.76, 
1.20) 
B 
F09 VIMP 0.93 
(0.73, 
1.13) 
OKAY 0.83 
(0.75, 
0.91) 
OKAY 
F10 SEPP1 0.70 
(0.35, 
1.05) 
OKAY 0.79 
(0.49, 
1.09) 
OKAY 
F11 SFTPD 8.18 
(2.88, 
13.48) 
OKAY 6.97 
(6.04, 
7.90) 
OKAY 
F12 SIRT2 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
G01 SOD1 2.98 
(2.38, 
3.58) 
OKAY 2.82 
(2.62, 
3.02) 
OKAY 
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G02 SOD2 1.00 
(0.39, 
1.61) 
OKAY 1.31 
(1.21, 
1.41) 
OKAY 
G03 SOD3 0.50 
(0.00001, 
1.23) 
C 0.55 
(0.38, 
0.72) 
C 
G04 SQSTM1 2.24 
(1.40, 
3.08) 
OKAY 1.57 
(0.95, 
2.19) 
B 
G05 SRXN1 0.84 
(0.56, 
1.12) 
OKAY 1.29 
(1.18, 
1.40) 
OKAY 
G06 STK25 1.28 
(0.87, 
1.69) 
OKAY 1.31 
(1.20, 
1.42) 
OKAY 
G07 TPO 0.96 
(0.57, 
1.35) 
A 1.18 
(0.90, 
1.46) 
A 
G08 TTN 1.01 
(0.91, 
1.11) 
B 0.96 
(0.75, 
1.17) 
B 
G09 TXN 0.67 
(0.43, 
0.91) 
OKAY 0.86 
(0.80, 
0.92) 
OKAY 
G10 TXNRD1 0.50 
(0.00001, 
1.23) 
C 0.62 
(0.39, 
0.85) 
B 
G11 TXNRD2 0.75 
(0.48, 
1.02) 
OKAY 0.81 
(0.74, 
0.88) 
OKAY 
G12 UCP2 1.11 
(0.44, 
1.78) 
OKAY 0.96 
(0.64, 
1.28) 
OKAY 
H01 ACTB 1.07 
(0.70, 
1.44) 
OKAY 1.10 
(1.00, 
1.20) 
OKAY 
H02 B2M 1.59 
(0.62, 
2.56) 
OKAY 1.43 
(1.28, 
1.58) 
OKAY 
H03 GAPDH 0.69 
(0.50, 
0.88) 
OKAY 0.78 
(0.67, 
0.89) 
OKAY 
H04 HPRT1 0.73 
(0.58, 
0.88) 
OKAY 0.72 
(0.66, 
0.78) 
OKAY 
H05 RPLP0 1.16 
(0.91, 
1.41) 
OKAY 1.13 
(1.02, 
1.24) 
OKAY 
 
Footnote: 
* Fold change values greater than 1 indicate a positive- or an up-regulation. Fold change values less than 1 
indicate a negative or down-regulation. 
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**Comments: 
(Comment A): This gene’s average threshold cycle is relatively high (> 30) in either the control or the test 
sample, and is reasonably low in the other sample (< 30). These data mean that the gene’s expression is 
relatively low in one sample and reasonably detected in the other sample suggesting that the actual fold-change 
value is at least as large as the calculated and reported fold-change result. This fold-change result may also have 
greater variations if p value > 0.05; therefore, it is important to have a sufficient number of biological replicates 
to validate the result for this gene. 
(Comment B): This gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression 
level is low, in both control and test samples, and the p-value for the fold-change is either unavailable or 
relatively high (p > 0.05). This fold-change result may also have greater variations; therefore, it is important to 
have a sufficient number of biological replicates to validate the result for this gene. 
(Comment C): This gene’s average threshold cycle is either not determined or greater than the defined cut-off 
value (default 35), in both samples meaning that its expression was undetected, making this fold-change result 
erroneous and un-interpretable.  
The following SABiosciences/Qiagen web link is the array gene list studied: 
https://www.qiagen.com/gb/shop/pcr/primer-sets/rt2-profiler-pcr-arrays/?catno=PAMM-
065Z#geneglobe (accessed 08-12-2016). 
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9.2 .Appendix  
 
Table 9.2 Oxidative stress genes that were either over- or under -expressed (> 2-fold change) in J7774-A1 
murine macrophages infected with E. coli EPI300 or HM605, each compared to uninfected controls. 
Increased expression (in red), no change (in black) and lowered expression (in green) (N=3). 
 
 
 
Footnote: 
Fold Regulation represents fold change results in a biologically meaningful way. Fold change values greater 
than 1 indicate a positive- or an up-regulation, and the fold regulation is equal to the fold change. Fold change 
values less than 1 indicate a negative or down-regulation, and the fold regulation is the negative inverse of the 
fold change. 
Fold Difference:
Arrays included in Test Group: EPI300, EPI300, EPI300
Arrays included in Control Group: Uninfec, Uninfec, Uninfec
Genes Over-Expressed in Genes Under-Expressed in 
Group 1 vs. Control Group Group 1 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog Position Gene Symbol Fold Regulation Comments RT2 Catalog
A07 Cat 4.054 OKAY PPM04394C B08 Fmo2 -2.1297 B PPM25634F
A08 Ccl5 1602.3793 A PPM02960F B10 Gclc -3.657 OKAY PPM05283A
C02 Gpx3 3.1152 B PPM06171A C03 Gpx4 -2.2048 OKAY PPM06010F
D09 Ncf1 2.0458 OKAY PPM25068A D01 Idh1 -2.9567 OKAY PPM25551A
D12 Nos2 125.8883 A PPM02928B F01 Prnp -2.0811 B PPM06209A
E11 Prdx5 2.2963 OKAY PPM60228E F03 Ptgs1 -4.4301 OKAY PPM03803F
F04 Ptgs2 141.6317 A PPM03647E F06 Recql4 -3.3342 OKAY PPM05394E
F11 Sod2 8.1832 OKAY PPM04371F H06 MGDC -2.6463 B
G01 Sqstm1 2.9814 OKAY PPM28731F
G04 Txn1 2.2387 OKAY PPM35777B
Note: only the genes which are checked are exported into this file
Arrays included in Test Group: HM605, HM605, HM605
Arrays included in Control Group: Uninfec, Uninfec, Uninfec
Genes Over-Expressed in Genes Under-Expressed in 
Group 2 vs. Control Group Group 2 vs. Control Group
Position Gene Symbol Fold Regulation Comments RT2 Catalog Position Gene Symbol Fold Regulation Comments RT2 Catalog
A07 Cat 4.7943 OKAY PPM04394C B10 Gclc -3.2913 OKAY PPM05283A
A08 Ccl5 1126.7877 A PPM02960F D01 Idh1 -2.3872 OKAY PPM25551A
C02 Gpx3 2.2836 OKAY PPM06171A F03 Ptgs1 -3.0427 OKAY PPM03803F
D09 Ncf1 2.3262 OKAY PPM25068A F06 Recql4 -2.98 OKAY PPM05394E
D12 Nos2 105.2736 A PPM02928B H06 MGDC -2.4261 OKAY
E11 Prdx5 2.666 OKAY PPM60228E
F04 Ptgs2 68.8157 A PPM03647E
F11 Sod2 6.9708 OKAY PPM04371F
G01 Sqstm1 2.818 OKAY PPM28731F
Note: only the genes which are checked are exported into this file
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9.3 Appendix - Supplementary Stress tolerance data  
 
 
 
Figure 9.1 Non-pathogenic clinical isolate Nissle 1917 (EcN) tolerated stress conditions. (Included as part 
of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). 
Bacteria growth in plain LB at pH 7 was used as a control.  Bacteria CFUs were frequently counted at dilution 
factor 105 and presented as relative growth response. Each value represents the mean ± standard error of the 
mean (SEM) of three independent experiments (N=4, n=3 replicate). * P ≤0.05, ** P ≤ 0.01, **** P ≤ 0.0001, 
ANOVA with Dunnett’s post-hoc test. 
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Figure 9.2 (A-I) E. coli isolates from healthy individuals were able to tolerate all stress conditions 
(Included as part of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). Each value 
represents the mean ± standard error of the mean (SEM) of three independent experiments (N=4, n=3 replicate).  
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Figure 9.3 (A-L) CD E. coli isolates, excepting LF86 and HM413 were intolerant to the superoxidative 
stress condition (included as part of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). 
Each value represents the mean ± standard error of the mean (SEM) of three independent experiments (N=4, 
n=3 replicate). * P ≤0.05, ** P ≤ 0.01, **** P ≤ 0.0001, ANOVA with Dunnett’s post-hoc test. 
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Figure 9.4 (A-G) E. coli isolates from UTI patients were tolerant to all stress conditions (Included as part 
of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). Each value represents the mean ± 
standard error of the mean (SEM) of three independent experiments (N=4, n=3 replicate).  
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Figure 9.5 (A-F) E. coli isolates, excepting HM229 were unable to tolerate the superoxidative stress 
conditions (Included as part of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). Each 
value represents the mean ± standard error of the mean (SEM) of three independent experiments (N=4, n=3 
replicate). * P ≤0.05, ** P ≤ 0.01, **** P ≤ 0.0001, ANOVA with Dunnett’s post-hoc test. 
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Figure 9.6 (A-F) E. coli isolates from UC patients were intolerant to the superoxidative stress condition 
(Included as part of the data set, regarding tolerance to MV, in Chapter 4, Figure 4.10). Each value 
represents the mean ± standard error of the mean (SEM) of three independent experiments (N=4, n=3 replicate). 
* P ≤0.05, ** P ≤ 0.01, **** P ≤ 0.0001, ANOVA with Dunnett’s post-hoc test. 
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